Compound Name,Synonyms,Batch Compound-Batch ID,Curated & Transformed MIC Data: Subset Person,Curated & Transformed MIC Data: Subset Conditions,Curated & Transformed MIC Data: Project Name,Curated & Transformed MIC Data: MIC (µg/mL),Curated & Transformed MIC Data: MIC/GIC reported as,Curated & Transformed MIC Data: Test Article Type,Curated & Transformed MIC Data: MIC (in µM) (µM),Curated & Transformed MIC Data: Threshold of growth inhibition,Curated & Transformed MIC Data: pMIC,Curated & Transformed MIC Data: Species,Curated & Transformed MIC Data: Strain,Curated & Transformed MIC Data: Strain - Other IDs,Curated & Transformed MIC Data: Accumulation phenotype,Curated & Transformed MIC Data: Strain Genotype,Curated & Transformed MIC Data: Strain notes,Curated & Transformed MIC Data: Solvent,Curated & Transformed MIC Data: Solvent Amt. (%),Curated & Transformed MIC Data: Condition,Curated & Transformed MIC Data: Media,Curated & Transformed MIC Data: Method used,Curated & Transformed MIC Data: Source,smiles
SPK-0255619,,SPK-0255619-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 31.4,Visual,< 4.5,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(O)C34CCC(CNc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255619,,SPK-0255619-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 31.4,Visual,< 4.5,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(O)C34CCC(CNc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255619,,SPK-0255619-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 31.4,Visual,< 4.5,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(O)C34CCC(CNc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255619,,SPK-0255619-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,1.00,MIC,Test article,1.96,Visual,5.7,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(O)C34CCC(CNc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255619,,SPK-0255619-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 31.4,Visual,< 4.5,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(O)C34CCC(CNc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255619,,SPK-0255619-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 31.4,Visual,< 4.5,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(O)C34CCC(CNc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255619,,SPK-0255619-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 31.4,Visual,< 4.5,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(O)C34CCC(CNc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255619,,SPK-0255619-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,8.00,MIC,Test article,15.7,Visual,4.8,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(O)C34CCC(CNc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255618,,SPK-0255618-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,32.0,MIC,Test article,64.7,Visual,4.2,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(O)C34CCC(CNc5cc6c(cn5)OCCC6)(CC3)CO4)c2n1
SPK-0255618,,SPK-0255618-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 64.7,Visual,< 4.2,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(O)C34CCC(CNc5cc6c(cn5)OCCC6)(CC3)CO4)c2n1
SPK-0255618,,SPK-0255618-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 64.7,Visual,< 4.2,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(O)C34CCC(CNc5cc6c(cn5)OCCC6)(CC3)CO4)c2n1
SPK-0255618,,SPK-0255618-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.250,MIC,Test article,0.505,Visual,6.3,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(O)C34CCC(CNc5cc6c(cn5)OCCC6)(CC3)CO4)c2n1
SPK-0255618,,SPK-0255618-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 64.7,Visual,< 4.2,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(O)C34CCC(CNc5cc6c(cn5)OCCC6)(CC3)CO4)c2n1
SPK-0255618,,SPK-0255618-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 64.7,Visual,< 4.2,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(O)C34CCC(CNc5cc6c(cn5)OCCC6)(CC3)CO4)c2n1
SPK-0255618,,SPK-0255618-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 64.7,Visual,< 4.2,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(O)C34CCC(CNc5cc6c(cn5)OCCC6)(CC3)CO4)c2n1
SPK-0255618,,SPK-0255618-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.500,MIC,Test article,1.01,Visual,6.0,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(O)C34CCC(CNc5cc6c(cn5)OCCC6)(CC3)CO4)c2n1
SPK-0255616,,SPK-0255616-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,4.00,MIC,Test article,8.09,Visual,5.1,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(C(=O)Nc5cc6c(cn5)OCCO6)(CC3)CO4)c2n1
SPK-0255616,,SPK-0255616-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 64.7,Visual,< 4.2,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(C(=O)Nc5cc6c(cn5)OCCO6)(CC3)CO4)c2n1
SPK-0255616,,SPK-0255616-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 64.7,Visual,< 4.2,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(C(=O)Nc5cc6c(cn5)OCCO6)(CC3)CO4)c2n1
SPK-0255616,,SPK-0255616-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.250,MIC,Test article,0.506,Visual,6.3,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(C(=O)Nc5cc6c(cn5)OCCO6)(CC3)CO4)c2n1
SPK-0255616,,SPK-0255616-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 64.7,Visual,< 4.2,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(C(=O)Nc5cc6c(cn5)OCCO6)(CC3)CO4)c2n1
SPK-0255616,,SPK-0255616-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 64.7,Visual,< 4.2,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(C(=O)Nc5cc6c(cn5)OCCO6)(CC3)CO4)c2n1
SPK-0255616,,SPK-0255616-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 64.7,Visual,< 4.2,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(C(=O)Nc5cc6c(cn5)OCCO6)(CC3)CO4)c2n1
SPK-0255616,,SPK-0255616-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0310,MIC,Test article,0.0627,Visual,7.2,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(C(=O)Nc5cc6c(cn5)OCCO6)(CC3)CO4)c2n1
SPK-0255615,,SPK-0255615-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 4.00,MIC,Test article,> 7.88,Visual,< 5.1,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(C(=O)Nc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255615,,SPK-0255615-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 4.00,MIC,Test article,> 7.88,Visual,< 5.1,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(C(=O)Nc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255615,,SPK-0255615-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 4.00,MIC,Test article,> 7.88,Visual,< 5.1,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(C(=O)Nc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255615,,SPK-0255615-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0310,MIC,Test article,0.0611,Visual,7.2,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(C(=O)Nc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255615,,SPK-0255615-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 4.00,MIC,Test article,> 7.88,Visual,< 5.1,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(C(=O)Nc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255615,,SPK-0255615-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 4.00,MIC,Test article,> 7.88,Visual,< 5.1,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(C(=O)Nc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255615,,SPK-0255615-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 4.00,MIC,Test article,> 7.88,Visual,< 5.1,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(C(=O)Nc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255615,,SPK-0255615-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,8.00E-03,MIC,Test article,0.0158,Visual,7.8,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(C(=O)Nc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255614,,SPK-0255614-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,4.00,MIC,Test article,8.12,Visual,5.1,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(C(=O)Nc5cc6c(cn5)OCCC6)(CC3)CO4)c2n1
SPK-0255614,,SPK-0255614-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 32.5,Visual,< 4.5,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(C(=O)Nc5cc6c(cn5)OCCC6)(CC3)CO4)c2n1
SPK-0255614,,SPK-0255614-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 32.5,Visual,< 4.5,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(C(=O)Nc5cc6c(cn5)OCCC6)(CC3)CO4)c2n1
SPK-0255614,,SPK-0255614-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.250,MIC,Test article,0.508,Visual,6.3,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(C(=O)Nc5cc6c(cn5)OCCC6)(CC3)CO4)c2n1
SPK-0255614,,SPK-0255614-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 32.5,Visual,< 4.5,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(C(=O)Nc5cc6c(cn5)OCCC6)(CC3)CO4)c2n1
SPK-0255614,,SPK-0255614-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 32.5,Visual,< 4.5,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(C(=O)Nc5cc6c(cn5)OCCC6)(CC3)CO4)c2n1
SPK-0255614,,SPK-0255614-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 32.5,Visual,< 4.5,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(C(=O)Nc5cc6c(cn5)OCCC6)(CC3)CO4)c2n1
SPK-0255614,,SPK-0255614-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0310,MIC,Test article,0.0629,Visual,7.2,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(C(=O)Nc5cc6c(cn5)OCCC6)(CC3)CO4)c2n1
SPK-0255613,,SPK-0255613-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 66.9,Visual,< 4.2,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(CNc5cc6c(cn5)OCCC6)(CC3)CO4)c2n1
SPK-0255613,,SPK-0255613-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 66.9,Visual,< 4.2,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(CNc5cc6c(cn5)OCCC6)(CC3)CO4)c2n1
SPK-0255613,,SPK-0255613-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 66.9,Visual,< 4.2,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(CNc5cc6c(cn5)OCCC6)(CC3)CO4)c2n1
SPK-0255613,,SPK-0255613-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,1.00,MIC,Test article,2.09,Visual,5.7,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(CNc5cc6c(cn5)OCCC6)(CC3)CO4)c2n1
SPK-0255613,,SPK-0255613-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 66.9,Visual,< 4.2,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(CNc5cc6c(cn5)OCCC6)(CC3)CO4)c2n1
SPK-0255613,,SPK-0255613-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 66.9,Visual,< 4.2,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(CNc5cc6c(cn5)OCCC6)(CC3)CO4)c2n1
SPK-0255613,,SPK-0255613-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 66.9,Visual,< 4.2,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(CNc5cc6c(cn5)OCCC6)(CC3)CO4)c2n1
SPK-0255613,,SPK-0255613-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.250,MIC,Test article,0.522,Visual,6.3,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(CNc5cc6c(cn5)OCCC6)(CC3)CO4)c2n1
SPK-0255612,,SPK-0255612-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,2.00,MIC,Test article,4.04,Visual,5.4,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(C[C@H](O)C34CCC(NCc5cc6c(cn5)OCCC6)(CC3)CO4)c2n1
SPK-0255612,,SPK-0255612-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,16.0,MIC,Test article,32.4,Visual,4.5,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(C[C@H](O)C34CCC(NCc5cc6c(cn5)OCCC6)(CC3)CO4)c2n1
SPK-0255612,,SPK-0255612-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 64.7,Visual,< 4.2,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(C[C@H](O)C34CCC(NCc5cc6c(cn5)OCCC6)(CC3)CO4)c2n1
SPK-0255612,,SPK-0255612-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0310,MIC,Test article,0.0627,Visual,7.2,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(C[C@H](O)C34CCC(NCc5cc6c(cn5)OCCC6)(CC3)CO4)c2n1
SPK-0255612,,SPK-0255612-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 64.7,Visual,< 4.2,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(C[C@H](O)C34CCC(NCc5cc6c(cn5)OCCC6)(CC3)CO4)c2n1
SPK-0255612,,SPK-0255612-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 64.7,Visual,< 4.2,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(C[C@H](O)C34CCC(NCc5cc6c(cn5)OCCC6)(CC3)CO4)c2n1
SPK-0255612,,SPK-0255612-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 64.7,Visual,< 4.2,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(C[C@H](O)C34CCC(NCc5cc6c(cn5)OCCC6)(CC3)CO4)c2n1
SPK-0255612,,SPK-0255612-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0630,MIC,Test article,0.127,Visual,6.9,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(C[C@H](O)C34CCC(NCc5cc6c(cn5)OCCC6)(CC3)CO4)c2n1
SPK-0255611,,SPK-0255611-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,2.00,MIC,Test article,3.82,Visual,5.4,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(C[C@H](O)C34CCC(NC(=O)c5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255611,,SPK-0255611-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,16.0,MIC,Test article,30.6,Visual,4.5,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(C[C@H](O)C34CCC(NC(=O)c5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255611,,SPK-0255611-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 61.1,Visual,< 4.2,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(C[C@H](O)C34CCC(NC(=O)c5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255611,,SPK-0255611-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0630,MIC,Test article,0.120,Visual,6.9,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(C[C@H](O)C34CCC(NC(=O)c5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255611,,SPK-0255611-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 61.1,Visual,< 4.2,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(C[C@H](O)C34CCC(NC(=O)c5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255611,,SPK-0255611-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 61.1,Visual,< 4.2,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(C[C@H](O)C34CCC(NC(=O)c5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255611,,SPK-0255611-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 61.1,Visual,< 4.2,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(C[C@H](O)C34CCC(NC(=O)c5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255611,,SPK-0255611-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0630,MIC,Test article,0.120,Visual,6.9,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(C[C@H](O)C34CCC(NC(=O)c5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255610,,SPK-0255610-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,32.0,MIC,Test article,62.9,Visual,4.2,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(C[C@H](O)C34CCC(NC(=O)c5cc6c(cn5)OCCC6)(CC3)CO4)c2n1
SPK-0255610,,SPK-0255610-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 62.9,Visual,< 4.2,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(C[C@H](O)C34CCC(NC(=O)c5cc6c(cn5)OCCC6)(CC3)CO4)c2n1
SPK-0255610,,SPK-0255610-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 62.9,Visual,< 4.2,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(C[C@H](O)C34CCC(NC(=O)c5cc6c(cn5)OCCC6)(CC3)CO4)c2n1
SPK-0255610,,SPK-0255610-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.250,MIC,Test article,0.492,Visual,6.3,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(C[C@H](O)C34CCC(NC(=O)c5cc6c(cn5)OCCC6)(CC3)CO4)c2n1
SPK-0255610,,SPK-0255610-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 62.9,Visual,< 4.2,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(C[C@H](O)C34CCC(NC(=O)c5cc6c(cn5)OCCC6)(CC3)CO4)c2n1
SPK-0255610,,SPK-0255610-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 62.9,Visual,< 4.2,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(C[C@H](O)C34CCC(NC(=O)c5cc6c(cn5)OCCC6)(CC3)CO4)c2n1
SPK-0255610,,SPK-0255610-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 62.9,Visual,< 4.2,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(C[C@H](O)C34CCC(NC(=O)c5cc6c(cn5)OCCC6)(CC3)CO4)c2n1
SPK-0255610,,SPK-0255610-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.500,MIC,Test article,0.983,Visual,6.0,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(C[C@H](O)C34CCC(NC(=O)c5cc6c(cn5)OCCC6)(CC3)CO4)c2n1
SPK-0255609,,SPK-0255609-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,32.0,MIC,Test article,62.7,Visual,4.2,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(C[C@H](O)C34CCC(NC(=O)c5cc6c(cn5)OCCO6)(CC3)CO4)c2n1
SPK-0255609,,SPK-0255609-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 62.7,Visual,< 4.2,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(C[C@H](O)C34CCC(NC(=O)c5cc6c(cn5)OCCO6)(CC3)CO4)c2n1
SPK-0255609,,SPK-0255609-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 62.7,Visual,< 4.2,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(C[C@H](O)C34CCC(NC(=O)c5cc6c(cn5)OCCO6)(CC3)CO4)c2n1
SPK-0255609,,SPK-0255609-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.500,MIC,Test article,0.979,Visual,6.0,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(C[C@H](O)C34CCC(NC(=O)c5cc6c(cn5)OCCO6)(CC3)CO4)c2n1
SPK-0255609,,SPK-0255609-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 62.7,Visual,< 4.2,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(C[C@H](O)C34CCC(NC(=O)c5cc6c(cn5)OCCO6)(CC3)CO4)c2n1
SPK-0255609,,SPK-0255609-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 62.7,Visual,< 4.2,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(C[C@H](O)C34CCC(NC(=O)c5cc6c(cn5)OCCO6)(CC3)CO4)c2n1
SPK-0255609,,SPK-0255609-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 62.7,Visual,< 4.2,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(C[C@H](O)C34CCC(NC(=O)c5cc6c(cn5)OCCO6)(CC3)CO4)c2n1
SPK-0255609,,SPK-0255609-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,1.00,MIC,Test article,1.96,Visual,5.7,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(C[C@H](O)C34CCC(NC(=O)c5cc6c(cn5)OCCO6)(CC3)CO4)c2n1
SPK-0255608,,SPK-0255608-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 4.00,MIC,Test article,> 7.74,Visual,< 5.1,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc(=O)n6c7c(cccc57)OC6)(CC3)CO4)c2n1
SPK-0255608,,SPK-0255608-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 4.00,MIC,Test article,> 7.74,Visual,< 5.1,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc(=O)n6c7c(cccc57)OC6)(CC3)CO4)c2n1
SPK-0255608,,SPK-0255608-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 4.00,MIC,Test article,> 7.74,Visual,< 5.1,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc(=O)n6c7c(cccc57)OC6)(CC3)CO4)c2n1
SPK-0255608,,SPK-0255608-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.500,MIC,Test article,0.968,Visual,6.0,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc(=O)n6c7c(cccc57)OC6)(CC3)CO4)c2n1
SPK-0255608,,SPK-0255608-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 4.00,MIC,Test article,> 7.74,Visual,< 5.1,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc(=O)n6c7c(cccc57)OC6)(CC3)CO4)c2n1
SPK-0255608,,SPK-0255608-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 4.00,MIC,Test article,> 7.74,Visual,< 5.1,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc(=O)n6c7c(cccc57)OC6)(CC3)CO4)c2n1
SPK-0255608,,SPK-0255608-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 4.00,MIC,Test article,> 7.74,Visual,< 5.1,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc(=O)n6c7c(cccc57)OC6)(CC3)CO4)c2n1
SPK-0255608,,SPK-0255608-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.250,MIC,Test article,0.484,Visual,6.3,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc(=O)n6c7c(cccc57)OC6)(CC3)CO4)c2n1
SPK-0255607,,SPK-0255607-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,4.00,MIC,Test article,7.29,Visual,5.1,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(N7CC[C@@H](O)C7)nc56)(CC3)OC4)nc2N1
SPK-0255607,,SPK-0255607-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 29.2,Visual,< 4.5,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(N7CC[C@@H](O)C7)nc56)(CC3)OC4)nc2N1
SPK-0255607,,SPK-0255607-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 29.2,Visual,< 4.5,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(N7CC[C@@H](O)C7)nc56)(CC3)OC4)nc2N1
SPK-0255607,,SPK-0255607-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0310,MIC,Test article,0.0565,Visual,7.2,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(N7CC[C@@H](O)C7)nc56)(CC3)OC4)nc2N1
SPK-0255607,,SPK-0255607-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 29.2,Visual,< 4.5,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(N7CC[C@@H](O)C7)nc56)(CC3)OC4)nc2N1
SPK-0255607,,SPK-0255607-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 29.2,Visual,< 4.5,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(N7CC[C@@H](O)C7)nc56)(CC3)OC4)nc2N1
SPK-0255607,,SPK-0255607-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 29.2,Visual,< 4.5,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(N7CC[C@@H](O)C7)nc56)(CC3)OC4)nc2N1
SPK-0255607,,SPK-0255607-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.250,MIC,Test article,0.456,Visual,6.3,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(N7CC[C@@H](O)C7)nc56)(CC3)OC4)nc2N1
SPK-0255606,,SPK-0255606-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 54.1,Visual,< 4.3,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2nc(N3CCN(C)CC3)c(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255606,,SPK-0255606-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 54.1,Visual,< 4.3,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2nc(N3CCN(C)CC3)c(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255606,,SPK-0255606-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 54.1,Visual,< 4.3,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2nc(N3CCN(C)CC3)c(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255606,,SPK-0255606-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,8.00,MIC,Test article,13.5,Visual,4.9,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2nc(N3CCN(C)CC3)c(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255606,,SPK-0255606-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 54.1,Visual,< 4.3,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2nc(N3CCN(C)CC3)c(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255606,,SPK-0255606-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 54.1,Visual,< 4.3,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2nc(N3CCN(C)CC3)c(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255606,,SPK-0255606-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 54.1,Visual,< 4.3,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2nc(N3CCN(C)CC3)c(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255606,,SPK-0255606-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 54.1,Visual,< 4.3,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2nc(N3CCN(C)CC3)c(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255605,,SPK-0255605-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 13.8,Visual,< 4.9,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2nc(N3CCNCC3)c(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255605,,SPK-0255605-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 13.8,Visual,< 4.9,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2nc(N3CCNCC3)c(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255605,,SPK-0255605-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 13.8,Visual,< 4.9,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2nc(N3CCNCC3)c(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255605,,SPK-0255605-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,8.00,MIC,Test article,13.8,Visual,4.9,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2nc(N3CCNCC3)c(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255605,,SPK-0255605-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 13.8,Visual,< 4.9,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2nc(N3CCNCC3)c(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255605,,SPK-0255605-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 13.8,Visual,< 4.9,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2nc(N3CCNCC3)c(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255605,,SPK-0255605-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 13.8,Visual,< 4.9,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2nc(N3CCNCC3)c(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255605,,SPK-0255605-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 13.8,Visual,< 4.9,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2nc(N3CCNCC3)c(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255604,,SPK-0255604-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,8.00,MIC,Test article,17.8,Visual,4.7,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NC/C=C/c5ccccn5)(CC3)CO4)c2n1
SPK-0255604,,SPK-0255604-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,32.0,MIC,Test article,71.3,Visual,4.1,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NC/C=C/c5ccccn5)(CC3)CO4)c2n1
SPK-0255604,,SPK-0255604-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 143,Visual,< 3.8,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NC/C=C/c5ccccn5)(CC3)CO4)c2n1
SPK-0255604,,SPK-0255604-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.250,MIC,Test article,0.557,Visual,6.3,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NC/C=C/c5ccccn5)(CC3)CO4)c2n1
SPK-0255604,,SPK-0255604-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 143,Visual,< 3.8,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NC/C=C/c5ccccn5)(CC3)CO4)c2n1
SPK-0255604,,SPK-0255604-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 143,Visual,< 3.8,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NC/C=C/c5ccccn5)(CC3)CO4)c2n1
SPK-0255604,,SPK-0255604-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 143,Visual,< 3.8,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NC/C=C/c5ccccn5)(CC3)CO4)c2n1
SPK-0255604,,SPK-0255604-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0630,MIC,Test article,0.140,Visual,6.9,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NC/C=C/c5ccccn5)(CC3)CO4)c2n1
SPK-0255603,,SPK-0255603-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,2.00,MIC,Test article,3.70,Visual,5.4,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CNC(=O)COc1ccc2ncc(F)c(CCC34CCC(NC/C=C/c5cc(F)ccc5F)(CC3)CO4)c2n1
SPK-0255603,,SPK-0255603-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,8.00,MIC,Test article,14.8,Visual,4.8,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CNC(=O)COc1ccc2ncc(F)c(CCC34CCC(NC/C=C/c5cc(F)ccc5F)(CC3)CO4)c2n1
SPK-0255603,,SPK-0255603-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 29.6,Visual,< 4.5,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CNC(=O)COc1ccc2ncc(F)c(CCC34CCC(NC/C=C/c5cc(F)ccc5F)(CC3)CO4)c2n1
SPK-0255603,,SPK-0255603-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.125,MIC,Test article,0.231,Visual,6.6,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CNC(=O)COc1ccc2ncc(F)c(CCC34CCC(NC/C=C/c5cc(F)ccc5F)(CC3)CO4)c2n1
SPK-0255603,,SPK-0255603-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 29.6,Visual,< 4.5,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CNC(=O)COc1ccc2ncc(F)c(CCC34CCC(NC/C=C/c5cc(F)ccc5F)(CC3)CO4)c2n1
SPK-0255603,,SPK-0255603-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 29.6,Visual,< 4.5,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CNC(=O)COc1ccc2ncc(F)c(CCC34CCC(NC/C=C/c5cc(F)ccc5F)(CC3)CO4)c2n1
SPK-0255603,,SPK-0255603-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 29.6,Visual,< 4.5,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CNC(=O)COc1ccc2ncc(F)c(CCC34CCC(NC/C=C/c5cc(F)ccc5F)(CC3)CO4)c2n1
SPK-0255603,,SPK-0255603-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0630,MIC,Test article,0.117,Visual,6.9,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CNC(=O)COc1ccc2ncc(F)c(CCC34CCC(NC/C=C/c5cc(F)ccc5F)(CC3)CO4)c2n1
SPK-0255602,,SPK-0255602-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,32.0,MIC,Test article,59.5,Visual,4.2,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CNC(=O)COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6c(cn5)OCCO6)(CC3)CO4)c2n1
SPK-0255602,,SPK-0255602-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,64.0,MIC,Test article,119,Visual,3.9,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CNC(=O)COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6c(cn5)OCCO6)(CC3)CO4)c2n1
SPK-0255602,,SPK-0255602-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 119,Visual,< 3.9,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CNC(=O)COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6c(cn5)OCCO6)(CC3)CO4)c2n1
SPK-0255602,,SPK-0255602-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.250,MIC,Test article,0.465,Visual,6.3,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CNC(=O)COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6c(cn5)OCCO6)(CC3)CO4)c2n1
SPK-0255602,,SPK-0255602-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 119,Visual,< 3.9,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CNC(=O)COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6c(cn5)OCCO6)(CC3)CO4)c2n1
SPK-0255602,,SPK-0255602-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 119,Visual,< 3.9,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CNC(=O)COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6c(cn5)OCCO6)(CC3)CO4)c2n1
SPK-0255602,,SPK-0255602-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 119,Visual,< 3.9,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CNC(=O)COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6c(cn5)OCCO6)(CC3)CO4)c2n1
SPK-0255602,,SPK-0255602-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.250,MIC,Test article,0.465,Visual,6.3,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CNC(=O)COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6c(cn5)OCCO6)(CC3)CO4)c2n1
SPK-0255601,,SPK-0255601-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,4.00,MIC,Test article,7.65,Visual,5.1,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(NCCO)nc56)(CC3)OC4)nc2N1
SPK-0255601,,SPK-0255601-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,16.0,MIC,Test article,30.6,Visual,4.5,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(NCCO)nc56)(CC3)OC4)nc2N1
SPK-0255601,,SPK-0255601-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 30.6,Visual,< 4.5,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(NCCO)nc56)(CC3)OC4)nc2N1
SPK-0255601,,SPK-0255601-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0630,MIC,Test article,0.121,Visual,6.9,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(NCCO)nc56)(CC3)OC4)nc2N1
SPK-0255601,,SPK-0255601-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 30.6,Visual,< 4.5,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(NCCO)nc56)(CC3)OC4)nc2N1
SPK-0255601,,SPK-0255601-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 30.6,Visual,< 4.5,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(NCCO)nc56)(CC3)OC4)nc2N1
SPK-0255601,,SPK-0255601-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 30.6,Visual,< 4.5,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(NCCO)nc56)(CC3)OC4)nc2N1
SPK-0255601,,SPK-0255601-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,1.00,MIC,Test article,1.91,Visual,5.7,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(NCCO)nc56)(CC3)OC4)nc2N1
SPK-0255600,,SPK-0255600-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,2.00,MIC,Test article,3.74,Visual,5.4,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(N7CC(O)C7)nc56)(CC3)OC4)nc2N1
SPK-0255600,,SPK-0255600-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,16.0,MIC,Test article,29.9,Visual,4.5,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(N7CC(O)C7)nc56)(CC3)OC4)nc2N1
SPK-0255600,,SPK-0255600-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 29.9,Visual,< 4.5,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(N7CC(O)C7)nc56)(CC3)OC4)nc2N1
SPK-0255600,,SPK-0255600-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0310,MIC,Test article,0.0580,Visual,7.2,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(N7CC(O)C7)nc56)(CC3)OC4)nc2N1
SPK-0255600,,SPK-0255600-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 29.9,Visual,< 4.5,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(N7CC(O)C7)nc56)(CC3)OC4)nc2N1
SPK-0255600,,SPK-0255600-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 29.9,Visual,< 4.5,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(N7CC(O)C7)nc56)(CC3)OC4)nc2N1
SPK-0255600,,SPK-0255600-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 29.9,Visual,< 4.5,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(N7CC(O)C7)nc56)(CC3)OC4)nc2N1
SPK-0255600,,SPK-0255600-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.500,MIC,Test article,0.935,Visual,6.0,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(N7CC(O)C7)nc56)(CC3)OC4)nc2N1
SPK-0255599,,SPK-0255599-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 16.6,Visual,< 4.8,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(CNc5cc6c(cn5)OCCO6)(CC3)CO4)c2n1
SPK-0255599,,SPK-0255599-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 16.6,Visual,< 4.8,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(CNc5cc6c(cn5)OCCO6)(CC3)CO4)c2n1
SPK-0255599,,SPK-0255599-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 16.6,Visual,< 4.8,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(CNc5cc6c(cn5)OCCO6)(CC3)CO4)c2n1
SPK-0255599,,SPK-0255599-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,1.00,MIC,Test article,2.08,Visual,5.7,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(CNc5cc6c(cn5)OCCO6)(CC3)CO4)c2n1
SPK-0255599,,SPK-0255599-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 16.6,Visual,< 4.8,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(CNc5cc6c(cn5)OCCO6)(CC3)CO4)c2n1
SPK-0255599,,SPK-0255599-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 16.6,Visual,< 4.8,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(CNc5cc6c(cn5)OCCO6)(CC3)CO4)c2n1
SPK-0255599,,SPK-0255599-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 16.6,Visual,< 4.8,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(CNc5cc6c(cn5)OCCO6)(CC3)CO4)c2n1
SPK-0255599,,SPK-0255599-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.250,MIC,Test article,0.520,Visual,6.3,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(CNc5cc6c(cn5)OCCO6)(CC3)CO4)c2n1
SPK-0255598,,SPK-0255598-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 16.2,Visual,< 4.8,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(CNc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255598,,SPK-0255598-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 16.2,Visual,< 4.8,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(CNc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255598,,SPK-0255598-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 16.2,Visual,< 4.8,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(CNc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255598,,SPK-0255598-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 16.2,Visual,< 4.8,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(CNc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255598,,SPK-0255598-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 16.2,Visual,< 4.8,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(CNc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255598,,SPK-0255598-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 16.2,Visual,< 4.8,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(CNc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255598,,SPK-0255598-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 16.2,Visual,< 4.8,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(CNc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255598,,SPK-0255598-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 16.2,Visual,< 4.8,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(CNc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255597,,SPK-0255597-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,4.00,MIC,Test article,7.29,Visual,5.1,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(N7CC[C@H](O)C7)nc56)(CC3)OC4)nc2N1
SPK-0255597,,SPK-0255597-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,16.0,MIC,Test article,29.2,Visual,4.5,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(N7CC[C@H](O)C7)nc56)(CC3)OC4)nc2N1
SPK-0255597,,SPK-0255597-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 29.2,Visual,< 4.5,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(N7CC[C@H](O)C7)nc56)(CC3)OC4)nc2N1
SPK-0255597,,SPK-0255597-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0310,MIC,Test article,0.0565,Visual,7.2,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(N7CC[C@H](O)C7)nc56)(CC3)OC4)nc2N1
SPK-0255597,,SPK-0255597-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 29.2,Visual,< 4.5,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(N7CC[C@H](O)C7)nc56)(CC3)OC4)nc2N1
SPK-0255597,,SPK-0255597-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 29.2,Visual,< 4.5,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(N7CC[C@H](O)C7)nc56)(CC3)OC4)nc2N1
SPK-0255597,,SPK-0255597-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 29.2,Visual,< 4.5,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(N7CC[C@H](O)C7)nc56)(CC3)OC4)nc2N1
SPK-0255597,,SPK-0255597-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.250,MIC,Test article,0.456,Visual,6.3,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(N7CC[C@H](O)C7)nc56)(CC3)OC4)nc2N1
SPK-0255596,,SPK-0255596-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,8.00,MIC,Test article,14.2,Visual,4.8,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(N7CCC(O)CC7)nc56)(CC3)OC4)nc2N1
SPK-0255596,,SPK-0255596-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 28.4,Visual,< 4.5,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(N7CCC(O)CC7)nc56)(CC3)OC4)nc2N1
SPK-0255596,,SPK-0255596-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 28.4,Visual,< 4.5,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(N7CCC(O)CC7)nc56)(CC3)OC4)nc2N1
SPK-0255596,,SPK-0255596-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0630,MIC,Test article,0.112,Visual,7.0,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(N7CCC(O)CC7)nc56)(CC3)OC4)nc2N1
SPK-0255596,,SPK-0255596-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 28.4,Visual,< 4.5,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(N7CCC(O)CC7)nc56)(CC3)OC4)nc2N1
SPK-0255596,,SPK-0255596-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 28.4,Visual,< 4.5,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(N7CCC(O)CC7)nc56)(CC3)OC4)nc2N1
SPK-0255596,,SPK-0255596-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 28.4,Visual,< 4.5,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(N7CCC(O)CC7)nc56)(CC3)OC4)nc2N1
SPK-0255596,,SPK-0255596-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.500,MIC,Test article,0.889,Visual,6.1,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(N7CCC(O)CC7)nc56)(CC3)OC4)nc2N1
SPK-0255595,,SPK-0255595-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,4.00,MIC,Test article,7.29,Visual,5.1,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(N7CCOC7=O)nc56)(CC3)OC4)nc2N1
SPK-0255595,,SPK-0255595-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 14.6,Visual,< 4.8,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(N7CCOC7=O)nc56)(CC3)OC4)nc2N1
SPK-0255595,,SPK-0255595-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 14.6,Visual,< 4.8,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(N7CCOC7=O)nc56)(CC3)OC4)nc2N1
SPK-0255595,,SPK-0255595-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0630,MIC,Test article,0.115,Visual,6.9,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(N7CCOC7=O)nc56)(CC3)OC4)nc2N1
SPK-0255595,,SPK-0255595-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 14.6,Visual,< 4.8,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(N7CCOC7=O)nc56)(CC3)OC4)nc2N1
SPK-0255595,,SPK-0255595-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 14.6,Visual,< 4.8,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(N7CCOC7=O)nc56)(CC3)OC4)nc2N1
SPK-0255595,,SPK-0255595-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 14.6,Visual,< 4.8,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(N7CCOC7=O)nc56)(CC3)OC4)nc2N1
SPK-0255595,,SPK-0255595-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.500,MIC,Test article,0.911,Visual,6.0,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(N7CCOC7=O)nc56)(CC3)OC4)nc2N1
SPK-0255594,,SPK-0255594-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,16.0,MIC,Test article,28.3,Visual,4.5,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CN(C)C(=O)COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255594,,SPK-0255594-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 28.3,Visual,< 4.5,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CN(C)C(=O)COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255594,,SPK-0255594-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 28.3,Visual,< 4.5,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CN(C)C(=O)COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255594,,SPK-0255594-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.125,MIC,Test article,0.221,Visual,6.7,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CN(C)C(=O)COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255594,,SPK-0255594-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 28.3,Visual,< 4.5,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CN(C)C(=O)COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255594,,SPK-0255594-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 28.3,Visual,< 4.5,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CN(C)C(=O)COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255594,,SPK-0255594-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 28.3,Visual,< 4.5,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CN(C)C(=O)COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255594,,SPK-0255594-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,2.00,MIC,Test article,3.54,Visual,5.5,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CN(C)C(=O)COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255593,,SPK-0255593-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 26.8,Visual,< 4.6,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(N7CCS(=O)(=O)CC7)nc56)(CC3)OC4)nc2N1
SPK-0255593,,SPK-0255593-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 26.8,Visual,< 4.6,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(N7CCS(=O)(=O)CC7)nc56)(CC3)OC4)nc2N1
SPK-0255593,,SPK-0255593-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 26.8,Visual,< 4.6,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(N7CCS(=O)(=O)CC7)nc56)(CC3)OC4)nc2N1
SPK-0255593,,SPK-0255593-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0630,MIC,Test article,0.106,Visual,7.0,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(N7CCS(=O)(=O)CC7)nc56)(CC3)OC4)nc2N1
SPK-0255593,,SPK-0255593-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 26.8,Visual,< 4.6,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(N7CCS(=O)(=O)CC7)nc56)(CC3)OC4)nc2N1
SPK-0255593,,SPK-0255593-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 26.8,Visual,< 4.6,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(N7CCS(=O)(=O)CC7)nc56)(CC3)OC4)nc2N1
SPK-0255593,,SPK-0255593-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 26.8,Visual,< 4.6,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(N7CCS(=O)(=O)CC7)nc56)(CC3)OC4)nc2N1
SPK-0255593,,SPK-0255593-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,1.00,MIC,Test article,1.68,Visual,5.8,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(N7CCS(=O)(=O)CC7)nc56)(CC3)OC4)nc2N1
SPK-0255592,,SPK-0255592-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 4.00,MIC,Test article,> 8.20,Visual,< 5.1,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCCOc5cc(F)ccc5F)(CC3)CO4)c2n1
SPK-0255592,,SPK-0255592-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 4.00,MIC,Test article,> 8.20,Visual,< 5.1,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCCOc5cc(F)ccc5F)(CC3)CO4)c2n1
SPK-0255592,,SPK-0255592-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 4.00,MIC,Test article,> 8.20,Visual,< 5.1,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCCOc5cc(F)ccc5F)(CC3)CO4)c2n1
SPK-0255592,,SPK-0255592-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.500,MIC,Test article,1.03,Visual,6.0,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCCOc5cc(F)ccc5F)(CC3)CO4)c2n1
SPK-0255592,,SPK-0255592-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 4.00,MIC,Test article,> 8.20,Visual,< 5.1,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCCOc5cc(F)ccc5F)(CC3)CO4)c2n1
SPK-0255592,,SPK-0255592-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 4.00,MIC,Test article,> 8.20,Visual,< 5.1,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCCOc5cc(F)ccc5F)(CC3)CO4)c2n1
SPK-0255592,,SPK-0255592-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 4.00,MIC,Test article,> 8.20,Visual,< 5.1,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCCOc5cc(F)ccc5F)(CC3)CO4)c2n1
SPK-0255592,,SPK-0255592-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.125,MIC,Test article,0.256,Visual,6.6,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCCOc5cc(F)ccc5F)(CC3)CO4)c2n1
SPK-0255591,,SPK-0255591-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 119,Visual,< 3.9,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6c(F)ccc(F)c6nc5OC)(CC3)CO4)c2n1
SPK-0255591,,SPK-0255591-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 119,Visual,< 3.9,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6c(F)ccc(F)c6nc5OC)(CC3)CO4)c2n1
SPK-0255591,,SPK-0255591-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 119,Visual,< 3.9,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6c(F)ccc(F)c6nc5OC)(CC3)CO4)c2n1
SPK-0255591,,SPK-0255591-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,64.0,MIC,Test article,119,Visual,3.9,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6c(F)ccc(F)c6nc5OC)(CC3)CO4)c2n1
SPK-0255591,,SPK-0255591-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 119,Visual,< 3.9,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6c(F)ccc(F)c6nc5OC)(CC3)CO4)c2n1
SPK-0255591,,SPK-0255591-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 119,Visual,< 3.9,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6c(F)ccc(F)c6nc5OC)(CC3)CO4)c2n1
SPK-0255591,,SPK-0255591-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 119,Visual,< 3.9,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6c(F)ccc(F)c6nc5OC)(CC3)CO4)c2n1
SPK-0255591,,SPK-0255591-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,1.00,MIC,Test article,1.86,Visual,5.7,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6c(F)ccc(F)c6nc5OC)(CC3)CO4)c2n1
SPK-0255590,,SPK-0255590-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,4.00,MIC,Test article,7.26,Visual,5.1,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CNC(=O)COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255590,,SPK-0255590-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,16.0,MIC,Test article,29.1,Visual,4.5,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CNC(=O)COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255590,,SPK-0255590-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,16.0,MIC,Test article,29.1,Visual,4.5,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CNC(=O)COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255590,,SPK-0255590-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0160,MIC,Test article,0.0291,Visual,7.5,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CNC(=O)COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255590,,SPK-0255590-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 58.1,Visual,< 4.2,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CNC(=O)COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255590,,SPK-0255590-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 58.1,Visual,< 4.2,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CNC(=O)COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255590,,SPK-0255590-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 58.1,Visual,< 4.2,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CNC(=O)COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255590,,SPK-0255590-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.250,MIC,Test article,0.454,Visual,6.3,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CNC(=O)COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255589,,SPK-0255589-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,1.00,MIC,Test article,2.16,Visual,5.7,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6cccnc56)(CC3)OC4)nc2N1
SPK-0255589,,SPK-0255589-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,4.00,MIC,Test article,8.63,Visual,5.1,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6cccnc56)(CC3)OC4)nc2N1
SPK-0255589,,SPK-0255589-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 34.5,Visual,< 4.5,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6cccnc56)(CC3)OC4)nc2N1
SPK-0255589,,SPK-0255589-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0310,MIC,Test article,0.0669,Visual,7.2,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6cccnc56)(CC3)OC4)nc2N1
SPK-0255589,,SPK-0255589-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 34.5,Visual,< 4.5,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6cccnc56)(CC3)OC4)nc2N1
SPK-0255589,,SPK-0255589-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 34.5,Visual,< 4.5,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6cccnc56)(CC3)OC4)nc2N1
SPK-0255589,,SPK-0255589-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 34.5,Visual,< 4.5,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6cccnc56)(CC3)OC4)nc2N1
SPK-0255589,,SPK-0255589-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.500,MIC,Test article,1.08,Visual,6.0,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6cccnc56)(CC3)OC4)nc2N1
SPK-0255588,,SPK-0255588-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 15.3,Visual,< 4.8,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6c(F)ccc(F)c6[nH]c5=O)(CC3)CO4)c2n1
SPK-0255588,,SPK-0255588-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 15.3,Visual,< 4.8,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6c(F)ccc(F)c6[nH]c5=O)(CC3)CO4)c2n1
SPK-0255588,,SPK-0255588-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 15.3,Visual,< 4.8,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6c(F)ccc(F)c6[nH]c5=O)(CC3)CO4)c2n1
SPK-0255588,,SPK-0255588-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.500,MIC,Test article,0.953,Visual,6.0,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6c(F)ccc(F)c6[nH]c5=O)(CC3)CO4)c2n1
SPK-0255588,,SPK-0255588-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 15.3,Visual,< 4.8,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6c(F)ccc(F)c6[nH]c5=O)(CC3)CO4)c2n1
SPK-0255588,,SPK-0255588-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 15.3,Visual,< 4.8,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6c(F)ccc(F)c6[nH]c5=O)(CC3)CO4)c2n1
SPK-0255588,,SPK-0255588-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 15.3,Visual,< 4.8,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6c(F)ccc(F)c6[nH]c5=O)(CC3)CO4)c2n1
SPK-0255588,,SPK-0255588-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.250,MIC,Test article,0.477,Visual,6.3,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6c(F)ccc(F)c6[nH]c5=O)(CC3)CO4)c2n1
SPK-0255587,,SPK-0255587-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 67.4,Visual,< 4.2,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5ccnc6ccc(OCCn7c(=O)ccc8nccc(CCC9%10CCC(NCc%11ccc%12c(n%11)NC(=O)CO%12)(CC9)CO%10)c87)nc56)(CC3)OC4)nc2N1
SPK-0255587,,SPK-0255587-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 67.4,Visual,< 4.2,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5ccnc6ccc(OCCn7c(=O)ccc8nccc(CCC9%10CCC(NCc%11ccc%12c(n%11)NC(=O)CO%12)(CC9)CO%10)c87)nc56)(CC3)OC4)nc2N1
SPK-0255587,,SPK-0255587-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 67.4,Visual,< 4.2,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5ccnc6ccc(OCCn7c(=O)ccc8nccc(CCC9%10CCC(NCc%11ccc%12c(n%11)NC(=O)CO%12)(CC9)CO%10)c87)nc56)(CC3)OC4)nc2N1
SPK-0255587,,SPK-0255587-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,2.00,MIC,Test article,2.11,Visual,5.7,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5ccnc6ccc(OCCn7c(=O)ccc8nccc(CCC9%10CCC(NCc%11ccc%12c(n%11)NC(=O)CO%12)(CC9)CO%10)c87)nc56)(CC3)OC4)nc2N1
SPK-0255587,,SPK-0255587-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 67.4,Visual,< 4.2,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5ccnc6ccc(OCCn7c(=O)ccc8nccc(CCC9%10CCC(NCc%11ccc%12c(n%11)NC(=O)CO%12)(CC9)CO%10)c87)nc56)(CC3)OC4)nc2N1
SPK-0255587,,SPK-0255587-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 67.4,Visual,< 4.2,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5ccnc6ccc(OCCn7c(=O)ccc8nccc(CCC9%10CCC(NCc%11ccc%12c(n%11)NC(=O)CO%12)(CC9)CO%10)c87)nc56)(CC3)OC4)nc2N1
SPK-0255587,,SPK-0255587-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 67.4,Visual,< 4.2,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5ccnc6ccc(OCCn7c(=O)ccc8nccc(CCC9%10CCC(NCc%11ccc%12c(n%11)NC(=O)CO%12)(CC9)CO%10)c87)nc56)(CC3)OC4)nc2N1
SPK-0255587,,SPK-0255587-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 67.4,Visual,< 4.2,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5ccnc6ccc(OCCn7c(=O)ccc8nccc(CCC9%10CCC(NCc%11ccc%12c(n%11)NC(=O)CO%12)(CC9)CO%10)c87)nc56)(CC3)OC4)nc2N1
SPK-0255586,,SPK-0255586-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 2.00,MIC,Test article,> 3.71,Visual,< 5.4,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6c(F)ccc(F)c6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255586,,SPK-0255586-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 2.00,MIC,Test article,> 3.71,Visual,< 5.4,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6c(F)ccc(F)c6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255586,,SPK-0255586-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 2.00,MIC,Test article,> 3.71,Visual,< 5.4,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6c(F)ccc(F)c6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255586,,SPK-0255586-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.500,MIC,Test article,0.928,Visual,6.0,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6c(F)ccc(F)c6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255586,,SPK-0255586-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 2.00,MIC,Test article,> 3.71,Visual,< 5.4,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6c(F)ccc(F)c6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255586,,SPK-0255586-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 2.00,MIC,Test article,> 3.71,Visual,< 5.4,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6c(F)ccc(F)c6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255586,,SPK-0255586-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 2.00,MIC,Test article,> 3.71,Visual,< 5.4,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6c(F)ccc(F)c6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255586,,SPK-0255586-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.500,MIC,Test article,0.928,Visual,6.0,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6c(F)ccc(F)c6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255585,,SPK-0255585-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 128,MIC,Test article,> 248,Visual,< 3.6,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(CNc5ccc6c(c5)OCCO6)(CC3)CO4)c2n1
SPK-0255585,,SPK-0255585-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 128,MIC,Test article,> 248,Visual,< 3.6,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(CNc5ccc6c(c5)OCCO6)(CC3)CO4)c2n1
SPK-0255585,,SPK-0255585-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 128,MIC,Test article,> 248,Visual,< 3.6,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(CNc5ccc6c(c5)OCCO6)(CC3)CO4)c2n1
SPK-0255585,,SPK-0255585-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,128,MIC,Test article,248,Visual,3.6,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(CNc5ccc6c(c5)OCCO6)(CC3)CO4)c2n1
SPK-0255585,,SPK-0255585-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 128,MIC,Test article,> 248,Visual,< 3.6,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(CNc5ccc6c(c5)OCCO6)(CC3)CO4)c2n1
SPK-0255585,,SPK-0255585-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 128,MIC,Test article,> 248,Visual,< 3.6,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(CNc5ccc6c(c5)OCCO6)(CC3)CO4)c2n1
SPK-0255585,,SPK-0255585-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 128,MIC,Test article,> 248,Visual,< 3.6,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(CNc5ccc6c(c5)OCCO6)(CC3)CO4)c2n1
SPK-0255585,,SPK-0255585-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.500,MIC,Test article,0.969,Visual,6.0,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(CNc5ccc6c(c5)OCCO6)(CC3)CO4)c2n1
SPK-0255584,,SPK-0255584-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.500,MIC,Test article,0.944,Visual,6.0,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OC(F)F)nc56)(CC3)OC4)nc2N1
SPK-0255584,,SPK-0255584-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,2.00,MIC,Test article,3.78,Visual,5.4,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OC(F)F)nc56)(CC3)OC4)nc2N1
SPK-0255584,,SPK-0255584-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,4.00,MIC,Test article,7.55,Visual,5.1,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OC(F)F)nc56)(CC3)OC4)nc2N1
SPK-0255584,,SPK-0255584-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,8.00E-03,MIC,Test article,0.0151,Visual,7.8,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OC(F)F)nc56)(CC3)OC4)nc2N1
SPK-0255584,,SPK-0255584-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 30.2,Visual,< 4.5,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OC(F)F)nc56)(CC3)OC4)nc2N1
SPK-0255584,,SPK-0255584-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,16.0,MIC,Test article,30.2,Visual,4.5,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OC(F)F)nc56)(CC3)OC4)nc2N1
SPK-0255584,,SPK-0255584-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,16.0,MIC,Test article,30.2,Visual,4.5,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OC(F)F)nc56)(CC3)OC4)nc2N1
SPK-0255584,,SPK-0255584-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0310,MIC,Test article,0.0585,Visual,7.2,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OC(F)F)nc56)(CC3)OC4)nc2N1
SPK-0255583,,SPK-0255583-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,2.00,MIC,Test article,3.58,Visual,5.4,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N#CC1(COc2ccc3ncc(F)c(CCC45CCC(NCc6ccc7c(n6)NC(=O)CO7)(CC4)CO5)c3n2)CC1
SPK-0255583,,SPK-0255583-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 28.6,Visual,< 4.5,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N#CC1(COc2ccc3ncc(F)c(CCC45CCC(NCc6ccc7c(n6)NC(=O)CO7)(CC4)CO5)c3n2)CC1
SPK-0255583,,SPK-0255583-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 28.6,Visual,< 4.5,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N#CC1(COc2ccc3ncc(F)c(CCC45CCC(NCc6ccc7c(n6)NC(=O)CO7)(CC4)CO5)c3n2)CC1
SPK-0255583,,SPK-0255583-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0160,MIC,Test article,0.0286,Visual,7.5,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N#CC1(COc2ccc3ncc(F)c(CCC45CCC(NCc6ccc7c(n6)NC(=O)CO7)(CC4)CO5)c3n2)CC1
SPK-0255583,,SPK-0255583-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 28.6,Visual,< 4.5,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N#CC1(COc2ccc3ncc(F)c(CCC45CCC(NCc6ccc7c(n6)NC(=O)CO7)(CC4)CO5)c3n2)CC1
SPK-0255583,,SPK-0255583-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 28.6,Visual,< 4.5,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N#CC1(COc2ccc3ncc(F)c(CCC45CCC(NCc6ccc7c(n6)NC(=O)CO7)(CC4)CO5)c3n2)CC1
SPK-0255583,,SPK-0255583-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 28.6,Visual,< 4.5,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N#CC1(COc2ccc3ncc(F)c(CCC45CCC(NCc6ccc7c(n6)NC(=O)CO7)(CC4)CO5)c3n2)CC1
SPK-0255583,,SPK-0255583-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.125,MIC,Test article,0.224,Visual,6.7,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N#CC1(COc2ccc3ncc(F)c(CCC45CCC(NCc6ccc7c(n6)NC(=O)CO7)(CC4)CO5)c3n2)CC1
SPK-0255582,,SPK-0255582-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 26.6,Visual,< 4.6,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OCCC(F)(F)C(=O)O)nc56)(CC3)OC4)nc2N1
SPK-0255582,,SPK-0255582-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 26.6,Visual,< 4.6,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OCCC(F)(F)C(=O)O)nc56)(CC3)OC4)nc2N1
SPK-0255582,,SPK-0255582-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 26.6,Visual,< 4.6,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OCCC(F)(F)C(=O)O)nc56)(CC3)OC4)nc2N1
SPK-0255582,,SPK-0255582-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,2.00,MIC,Test article,3.32,Visual,5.5,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OCCC(F)(F)C(=O)O)nc56)(CC3)OC4)nc2N1
SPK-0255582,,SPK-0255582-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 26.6,Visual,< 4.6,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OCCC(F)(F)C(=O)O)nc56)(CC3)OC4)nc2N1
SPK-0255582,,SPK-0255582-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 26.6,Visual,< 4.6,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OCCC(F)(F)C(=O)O)nc56)(CC3)OC4)nc2N1
SPK-0255582,,SPK-0255582-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 26.6,Visual,< 4.6,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OCCC(F)(F)C(=O)O)nc56)(CC3)OC4)nc2N1
SPK-0255582,,SPK-0255582-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 26.6,Visual,< 4.6,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OCCC(F)(F)C(=O)O)nc56)(CC3)OC4)nc2N1
SPK-0255581,,SPK-0255581-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,4.00,MIC,Test article,6.66,Visual,5.2,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,NC(=O)C(F)(F)CCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255581,,SPK-0255581-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,8.00,MIC,Test article,13.3,Visual,4.9,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,NC(=O)C(F)(F)CCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255581,,SPK-0255581-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,32.0,MIC,Test article,53.3,Visual,4.3,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,NC(=O)C(F)(F)CCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255581,,SPK-0255581-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0160,MIC,Test article,0.0266,Visual,7.6,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,NC(=O)C(F)(F)CCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255581,,SPK-0255581-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 53.3,Visual,< 4.3,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,NC(=O)C(F)(F)CCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255581,,SPK-0255581-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 53.3,Visual,< 4.3,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,NC(=O)C(F)(F)CCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255581,,SPK-0255581-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 53.3,Visual,< 4.3,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,NC(=O)C(F)(F)CCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255581,,SPK-0255581-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.125,MIC,Test article,0.208,Visual,6.7,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,NC(=O)C(F)(F)CCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255580,,SPK-0255580-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,32.0,MIC,Test article,50.8,Visual,4.3,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CCOC(=O)C(F)(F)CCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255580,,SPK-0255580-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 102,Visual,< 4.0,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CCOC(=O)C(F)(F)CCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255580,,SPK-0255580-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 102,Visual,< 4.0,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CCOC(=O)C(F)(F)CCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255580,,SPK-0255580-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,2.00,MIC,Test article,3.18,Visual,5.5,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CCOC(=O)C(F)(F)CCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255580,,SPK-0255580-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 102,Visual,< 4.0,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CCOC(=O)C(F)(F)CCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255580,,SPK-0255580-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 102,Visual,< 4.0,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CCOC(=O)C(F)(F)CCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255580,,SPK-0255580-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 102,Visual,< 4.0,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CCOC(=O)C(F)(F)CCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255580,,SPK-0255580-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,4.00,MIC,Test article,6.35,Visual,5.2,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CCOC(=O)C(F)(F)CCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255579,,SPK-0255579-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,8.00,MIC,Test article,13.5,Visual,4.9,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COC(=O)C1(COc2ccc3ncc(F)c(CCC45CCC(NCc6ccc7c(n6)NC(=O)CO7)(CC4)CO5)c3n2)CC1
SPK-0255579,,SPK-0255579-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 27.0,Visual,< 4.6,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COC(=O)C1(COc2ccc3ncc(F)c(CCC45CCC(NCc6ccc7c(n6)NC(=O)CO7)(CC4)CO5)c3n2)CC1
SPK-0255579,,SPK-0255579-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 27.0,Visual,< 4.6,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COC(=O)C1(COc2ccc3ncc(F)c(CCC45CCC(NCc6ccc7c(n6)NC(=O)CO7)(CC4)CO5)c3n2)CC1
SPK-0255579,,SPK-0255579-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.125,MIC,Test article,0.211,Visual,6.7,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COC(=O)C1(COc2ccc3ncc(F)c(CCC45CCC(NCc6ccc7c(n6)NC(=O)CO7)(CC4)CO5)c3n2)CC1
SPK-0255579,,SPK-0255579-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 27.0,Visual,< 4.6,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COC(=O)C1(COc2ccc3ncc(F)c(CCC45CCC(NCc6ccc7c(n6)NC(=O)CO7)(CC4)CO5)c3n2)CC1
SPK-0255579,,SPK-0255579-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 27.0,Visual,< 4.6,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COC(=O)C1(COc2ccc3ncc(F)c(CCC45CCC(NCc6ccc7c(n6)NC(=O)CO7)(CC4)CO5)c3n2)CC1
SPK-0255579,,SPK-0255579-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 27.0,Visual,< 4.6,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COC(=O)C1(COc2ccc3ncc(F)c(CCC45CCC(NCc6ccc7c(n6)NC(=O)CO7)(CC4)CO5)c3n2)CC1
SPK-0255579,,SPK-0255579-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.250,MIC,Test article,0.423,Visual,6.4,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COC(=O)C1(COc2ccc3ncc(F)c(CCC45CCC(NCc6ccc7c(n6)NC(=O)CO7)(CC4)CO5)c3n2)CC1
SPK-0255578,,SPK-0255578-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,1.00,MIC,Test article,1.77,Visual,5.8,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N[C@H]1CO[C@H]1COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255578,,SPK-0255578-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,4.00,MIC,Test article,7.08,Visual,5.1,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N[C@H]1CO[C@H]1COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255578,,SPK-0255578-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,32.0,MIC,Test article,56.7,Visual,4.2,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N[C@H]1CO[C@H]1COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255578,,SPK-0255578-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,8.00E-03,MIC,Test article,0.0142,Visual,7.8,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N[C@H]1CO[C@H]1COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255578,,SPK-0255578-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 113,Visual,< 3.9,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N[C@H]1CO[C@H]1COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255578,,SPK-0255578-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,64.0,MIC,Test article,113,Visual,3.9,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N[C@H]1CO[C@H]1COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255578,,SPK-0255578-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 113,Visual,< 3.9,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N[C@H]1CO[C@H]1COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255578,,SPK-0255578-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.125,MIC,Test article,0.221,Visual,6.7,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N[C@H]1CO[C@H]1COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255577,,SPK-0255577-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 31.5,Visual,< 4.5,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(C(=O)O)nc56)(CC3)OC4)nc2N1
SPK-0255577,,SPK-0255577-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 31.5,Visual,< 4.5,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(C(=O)O)nc56)(CC3)OC4)nc2N1
SPK-0255577,,SPK-0255577-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 31.5,Visual,< 4.5,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(C(=O)O)nc56)(CC3)OC4)nc2N1
SPK-0255577,,SPK-0255577-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,2.00,MIC,Test article,3.94,Visual,5.4,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(C(=O)O)nc56)(CC3)OC4)nc2N1
SPK-0255577,,SPK-0255577-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 31.5,Visual,< 4.5,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(C(=O)O)nc56)(CC3)OC4)nc2N1
SPK-0255577,,SPK-0255577-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 31.5,Visual,< 4.5,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(C(=O)O)nc56)(CC3)OC4)nc2N1
SPK-0255577,,SPK-0255577-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 31.5,Visual,< 4.5,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(C(=O)O)nc56)(CC3)OC4)nc2N1
SPK-0255577,,SPK-0255577-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 31.5,Visual,< 4.5,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(C(=O)O)nc56)(CC3)OC4)nc2N1
SPK-0255576,,SPK-0255576-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,2.00,MIC,Test article,3.83,Visual,5.4,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COC(=O)c1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255576,,SPK-0255576-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,8.00,MIC,Test article,15.3,Visual,4.8,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COC(=O)c1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255576,,SPK-0255576-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 30.7,Visual,< 4.5,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COC(=O)c1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255576,,SPK-0255576-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0160,MIC,Test article,0.0307,Visual,7.5,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COC(=O)c1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255576,,SPK-0255576-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 30.7,Visual,< 4.5,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COC(=O)c1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255576,,SPK-0255576-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 30.7,Visual,< 4.5,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COC(=O)c1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255576,,SPK-0255576-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 30.7,Visual,< 4.5,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COC(=O)c1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255576,,SPK-0255576-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.250,MIC,Test article,0.479,Visual,6.3,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COC(=O)c1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255575,,SPK-0255575-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.500,MIC,Test article,0.886,Visual,6.1,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N[C@H]1CO[C@@H]1COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255575,,SPK-0255575-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,4.00,MIC,Test article,7.08,Visual,5.1,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N[C@H]1CO[C@@H]1COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255575,,SPK-0255575-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,16.0,MIC,Test article,28.3,Visual,4.5,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N[C@H]1CO[C@@H]1COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255575,,SPK-0255575-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0160,MIC,Test article,0.0283,Visual,7.5,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N[C@H]1CO[C@@H]1COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255575,,SPK-0255575-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 56.7,Visual,< 4.2,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N[C@H]1CO[C@@H]1COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255575,,SPK-0255575-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,32.0,MIC,Test article,56.7,Visual,4.2,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N[C@H]1CO[C@@H]1COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255575,,SPK-0255575-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 56.7,Visual,< 4.2,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N[C@H]1CO[C@@H]1COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255575,,SPK-0255575-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.250,MIC,Test article,0.443,Visual,6.4,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N[C@H]1CO[C@@H]1COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255574,,SPK-0255574-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,16.0,MIC,Test article,27.6,Visual,4.6,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C(O)CCCCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255574,,SPK-0255574-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 27.6,Visual,< 4.6,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C(O)CCCCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255574,,SPK-0255574-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 27.6,Visual,< 4.6,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C(O)CCCCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255574,,SPK-0255574-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.500,MIC,Test article,0.863,Visual,6.1,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C(O)CCCCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255574,,SPK-0255574-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 27.6,Visual,< 4.6,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C(O)CCCCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255574,,SPK-0255574-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 27.6,Visual,< 4.6,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C(O)CCCCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255574,,SPK-0255574-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 27.6,Visual,< 4.6,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C(O)CCCCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255574,,SPK-0255574-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.250,MIC,Test article,0.431,Visual,6.4,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C(O)CCCCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255573,,SPK-0255573-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 4.00,MIC,Test article,> 6.74,Visual,< 5.2,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COC(=O)CCCCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255573,,SPK-0255573-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 4.00,MIC,Test article,> 6.74,Visual,< 5.2,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COC(=O)CCCCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255573,,SPK-0255573-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 4.00,MIC,Test article,> 6.74,Visual,< 5.2,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COC(=O)CCCCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255573,,SPK-0255573-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.125,MIC,Test article,0.211,Visual,6.7,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COC(=O)CCCCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255573,,SPK-0255573-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 4.00,MIC,Test article,> 6.74,Visual,< 5.2,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COC(=O)CCCCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255573,,SPK-0255573-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 4.00,MIC,Test article,> 6.74,Visual,< 5.2,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COC(=O)CCCCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255573,,SPK-0255573-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 4.00,MIC,Test article,> 6.74,Visual,< 5.2,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COC(=O)CCCCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255573,,SPK-0255573-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.125,MIC,Test article,0.211,Visual,6.7,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COC(=O)CCCCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255572,,SPK-0255572-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,1.00,MIC,Test article,1.77,Visual,5.8,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N[C@@H]1CO[C@@H]1COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255572,,SPK-0255572-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,8.00,MIC,Test article,14.2,Visual,4.8,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N[C@@H]1CO[C@@H]1COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255572,,SPK-0255572-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,32.0,MIC,Test article,56.7,Visual,4.2,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N[C@@H]1CO[C@@H]1COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255572,,SPK-0255572-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0310,MIC,Test article,0.0549,Visual,7.3,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N[C@@H]1CO[C@@H]1COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255572,,SPK-0255572-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 113,Visual,< 3.9,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N[C@@H]1CO[C@@H]1COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255572,,SPK-0255572-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 113,Visual,< 3.9,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N[C@@H]1CO[C@@H]1COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255572,,SPK-0255572-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 113,Visual,< 3.9,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N[C@@H]1CO[C@@H]1COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255572,,SPK-0255572-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.250,MIC,Test article,0.443,Visual,6.4,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N[C@@H]1CO[C@@H]1COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255571,,SPK-0255571-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,8.00,MIC,Test article,13.3,Visual,4.9,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CCOC(=O)CCCOc1ccc2ncc(C#N)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255571,,SPK-0255571-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,16.0,MIC,Test article,26.6,Visual,4.6,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CCOC(=O)CCCOc1ccc2ncc(C#N)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255571,,SPK-0255571-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 26.6,Visual,< 4.6,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CCOC(=O)CCCOc1ccc2ncc(C#N)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255571,,SPK-0255571-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0310,MIC,Test article,0.0516,Visual,7.3,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CCOC(=O)CCCOc1ccc2ncc(C#N)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255571,,SPK-0255571-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 26.6,Visual,< 4.6,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CCOC(=O)CCCOc1ccc2ncc(C#N)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255571,,SPK-0255571-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 26.6,Visual,< 4.6,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CCOC(=O)CCCOc1ccc2ncc(C#N)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255571,,SPK-0255571-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 26.6,Visual,< 4.6,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CCOC(=O)CCCOc1ccc2ncc(C#N)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255571,,SPK-0255571-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0630,MIC,Test article,0.105,Visual,7.0,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CCOC(=O)CCCOc1ccc2ncc(C#N)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255570,,SPK-0255570-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,2.00,MIC,Test article,3.66,Visual,5.4,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N#CCCCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255570,,SPK-0255570-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,4.00,MIC,Test article,7.32,Visual,5.1,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N#CCCCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255570,,SPK-0255570-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,16.0,MIC,Test article,29.3,Visual,4.5,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N#CCCCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255570,,SPK-0255570-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0160,MIC,Test article,0.0293,Visual,7.5,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N#CCCCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255570,,SPK-0255570-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 29.3,Visual,< 4.5,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N#CCCCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255570,,SPK-0255570-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 29.3,Visual,< 4.5,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N#CCCCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255570,,SPK-0255570-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 29.3,Visual,< 4.5,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N#CCCCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255570,,SPK-0255570-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0630,MIC,Test article,0.115,Visual,6.9,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N#CCCCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255569,,SPK-0255569-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.250,MIC,Test article,0.456,Visual,6.3,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,NC1CC1COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255569,,SPK-0255569-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,2.00,MIC,Test article,3.65,Visual,5.4,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,NC1CC1COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255569,,SPK-0255569-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,16.0,MIC,Test article,29.2,Visual,4.5,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,NC1CC1COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255569,,SPK-0255569-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0310,MIC,Test article,0.0565,Visual,7.2,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,NC1CC1COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255569,,SPK-0255569-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 29.2,Visual,< 4.5,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,NC1CC1COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255569,,SPK-0255569-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 29.2,Visual,< 4.5,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,NC1CC1COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255569,,SPK-0255569-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 29.2,Visual,< 4.5,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,NC1CC1COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255569,,SPK-0255569-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.250,MIC,Test article,0.456,Visual,6.3,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,NC1CC1COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255568,,SPK-0255568-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 29.6,Visual,< 4.5,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6nccnc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255568,,SPK-0255568-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 29.6,Visual,< 4.5,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6nccnc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255568,,SPK-0255568-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 29.6,Visual,< 4.5,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6nccnc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255568,,SPK-0255568-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.500,MIC,Test article,0.924,Visual,6.0,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6nccnc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255568,,SPK-0255568-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 29.6,Visual,< 4.5,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6nccnc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255568,,SPK-0255568-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 29.6,Visual,< 4.5,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6nccnc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255568,,SPK-0255568-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 29.6,Visual,< 4.5,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6nccnc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255568,,SPK-0255568-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,2.00,MIC,Test article,3.70,Visual,5.4,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6nccnc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255567,,SPK-0255567-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,2.00,MIC,Test article,3.37,Visual,5.5,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CCOC(=O)CCCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255567,,SPK-0255567-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,8.00,MIC,Test article,13.5,Visual,4.9,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CCOC(=O)CCCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255567,,SPK-0255567-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 13.5,Visual,< 4.9,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CCOC(=O)CCCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255567,,SPK-0255567-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0310,MIC,Test article,0.0522,Visual,7.3,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CCOC(=O)CCCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255567,,SPK-0255567-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 13.5,Visual,< 4.9,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CCOC(=O)CCCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255567,,SPK-0255567-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 13.5,Visual,< 4.9,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CCOC(=O)CCCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255567,,SPK-0255567-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 13.5,Visual,< 4.9,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CCOC(=O)CCCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255567,,SPK-0255567-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0630,MIC,Test article,0.106,Visual,7.0,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CCOC(=O)CCCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255566,,SPK-0255566-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,1.00,MIC,Test article,1.77,Visual,5.8,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N[C@@H]1CO[C@H]1COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255566,,SPK-0255566-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,4.00,MIC,Test article,7.08,Visual,5.1,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N[C@@H]1CO[C@H]1COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255566,,SPK-0255566-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,16.0,MIC,Test article,28.3,Visual,4.5,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N[C@@H]1CO[C@H]1COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255566,,SPK-0255566-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0160,MIC,Test article,0.0283,Visual,7.5,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N[C@@H]1CO[C@H]1COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255566,,SPK-0255566-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,128,MIC,Test article,227,Visual,3.6,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N[C@@H]1CO[C@H]1COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255566,,SPK-0255566-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,64.0,MIC,Test article,113,Visual,3.9,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N[C@@H]1CO[C@H]1COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255566,,SPK-0255566-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,128,MIC,Test article,227,Visual,3.6,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N[C@@H]1CO[C@H]1COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255566,,SPK-0255566-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.500,MIC,Test article,0.886,Visual,6.1,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N[C@@H]1CO[C@H]1COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255564,,SPK-0255564-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 27.7,Visual,< 4.6,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N[C@@H]1C(=O)NC[C@H]1Oc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255564,,SPK-0255564-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 27.7,Visual,< 4.6,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N[C@@H]1C(=O)NC[C@H]1Oc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255564,,SPK-0255564-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 27.7,Visual,< 4.6,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N[C@@H]1C(=O)NC[C@H]1Oc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255564,,SPK-0255564-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,4.00,MIC,Test article,6.93,Visual,5.2,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N[C@@H]1C(=O)NC[C@H]1Oc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255564,,SPK-0255564-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 27.7,Visual,< 4.6,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N[C@@H]1C(=O)NC[C@H]1Oc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255564,,SPK-0255564-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 27.7,Visual,< 4.6,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N[C@@H]1C(=O)NC[C@H]1Oc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255564,,SPK-0255564-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 27.7,Visual,< 4.6,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N[C@@H]1C(=O)NC[C@H]1Oc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255564,,SPK-0255564-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,,MIC,Test article,,Visual,,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N[C@@H]1C(=O)NC[C@H]1Oc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255563,,SPK-0255563-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,1.00,MIC,Test article,1.77,Visual,5.8,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N[C@H]1COC[C@@H]1Oc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255563,,SPK-0255563-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,4.00,MIC,Test article,7.08,Visual,5.1,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N[C@H]1COC[C@@H]1Oc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255563,,SPK-0255563-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,16.0,MIC,Test article,28.3,Visual,4.5,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N[C@H]1COC[C@@H]1Oc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255563,,SPK-0255563-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0160,MIC,Test article,0.0283,Visual,7.5,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N[C@H]1COC[C@@H]1Oc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255563,,SPK-0255563-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 113,Visual,< 3.9,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N[C@H]1COC[C@@H]1Oc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255563,,SPK-0255563-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,64.0,MIC,Test article,113,Visual,3.9,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N[C@H]1COC[C@@H]1Oc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255563,,SPK-0255563-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,64.0,MIC,Test article,113,Visual,3.9,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N[C@H]1COC[C@@H]1Oc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255563,,SPK-0255563-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,,MIC,Test article,,Visual,,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N[C@H]1COC[C@@H]1Oc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255562,,SPK-0255562-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 2.00,MIC,Test article,> 3.72,Visual,< 5.4,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6cccc(Cl)c6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255562,,SPK-0255562-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 2.00,MIC,Test article,> 3.72,Visual,< 5.4,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6cccc(Cl)c6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255562,,SPK-0255562-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 2.00,MIC,Test article,> 3.72,Visual,< 5.4,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6cccc(Cl)c6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255562,,SPK-0255562-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 2.00,MIC,Test article,> 3.72,Visual,< 5.4,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6cccc(Cl)c6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255562,,SPK-0255562-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 2.00,MIC,Test article,> 3.72,Visual,< 5.4,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6cccc(Cl)c6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255562,,SPK-0255562-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 2.00,MIC,Test article,> 3.72,Visual,< 5.4,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6cccc(Cl)c6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255562,,SPK-0255562-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 2.00,MIC,Test article,> 3.72,Visual,< 5.4,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6cccc(Cl)c6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255562,,SPK-0255562-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,,MIC,Test article,,Visual,,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6cccc(Cl)c6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255561,,SPK-0255561-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,8.00,MIC,Test article,15.1,Visual,4.8,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cnc6c(c5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255561,,SPK-0255561-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,8.00,MIC,Test article,15.1,Visual,4.8,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cnc6c(c5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255561,,SPK-0255561-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 30.2,Visual,< 4.5,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cnc6c(c5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255561,,SPK-0255561-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0310,MIC,Test article,0.0585,Visual,7.2,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cnc6c(c5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255561,,SPK-0255561-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 30.2,Visual,< 4.5,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cnc6c(c5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255561,,SPK-0255561-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 30.2,Visual,< 4.5,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cnc6c(c5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255561,,SPK-0255561-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 30.2,Visual,< 4.5,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cnc6c(c5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255561,,SPK-0255561-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,,MIC,Test article,,Visual,,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cnc6c(c5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255560,,SPK-0255560-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 51.9,Visual,< 4.3,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OCCc7cc(=O)c(O)c[nH]7)nc56)(CC3)OC4)nc2N1
SPK-0255560,,SPK-0255560-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 51.9,Visual,< 4.3,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OCCc7cc(=O)c(O)c[nH]7)nc56)(CC3)OC4)nc2N1
SPK-0255560,,SPK-0255560-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 51.9,Visual,< 4.3,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OCCc7cc(=O)c(O)c[nH]7)nc56)(CC3)OC4)nc2N1
SPK-0255560,,SPK-0255560-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,2.00,MIC,Test article,3.24,Visual,5.5,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OCCc7cc(=O)c(O)c[nH]7)nc56)(CC3)OC4)nc2N1
SPK-0255560,,SPK-0255560-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 51.9,Visual,< 4.3,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OCCc7cc(=O)c(O)c[nH]7)nc56)(CC3)OC4)nc2N1
SPK-0255560,,SPK-0255560-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 51.9,Visual,< 4.3,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OCCc7cc(=O)c(O)c[nH]7)nc56)(CC3)OC4)nc2N1
SPK-0255560,,SPK-0255560-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 51.9,Visual,< 4.3,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OCCc7cc(=O)c(O)c[nH]7)nc56)(CC3)OC4)nc2N1
SPK-0255560,,SPK-0255560-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,,MIC,Test article,,Visual,,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OCCc7cc(=O)c(O)c[nH]7)nc56)(CC3)OC4)nc2N1
SPK-0255559,,SPK-0255559-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,2.00,MIC,Test article,4.17,Visual,5.4,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(=O)[nH]c56)(CC3)OC4)nc2N1
SPK-0255559,,SPK-0255559-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,4.00,MIC,Test article,8.34,Visual,5.1,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(=O)[nH]c56)(CC3)OC4)nc2N1
SPK-0255559,,SPK-0255559-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,32.0,MIC,Test article,66.7,Visual,4.2,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(=O)[nH]c56)(CC3)OC4)nc2N1
SPK-0255559,,SPK-0255559-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0310,MIC,Test article,0.0646,Visual,7.2,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(=O)[nH]c56)(CC3)OC4)nc2N1
SPK-0255559,,SPK-0255559-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 66.7,Visual,< 4.2,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(=O)[nH]c56)(CC3)OC4)nc2N1
SPK-0255559,,SPK-0255559-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 66.7,Visual,< 4.2,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(=O)[nH]c56)(CC3)OC4)nc2N1
SPK-0255559,,SPK-0255559-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 66.7,Visual,< 4.2,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(=O)[nH]c56)(CC3)OC4)nc2N1
SPK-0255559,,SPK-0255559-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,,MIC,Test article,,Visual,,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(=O)[nH]c56)(CC3)OC4)nc2N1
SPK-0255557,,SPK-0255557-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 2.00,MIC,Test article,> 3.97,Visual,< 5.4,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6ncccc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255557,,SPK-0255557-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 2.00,MIC,Test article,> 3.97,Visual,< 5.4,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6ncccc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255557,,SPK-0255557-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 2.00,MIC,Test article,> 3.97,Visual,< 5.4,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6ncccc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255557,,SPK-0255557-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 2.00,MIC,Test article,> 3.97,Visual,< 5.4,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6ncccc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255557,,SPK-0255557-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 2.00,MIC,Test article,> 3.97,Visual,< 5.4,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6ncccc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255557,,SPK-0255557-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 2.00,MIC,Test article,> 3.97,Visual,< 5.4,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6ncccc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255557,,SPK-0255557-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 2.00,MIC,Test article,> 3.97,Visual,< 5.4,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6ncccc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255557,,SPK-0255557-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,,MIC,Test article,,Visual,,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6ncccc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255556,,SPK-0255556-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 26.6,Visual,< 4.6,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OCc7cc(=O)c(O)c[nH]7)nc56)(CC3)OC4)nc2N1
SPK-0255556,,SPK-0255556-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 26.6,Visual,< 4.6,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OCc7cc(=O)c(O)c[nH]7)nc56)(CC3)OC4)nc2N1
SPK-0255556,,SPK-0255556-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 26.6,Visual,< 4.6,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OCc7cc(=O)c(O)c[nH]7)nc56)(CC3)OC4)nc2N1
SPK-0255556,,SPK-0255556-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.500,MIC,Test article,0.830,Visual,6.1,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OCc7cc(=O)c(O)c[nH]7)nc56)(CC3)OC4)nc2N1
SPK-0255556,,SPK-0255556-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 26.6,Visual,< 4.6,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OCc7cc(=O)c(O)c[nH]7)nc56)(CC3)OC4)nc2N1
SPK-0255556,,SPK-0255556-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 26.6,Visual,< 4.6,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OCc7cc(=O)c(O)c[nH]7)nc56)(CC3)OC4)nc2N1
SPK-0255556,,SPK-0255556-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 26.6,Visual,< 4.6,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OCc7cc(=O)c(O)c[nH]7)nc56)(CC3)OC4)nc2N1
SPK-0255556,,SPK-0255556-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,16.0,MIC,Test article,26.6,Visual,4.6,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OCc7cc(=O)c(O)c[nH]7)nc56)(CC3)OC4)nc2N1
SPK-0255555,,SPK-0255555-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 60.4,Visual,< 4.2,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NS(=O)(=O)CO6)(CC3)CO4)c2n1
SPK-0255555,,SPK-0255555-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 60.4,Visual,< 4.2,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NS(=O)(=O)CO6)(CC3)CO4)c2n1
SPK-0255555,,SPK-0255555-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 60.4,Visual,< 4.2,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NS(=O)(=O)CO6)(CC3)CO4)c2n1
SPK-0255555,,SPK-0255555-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,2.00,MIC,Test article,3.78,Visual,5.4,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NS(=O)(=O)CO6)(CC3)CO4)c2n1
SPK-0255555,,SPK-0255555-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 60.4,Visual,< 4.2,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NS(=O)(=O)CO6)(CC3)CO4)c2n1
SPK-0255555,,SPK-0255555-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 60.4,Visual,< 4.2,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NS(=O)(=O)CO6)(CC3)CO4)c2n1
SPK-0255555,,SPK-0255555-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 60.4,Visual,< 4.2,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NS(=O)(=O)CO6)(CC3)CO4)c2n1
SPK-0255555,,SPK-0255555-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,4.00,MIC,Test article,7.55,Visual,5.1,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NS(=O)(=O)CO6)(CC3)CO4)c2n1
SPK-0255554,,SPK-0255554-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,32.0,MIC,Test article,51.2,Visual,4.3,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,NCC(O)COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255554,,SPK-0255554-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,8.00,MIC,Test article,12.8,Visual,4.9,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,NCC(O)COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255554,,SPK-0255554-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,16.0,MIC,Test article,25.6,Visual,4.6,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,NCC(O)COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255554,,SPK-0255554-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0630,MIC,Test article,0.101,Visual,7.0,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,NCC(O)COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255554,,SPK-0255554-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 51.2,Visual,< 4.3,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,NCC(O)COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255554,,SPK-0255554-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,32.0,MIC,Test article,51.2,Visual,4.3,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,NCC(O)COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255554,,SPK-0255554-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 51.2,Visual,< 4.3,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,NCC(O)COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255554,,SPK-0255554-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,4.00,MIC,Test article,6.39,Visual,5.2,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,NCC(O)COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255553,,SPK-0255553-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,32.0,MIC,Test article,50.8,Visual,4.3,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OC7CC(O)CC(O)C7)nc56)(CC3)OC4)nc2N1
SPK-0255553,,SPK-0255553-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,64.0,MIC,Test article,102,Visual,4.0,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OC7CC(O)CC(O)C7)nc56)(CC3)OC4)nc2N1
SPK-0255553,,SPK-0255553-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 102,Visual,< 4.0,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OC7CC(O)CC(O)C7)nc56)(CC3)OC4)nc2N1
SPK-0255553,,SPK-0255553-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.125,MIC,Test article,0.198,Visual,6.7,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OC7CC(O)CC(O)C7)nc56)(CC3)OC4)nc2N1
SPK-0255553,,SPK-0255553-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 102,Visual,< 4.0,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OC7CC(O)CC(O)C7)nc56)(CC3)OC4)nc2N1
SPK-0255553,,SPK-0255553-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 102,Visual,< 4.0,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OC7CC(O)CC(O)C7)nc56)(CC3)OC4)nc2N1
SPK-0255553,,SPK-0255553-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 102,Visual,< 4.0,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OC7CC(O)CC(O)C7)nc56)(CC3)OC4)nc2N1
SPK-0255553,,SPK-0255553-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,1.00,MIC,Test article,1.59,Visual,5.8,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OC7CC(O)CC(O)C7)nc56)(CC3)OC4)nc2N1
SPK-0255552,,SPK-0255552-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,8.00,MIC,Test article,13.5,Visual,4.9,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OC[C@H]7C[C@@H](O)[C@@H](O)C7)nc56)(CC3)OC4)nc2N1
SPK-0255552,,SPK-0255552-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 13.5,Visual,< 4.9,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OC[C@H]7C[C@@H](O)[C@@H](O)C7)nc56)(CC3)OC4)nc2N1
SPK-0255552,,SPK-0255552-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 13.5,Visual,< 4.9,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OC[C@H]7C[C@@H](O)[C@@H](O)C7)nc56)(CC3)OC4)nc2N1
SPK-0255552,,SPK-0255552-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0310,MIC,Test article,0.0522,Visual,7.3,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OC[C@H]7C[C@@H](O)[C@@H](O)C7)nc56)(CC3)OC4)nc2N1
SPK-0255552,,SPK-0255552-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 13.5,Visual,< 4.9,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OC[C@H]7C[C@@H](O)[C@@H](O)C7)nc56)(CC3)OC4)nc2N1
SPK-0255552,,SPK-0255552-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 13.5,Visual,< 4.9,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OC[C@H]7C[C@@H](O)[C@@H](O)C7)nc56)(CC3)OC4)nc2N1
SPK-0255552,,SPK-0255552-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 13.5,Visual,< 4.9,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OC[C@H]7C[C@@H](O)[C@@H](O)C7)nc56)(CC3)OC4)nc2N1
SPK-0255552,,SPK-0255552-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.125,MIC,Test article,0.211,Visual,6.7,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OC[C@H]7C[C@@H](O)[C@@H](O)C7)nc56)(CC3)OC4)nc2N1
SPK-0255551,,SPK-0255551-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,2.00,MIC,Test article,3.47,Visual,5.5,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(C(O)Cc5c(F)cnc6ccc(OCCO)nc56)(CC3)OC4)nc2N1
SPK-0255551,,SPK-0255551-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,8.00,MIC,Test article,13.9,Visual,4.9,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(C(O)Cc5c(F)cnc6ccc(OCCO)nc56)(CC3)OC4)nc2N1
SPK-0255551,,SPK-0255551-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,16.0,MIC,Test article,27.8,Visual,4.6,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(C(O)Cc5c(F)cnc6ccc(OCCO)nc56)(CC3)OC4)nc2N1
SPK-0255551,,SPK-0255551-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0160,MIC,Test article,0.0278,Visual,7.6,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(C(O)Cc5c(F)cnc6ccc(OCCO)nc56)(CC3)OC4)nc2N1
SPK-0255551,,SPK-0255551-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,128,MIC,Test article,222,Visual,3.7,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(C(O)Cc5c(F)cnc6ccc(OCCO)nc56)(CC3)OC4)nc2N1
SPK-0255551,,SPK-0255551-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,64.0,MIC,Test article,111,Visual,4.0,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(C(O)Cc5c(F)cnc6ccc(OCCO)nc56)(CC3)OC4)nc2N1
SPK-0255551,,SPK-0255551-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,128,MIC,Test article,222,Visual,3.7,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(C(O)Cc5c(F)cnc6ccc(OCCO)nc56)(CC3)OC4)nc2N1
SPK-0255551,,SPK-0255551-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.250,MIC,Test article,0.434,Visual,6.4,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(C(O)Cc5c(F)cnc6ccc(OCCO)nc56)(CC3)OC4)nc2N1
SPK-0255550,,SPK-0255550-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,2.00,MIC,Test article,3.76,Visual,5.4,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(O)C34CCC(NCc5ccc6c(c5)OCCO6)(CC3)CO4)c2n1
SPK-0255550,,SPK-0255550-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,16.0,MIC,Test article,30.1,Visual,4.5,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(O)C34CCC(NCc5ccc6c(c5)OCCO6)(CC3)CO4)c2n1
SPK-0255550,,SPK-0255550-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 120,Visual,< 3.9,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(O)C34CCC(NCc5ccc6c(c5)OCCO6)(CC3)CO4)c2n1
SPK-0255550,,SPK-0255550-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0310,MIC,Test article,0.0583,Visual,7.2,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(O)C34CCC(NCc5ccc6c(c5)OCCO6)(CC3)CO4)c2n1
SPK-0255550,,SPK-0255550-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 120,Visual,< 3.9,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(O)C34CCC(NCc5ccc6c(c5)OCCO6)(CC3)CO4)c2n1
SPK-0255550,,SPK-0255550-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 120,Visual,< 3.9,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(O)C34CCC(NCc5ccc6c(c5)OCCO6)(CC3)CO4)c2n1
SPK-0255550,,SPK-0255550-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 120,Visual,< 3.9,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(O)C34CCC(NCc5ccc6c(c5)OCCO6)(CC3)CO4)c2n1
SPK-0255550,,SPK-0255550-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0630,MIC,Test article,0.118,Visual,6.9,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(O)C34CCC(NCc5ccc6c(c5)OCCO6)(CC3)CO4)c2n1
SPK-0255549,,SPK-0255549-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 33.1,Visual,< 4.5,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(O)C34CCC(NC(=O)c5ccc(C)c(F)c5)(CC3)CO4)c2n1
SPK-0255549,,SPK-0255549-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 33.1,Visual,< 4.5,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(O)C34CCC(NC(=O)c5ccc(C)c(F)c5)(CC3)CO4)c2n1
SPK-0255549,,SPK-0255549-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 33.1,Visual,< 4.5,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(O)C34CCC(NC(=O)c5ccc(C)c(F)c5)(CC3)CO4)c2n1
SPK-0255549,,SPK-0255549-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.500,MIC,Test article,1.03,Visual,6.0,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(O)C34CCC(NC(=O)c5ccc(C)c(F)c5)(CC3)CO4)c2n1
SPK-0255549,,SPK-0255549-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 33.1,Visual,< 4.5,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(O)C34CCC(NC(=O)c5ccc(C)c(F)c5)(CC3)CO4)c2n1
SPK-0255549,,SPK-0255549-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 33.1,Visual,< 4.5,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(O)C34CCC(NC(=O)c5ccc(C)c(F)c5)(CC3)CO4)c2n1
SPK-0255549,,SPK-0255549-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 33.1,Visual,< 4.5,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(O)C34CCC(NC(=O)c5ccc(C)c(F)c5)(CC3)CO4)c2n1
SPK-0255549,,SPK-0255549-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.250,MIC,Test article,0.517,Visual,6.3,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(O)C34CCC(NC(=O)c5ccc(C)c(F)c5)(CC3)CO4)c2n1
SPK-0255548,,SPK-0255548-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,1.00,MIC,Test article,1.82,Visual,5.7,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1nc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c(F)cnc2cc1F
SPK-0255548,,SPK-0255548-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,4.00,MIC,Test article,7.30,Visual,5.1,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1nc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c(F)cnc2cc1F
SPK-0255548,,SPK-0255548-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,8.00,MIC,Test article,14.6,Visual,4.8,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1nc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c(F)cnc2cc1F
SPK-0255548,,SPK-0255548-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0160,MIC,Test article,0.0292,Visual,7.5,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1nc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c(F)cnc2cc1F
SPK-0255548,,SPK-0255548-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 14.6,Visual,< 4.8,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1nc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c(F)cnc2cc1F
SPK-0255548,,SPK-0255548-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 14.6,Visual,< 4.8,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1nc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c(F)cnc2cc1F
SPK-0255548,,SPK-0255548-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 14.6,Visual,< 4.8,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1nc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c(F)cnc2cc1F
SPK-0255548,,SPK-0255548-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0630,MIC,Test article,0.115,Visual,6.9,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1nc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c(F)cnc2cc1F
SPK-0255547,,SPK-0255547-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,16.0,MIC,Test article,26.6,Visual,4.6,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CC(C)(O)CCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255547,,SPK-0255547-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 26.6,Visual,< 4.6,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CC(C)(O)CCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255547,,SPK-0255547-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 26.6,Visual,< 4.6,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CC(C)(O)CCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255547,,SPK-0255547-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.250,MIC,Test article,0.415,Visual,6.4,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CC(C)(O)CCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255547,,SPK-0255547-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 26.6,Visual,< 4.6,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CC(C)(O)CCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255547,,SPK-0255547-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 26.6,Visual,< 4.6,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CC(C)(O)CCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255547,,SPK-0255547-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 26.6,Visual,< 4.6,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CC(C)(O)CCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255547,,SPK-0255547-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,2.00,MIC,Test article,3.32,Visual,5.5,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CC(C)(O)CCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255546,,SPK-0255546-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,64.0,MIC,Test article,121,Visual,3.9,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6c(nn5)OCC(=O)N6)(CC3)CO4)c2n1
SPK-0255546,,SPK-0255546-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 121,Visual,< 3.9,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6c(nn5)OCC(=O)N6)(CC3)CO4)c2n1
SPK-0255546,,SPK-0255546-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 121,Visual,< 3.9,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6c(nn5)OCC(=O)N6)(CC3)CO4)c2n1
SPK-0255546,,SPK-0255546-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,2.00,MIC,Test article,3.77,Visual,5.4,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6c(nn5)OCC(=O)N6)(CC3)CO4)c2n1
SPK-0255546,,SPK-0255546-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 121,Visual,< 3.9,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6c(nn5)OCC(=O)N6)(CC3)CO4)c2n1
SPK-0255546,,SPK-0255546-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 121,Visual,< 3.9,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6c(nn5)OCC(=O)N6)(CC3)CO4)c2n1
SPK-0255546,,SPK-0255546-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 121,Visual,< 3.9,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6c(nn5)OCC(=O)N6)(CC3)CO4)c2n1
SPK-0255546,,SPK-0255546-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,2.00,MIC,Test article,3.77,Visual,5.4,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6c(nn5)OCC(=O)N6)(CC3)CO4)c2n1
SPK-0255545,,SPK-0255545-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,4.00,MIC,Test article,7.59,Visual,5.1,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6ncc(=O)[nH]c6n5)(CC3)CO4)c2n1
SPK-0255545,,SPK-0255545-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,16.0,MIC,Test article,30.4,Visual,4.5,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6ncc(=O)[nH]c6n5)(CC3)CO4)c2n1
SPK-0255545,,SPK-0255545-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 30.4,Visual,< 4.5,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6ncc(=O)[nH]c6n5)(CC3)CO4)c2n1
SPK-0255545,,SPK-0255545-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.250,MIC,Test article,0.474,Visual,6.3,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6ncc(=O)[nH]c6n5)(CC3)CO4)c2n1
SPK-0255545,,SPK-0255545-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 30.4,Visual,< 4.5,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6ncc(=O)[nH]c6n5)(CC3)CO4)c2n1
SPK-0255545,,SPK-0255545-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 30.4,Visual,< 4.5,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6ncc(=O)[nH]c6n5)(CC3)CO4)c2n1
SPK-0255545,,SPK-0255545-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 30.4,Visual,< 4.5,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6ncc(=O)[nH]c6n5)(CC3)CO4)c2n1
SPK-0255545,,SPK-0255545-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.125,MIC,Test article,0.237,Visual,6.6,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6ncc(=O)[nH]c6n5)(CC3)CO4)c2n1
SPK-0255544,,SPK-0255544-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,8.00,MIC,Test article,15.2,Visual,4.8,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6[nH]c(=O)cnc6cn5)(CC3)CO4)c2n1
SPK-0255544,,SPK-0255544-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,64.0,MIC,Test article,121,Visual,3.9,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6[nH]c(=O)cnc6cn5)(CC3)CO4)c2n1
SPK-0255544,,SPK-0255544-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 121,Visual,< 3.9,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6[nH]c(=O)cnc6cn5)(CC3)CO4)c2n1
SPK-0255544,,SPK-0255544-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,2.00,MIC,Test article,3.80,Visual,5.4,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6[nH]c(=O)cnc6cn5)(CC3)CO4)c2n1
SPK-0255544,,SPK-0255544-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 121,Visual,< 3.9,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6[nH]c(=O)cnc6cn5)(CC3)CO4)c2n1
SPK-0255544,,SPK-0255544-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 121,Visual,< 3.9,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6[nH]c(=O)cnc6cn5)(CC3)CO4)c2n1
SPK-0255544,,SPK-0255544-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 121,Visual,< 3.9,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6[nH]c(=O)cnc6cn5)(CC3)CO4)c2n1
SPK-0255544,,SPK-0255544-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,1.00,MIC,Test article,1.90,Visual,5.7,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6[nH]c(=O)cnc6cn5)(CC3)CO4)c2n1
SPK-0255543,,SPK-0255543-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,16.0,MIC,Test article,27.2,Visual,4.6,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CC(O)CCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255543,,SPK-0255543-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 27.2,Visual,< 4.6,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CC(O)CCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255543,,SPK-0255543-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 27.2,Visual,< 4.6,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CC(O)CCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255543,,SPK-0255543-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.125,MIC,Test article,0.213,Visual,6.7,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CC(O)CCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255543,,SPK-0255543-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 27.2,Visual,< 4.6,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CC(O)CCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255543,,SPK-0255543-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 27.2,Visual,< 4.6,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CC(O)CCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255543,,SPK-0255543-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 27.2,Visual,< 4.6,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CC(O)CCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255543,,SPK-0255543-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.250,MIC,Test article,0.425,Visual,6.4,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CC(O)CCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255542,,SPK-0255542-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 60.8,Visual,< 4.2,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc3c(c2n1)CC(C12CCC(NCc4ccc5c(n4)NC(=O)CO5)(CC1)CO2)O3
SPK-0255542,,SPK-0255542-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 60.8,Visual,< 4.2,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc3c(c2n1)CC(C12CCC(NCc4ccc5c(n4)NC(=O)CO5)(CC1)CO2)O3
SPK-0255542,,SPK-0255542-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 60.8,Visual,< 4.2,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc3c(c2n1)CC(C12CCC(NCc4ccc5c(n4)NC(=O)CO5)(CC1)CO2)O3
SPK-0255542,,SPK-0255542-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,2.00,MIC,Test article,3.80,Visual,5.4,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc3c(c2n1)CC(C12CCC(NCc4ccc5c(n4)NC(=O)CO5)(CC1)CO2)O3
SPK-0255542,,SPK-0255542-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 60.8,Visual,< 4.2,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc3c(c2n1)CC(C12CCC(NCc4ccc5c(n4)NC(=O)CO5)(CC1)CO2)O3
SPK-0255542,,SPK-0255542-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 60.8,Visual,< 4.2,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc3c(c2n1)CC(C12CCC(NCc4ccc5c(n4)NC(=O)CO5)(CC1)CO2)O3
SPK-0255542,,SPK-0255542-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 60.8,Visual,< 4.2,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc3c(c2n1)CC(C12CCC(NCc4ccc5c(n4)NC(=O)CO5)(CC1)CO2)O3
SPK-0255542,,SPK-0255542-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,16.0,MIC,Test article,30.4,Visual,4.5,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc3c(c2n1)CC(C12CCC(NCc4ccc5c(n4)NC(=O)CO5)(CC1)CO2)O3
SPK-0255541,,SPK-0255541-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 118,Visual,< 3.9,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(O)C34CCC(NCc5cc6[nH]c(=O)cnc6cn5)(CC3)CO4)c2n1
SPK-0255541,,SPK-0255541-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 118,Visual,< 3.9,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(O)C34CCC(NCc5cc6[nH]c(=O)cnc6cn5)(CC3)CO4)c2n1
SPK-0255541,,SPK-0255541-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 118,Visual,< 3.9,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(O)C34CCC(NCc5cc6[nH]c(=O)cnc6cn5)(CC3)CO4)c2n1
SPK-0255541,,SPK-0255541-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,4.00,MIC,Test article,7.37,Visual,5.1,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(O)C34CCC(NCc5cc6[nH]c(=O)cnc6cn5)(CC3)CO4)c2n1
SPK-0255541,,SPK-0255541-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 118,Visual,< 3.9,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(O)C34CCC(NCc5cc6[nH]c(=O)cnc6cn5)(CC3)CO4)c2n1
SPK-0255541,,SPK-0255541-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 118,Visual,< 3.9,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(O)C34CCC(NCc5cc6[nH]c(=O)cnc6cn5)(CC3)CO4)c2n1
SPK-0255541,,SPK-0255541-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 118,Visual,< 3.9,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(O)C34CCC(NCc5cc6[nH]c(=O)cnc6cn5)(CC3)CO4)c2n1
SPK-0255541,,SPK-0255541-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,8.00,MIC,Test article,14.7,Visual,4.8,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(O)C34CCC(NCc5cc6[nH]c(=O)cnc6cn5)(CC3)CO4)c2n1
SPK-0255540,,SPK-0255540-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 4.00,MIC,Test article,> 7.41,Visual,< 5.1,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6cccnc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255540,,SPK-0255540-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 4.00,MIC,Test article,> 7.41,Visual,< 5.1,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6cccnc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255540,,SPK-0255540-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 4.00,MIC,Test article,> 7.41,Visual,< 5.1,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6cccnc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255540,,SPK-0255540-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.500,MIC,Test article,0.926,Visual,6.0,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6cccnc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255540,,SPK-0255540-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 4.00,MIC,Test article,> 7.41,Visual,< 5.1,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6cccnc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255540,,SPK-0255540-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 4.00,MIC,Test article,> 7.41,Visual,< 5.1,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6cccnc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255540,,SPK-0255540-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 4.00,MIC,Test article,> 7.41,Visual,< 5.1,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6cccnc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255540,,SPK-0255540-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,1.00,MIC,Test article,1.85,Visual,5.7,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6cccnc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255539,,SPK-0255539-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,2.00,MIC,Test article,3.54,Visual,5.5,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N[C@@H]1COC[C@H]1Oc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255539,,SPK-0255539-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,8.00,MIC,Test article,14.2,Visual,4.8,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N[C@@H]1COC[C@H]1Oc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255539,,SPK-0255539-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,32.0,MIC,Test article,56.7,Visual,4.2,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N[C@@H]1COC[C@H]1Oc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255539,,SPK-0255539-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0630,MIC,Test article,0.112,Visual,7.0,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N[C@@H]1COC[C@H]1Oc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255539,,SPK-0255539-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 56.7,Visual,< 4.2,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N[C@@H]1COC[C@H]1Oc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255539,,SPK-0255539-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 56.7,Visual,< 4.2,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N[C@@H]1COC[C@H]1Oc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255539,,SPK-0255539-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 56.7,Visual,< 4.2,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N[C@@H]1COC[C@H]1Oc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255539,,SPK-0255539-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.500,MIC,Test article,0.886,Visual,6.1,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N[C@@H]1COC[C@H]1Oc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255538,,SPK-0255538-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,1.00,MIC,Test article,1.77,Visual,5.8,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,NC1COCC1Oc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255538,,SPK-0255538-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,4.00,MIC,Test article,7.08,Visual,5.1,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,NC1COCC1Oc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255538,,SPK-0255538-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,16.0,MIC,Test article,28.3,Visual,4.5,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,NC1COCC1Oc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255538,,SPK-0255538-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0310,MIC,Test article,0.0549,Visual,7.3,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,NC1COCC1Oc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255538,,SPK-0255538-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 113,Visual,< 3.9,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,NC1COCC1Oc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255538,,SPK-0255538-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,64.0,MIC,Test article,113,Visual,3.9,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,NC1COCC1Oc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255538,,SPK-0255538-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,64.0,MIC,Test article,113,Visual,3.9,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,NC1COCC1Oc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255538,,SPK-0255538-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.500,MIC,Test article,0.886,Visual,6.1,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,NC1COCC1Oc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255537,,SPK-0255537-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,2.00,MIC,Test article,3.39,Visual,5.5,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(C(O)Cc5c(F)cnc6ccc(OCCCO)nc56)(CC3)OC4)nc2N1
SPK-0255537,,SPK-0255537-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,16.0,MIC,Test article,27.1,Visual,4.6,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(C(O)Cc5c(F)cnc6ccc(OCCCO)nc56)(CC3)OC4)nc2N1
SPK-0255537,,SPK-0255537-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 27.1,Visual,< 4.6,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(C(O)Cc5c(F)cnc6ccc(OCCCO)nc56)(CC3)OC4)nc2N1
SPK-0255537,,SPK-0255537-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0160,MIC,Test article,0.0271,Visual,7.6,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(C(O)Cc5c(F)cnc6ccc(OCCCO)nc56)(CC3)OC4)nc2N1
SPK-0255537,,SPK-0255537-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 27.1,Visual,< 4.6,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(C(O)Cc5c(F)cnc6ccc(OCCCO)nc56)(CC3)OC4)nc2N1
SPK-0255537,,SPK-0255537-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 27.1,Visual,< 4.6,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(C(O)Cc5c(F)cnc6ccc(OCCCO)nc56)(CC3)OC4)nc2N1
SPK-0255537,,SPK-0255537-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 27.1,Visual,< 4.6,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(C(O)Cc5c(F)cnc6ccc(OCCCO)nc56)(CC3)OC4)nc2N1
SPK-0255537,,SPK-0255537-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.250,MIC,Test article,0.424,Visual,6.4,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(C(O)Cc5c(F)cnc6ccc(OCCCO)nc56)(CC3)OC4)nc2N1
SPK-0255536,,SPK-0255536-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,2.00,MIC,Test article,3.60,Visual,5.4,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,C=CCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255536,,SPK-0255536-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,8.00,MIC,Test article,14.4,Visual,4.8,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,C=CCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255536,,SPK-0255536-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 28.8,Visual,< 4.5,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,C=CCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255536,,SPK-0255536-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0310,MIC,Test article,0.0558,Visual,7.3,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,C=CCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255536,,SPK-0255536-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 28.8,Visual,< 4.5,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,C=CCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255536,,SPK-0255536-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 28.8,Visual,< 4.5,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,C=CCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255536,,SPK-0255536-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 28.8,Visual,< 4.5,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,C=CCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255536,,SPK-0255536-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.125,MIC,Test article,0.225,Visual,6.6,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,C=CCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255535,,SPK-0255535-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,8.00,MIC,Test article,13.4,Visual,4.9,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OCC(F)(F)F)nc56)(CC3)OC4)nc2N1
SPK-0255535,,SPK-0255535-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,16.0,MIC,Test article,26.8,Visual,4.6,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OCC(F)(F)F)nc56)(CC3)OC4)nc2N1
SPK-0255535,,SPK-0255535-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 26.8,Visual,< 4.6,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OCC(F)(F)F)nc56)(CC3)OC4)nc2N1
SPK-0255535,,SPK-0255535-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0630,MIC,Test article,0.105,Visual,7.0,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OCC(F)(F)F)nc56)(CC3)OC4)nc2N1
SPK-0255535,,SPK-0255535-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 26.8,Visual,< 4.6,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OCC(F)(F)F)nc56)(CC3)OC4)nc2N1
SPK-0255535,,SPK-0255535-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 26.8,Visual,< 4.6,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OCC(F)(F)F)nc56)(CC3)OC4)nc2N1
SPK-0255535,,SPK-0255535-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 26.8,Visual,< 4.6,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OCC(F)(F)F)nc56)(CC3)OC4)nc2N1
SPK-0255535,,SPK-0255535-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.125,MIC,Test article,0.209,Visual,6.7,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OCC(F)(F)F)nc56)(CC3)OC4)nc2N1
SPK-0255534,,SPK-0255534-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,2.00,MIC,Test article,3.48,Visual,5.5,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CC(O)COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255534,,SPK-0255534-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,16.0,MIC,Test article,27.9,Visual,4.6,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CC(O)COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255534,,SPK-0255534-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 27.9,Visual,< 4.6,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CC(O)COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255534,,SPK-0255534-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0310,MIC,Test article,0.0540,Visual,7.3,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CC(O)COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255534,,SPK-0255534-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 27.9,Visual,< 4.6,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CC(O)COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255534,,SPK-0255534-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 27.9,Visual,< 4.6,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CC(O)COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255534,,SPK-0255534-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 27.9,Visual,< 4.6,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CC(O)COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255534,,SPK-0255534-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.125,MIC,Test article,0.218,Visual,6.7,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CC(O)COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255533,,SPK-0255533-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 31.3,Visual,< 4.5,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6ccccc6n5C)(CC3)CO4)c2n1
SPK-0255533,,SPK-0255533-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 31.3,Visual,< 4.5,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6ccccc6n5C)(CC3)CO4)c2n1
SPK-0255533,,SPK-0255533-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 31.3,Visual,< 4.5,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6ccccc6n5C)(CC3)CO4)c2n1
SPK-0255533,,SPK-0255533-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 31.3,Visual,< 4.5,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6ccccc6n5C)(CC3)CO4)c2n1
SPK-0255533,,SPK-0255533-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 31.3,Visual,< 4.5,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6ccccc6n5C)(CC3)CO4)c2n1
SPK-0255533,,SPK-0255533-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 31.3,Visual,< 4.5,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6ccccc6n5C)(CC3)CO4)c2n1
SPK-0255533,,SPK-0255533-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 31.3,Visual,< 4.5,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6ccccc6n5C)(CC3)CO4)c2n1
SPK-0255533,,SPK-0255533-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,2.00,MIC,Test article,3.91,Visual,5.4,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6ccccc6n5C)(CC3)CO4)c2n1
SPK-0255532,,SPK-0255532-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 64.4,Visual,< 4.2,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6ccccc6[nH]5)(CC3)CO4)c2n1
SPK-0255532,,SPK-0255532-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 64.4,Visual,< 4.2,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6ccccc6[nH]5)(CC3)CO4)c2n1
SPK-0255532,,SPK-0255532-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 64.4,Visual,< 4.2,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6ccccc6[nH]5)(CC3)CO4)c2n1
SPK-0255532,,SPK-0255532-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,8.00,MIC,Test article,16.1,Visual,4.8,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6ccccc6[nH]5)(CC3)CO4)c2n1
SPK-0255532,,SPK-0255532-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 64.4,Visual,< 4.2,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6ccccc6[nH]5)(CC3)CO4)c2n1
SPK-0255532,,SPK-0255532-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 64.4,Visual,< 4.2,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6ccccc6[nH]5)(CC3)CO4)c2n1
SPK-0255532,,SPK-0255532-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 64.4,Visual,< 4.2,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6ccccc6[nH]5)(CC3)CO4)c2n1
SPK-0255532,,SPK-0255532-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,1.00,MIC,Test article,2.01,Visual,5.7,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6ccccc6[nH]5)(CC3)CO4)c2n1
SPK-0255531,,SPK-0255531-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,4.00,MIC,Test article,6.78,Visual,5.2,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OCC(O)CO)nc56)(CC3)OC4)nc2N1
SPK-0255531,,SPK-0255531-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,16.0,MIC,Test article,27.1,Visual,4.6,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OCC(O)CO)nc56)(CC3)OC4)nc2N1
SPK-0255531,,SPK-0255531-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,32.0,MIC,Test article,54.2,Visual,4.3,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OCC(O)CO)nc56)(CC3)OC4)nc2N1
SPK-0255531,,SPK-0255531-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0310,MIC,Test article,0.0525,Visual,7.3,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OCC(O)CO)nc56)(CC3)OC4)nc2N1
SPK-0255531,,SPK-0255531-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 54.2,Visual,< 4.3,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OCC(O)CO)nc56)(CC3)OC4)nc2N1
SPK-0255531,,SPK-0255531-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 54.2,Visual,< 4.3,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OCC(O)CO)nc56)(CC3)OC4)nc2N1
SPK-0255531,,SPK-0255531-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 54.2,Visual,< 4.3,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OCC(O)CO)nc56)(CC3)OC4)nc2N1
SPK-0255531,,SPK-0255531-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.500,MIC,Test article,0.847,Visual,6.1,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OCC(O)CO)nc56)(CC3)OC4)nc2N1
SPK-0255530,,SPK-0255530-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,16.0,MIC,Test article,30.8,Visual,4.5,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6c(cn5)OCS6)(CC3)CO4)c2n1
SPK-0255530,,SPK-0255530-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 61.7,Visual,< 4.2,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6c(cn5)OCS6)(CC3)CO4)c2n1
SPK-0255530,,SPK-0255530-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 61.7,Visual,< 4.2,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6c(cn5)OCS6)(CC3)CO4)c2n1
SPK-0255530,,SPK-0255530-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.250,MIC,Test article,0.482,Visual,6.3,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6c(cn5)OCS6)(CC3)CO4)c2n1
SPK-0255530,,SPK-0255530-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 61.7,Visual,< 4.2,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6c(cn5)OCS6)(CC3)CO4)c2n1
SPK-0255530,,SPK-0255530-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 61.7,Visual,< 4.2,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6c(cn5)OCS6)(CC3)CO4)c2n1
SPK-0255530,,SPK-0255530-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 61.7,Visual,< 4.2,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6c(cn5)OCS6)(CC3)CO4)c2n1
SPK-0255530,,SPK-0255530-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.250,MIC,Test article,0.482,Visual,6.3,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6c(cn5)OCS6)(CC3)CO4)c2n1
SPK-0255529,,SPK-0255529-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,1.00,MIC,Test article,1.82,Visual,5.7,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,NC1(COc2ccc3ncc(F)c(CCC45CCC(NCc6ccc7c(n6)NC(=O)CO7)(CC4)CO5)c3n2)CC1
SPK-0255529,,SPK-0255529-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,2.00,MIC,Test article,3.65,Visual,5.4,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,NC1(COc2ccc3ncc(F)c(CCC45CCC(NCc6ccc7c(n6)NC(=O)CO7)(CC4)CO5)c3n2)CC1
SPK-0255529,,SPK-0255529-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,16.0,MIC,Test article,29.2,Visual,4.5,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,NC1(COc2ccc3ncc(F)c(CCC45CCC(NCc6ccc7c(n6)NC(=O)CO7)(CC4)CO5)c3n2)CC1
SPK-0255529,,SPK-0255529-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0310,MIC,Test article,0.0565,Visual,7.2,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,NC1(COc2ccc3ncc(F)c(CCC45CCC(NCc6ccc7c(n6)NC(=O)CO7)(CC4)CO5)c3n2)CC1
SPK-0255529,,SPK-0255529-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 29.2,Visual,< 4.5,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,NC1(COc2ccc3ncc(F)c(CCC45CCC(NCc6ccc7c(n6)NC(=O)CO7)(CC4)CO5)c3n2)CC1
SPK-0255529,,SPK-0255529-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 29.2,Visual,< 4.5,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,NC1(COc2ccc3ncc(F)c(CCC45CCC(NCc6ccc7c(n6)NC(=O)CO7)(CC4)CO5)c3n2)CC1
SPK-0255529,,SPK-0255529-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 29.2,Visual,< 4.5,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,NC1(COc2ccc3ncc(F)c(CCC45CCC(NCc6ccc7c(n6)NC(=O)CO7)(CC4)CO5)c3n2)CC1
SPK-0255529,,SPK-0255529-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.250,MIC,Test article,0.456,Visual,6.3,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,NC1(COc2ccc3ncc(F)c(CCC45CCC(NCc6ccc7c(n6)NC(=O)CO7)(CC4)CO5)c3n2)CC1
SPK-0255528,,SPK-0255528-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,2.00,MIC,Test article,4.04,Visual,5.4,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N#Cc1ccc2ncc(C#N)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255528,,SPK-0255528-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,8.00,MIC,Test article,16.1,Visual,4.8,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N#Cc1ccc2ncc(C#N)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255528,,SPK-0255528-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 32.3,Visual,< 4.5,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N#Cc1ccc2ncc(C#N)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255528,,SPK-0255528-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0310,MIC,Test article,0.0626,Visual,7.2,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N#Cc1ccc2ncc(C#N)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255528,,SPK-0255528-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 32.3,Visual,< 4.5,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N#Cc1ccc2ncc(C#N)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255528,,SPK-0255528-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 32.3,Visual,< 4.5,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N#Cc1ccc2ncc(C#N)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255528,,SPK-0255528-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 32.3,Visual,< 4.5,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N#Cc1ccc2ncc(C#N)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255528,,SPK-0255528-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.250,MIC,Test article,0.504,Visual,6.3,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N#Cc1ccc2ncc(C#N)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255527,,SPK-0255527-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,8.00,MIC,Test article,14.0,Visual,4.9,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OC7CCC7)nc56)(CC3)OC4)nc2N1
SPK-0255527,,SPK-0255527-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,64.0,MIC,Test article,112,Visual,3.9,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OC7CCC7)nc56)(CC3)OC4)nc2N1
SPK-0255527,,SPK-0255527-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 112,Visual,< 3.9,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OC7CCC7)nc56)(CC3)OC4)nc2N1
SPK-0255527,,SPK-0255527-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.125,MIC,Test article,0.219,Visual,6.7,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OC7CCC7)nc56)(CC3)OC4)nc2N1
SPK-0255527,,SPK-0255527-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 112,Visual,< 3.9,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OC7CCC7)nc56)(CC3)OC4)nc2N1
SPK-0255527,,SPK-0255527-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 112,Visual,< 3.9,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OC7CCC7)nc56)(CC3)OC4)nc2N1
SPK-0255527,,SPK-0255527-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 112,Visual,< 3.9,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OC7CCC7)nc56)(CC3)OC4)nc2N1
SPK-0255527,,SPK-0255527-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.250,MIC,Test article,0.439,Visual,6.4,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OC7CCC7)nc56)(CC3)OC4)nc2N1
SPK-0255526,,SPK-0255526-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,16.0,MIC,Test article,26.5,Visual,4.6,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OCCOCCO)nc56)(CC3)OC4)nc2N1
SPK-0255526,,SPK-0255526-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,32.0,MIC,Test article,53.0,Visual,4.3,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OCCOCCO)nc56)(CC3)OC4)nc2N1
SPK-0255526,,SPK-0255526-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 53.0,Visual,< 4.3,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OCCOCCO)nc56)(CC3)OC4)nc2N1
SPK-0255526,,SPK-0255526-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0630,MIC,Test article,0.104,Visual,7.0,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OCCOCCO)nc56)(CC3)OC4)nc2N1
SPK-0255526,,SPK-0255526-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 53.0,Visual,< 4.3,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OCCOCCO)nc56)(CC3)OC4)nc2N1
SPK-0255526,,SPK-0255526-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 53.0,Visual,< 4.3,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OCCOCCO)nc56)(CC3)OC4)nc2N1
SPK-0255526,,SPK-0255526-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 53.0,Visual,< 4.3,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OCCOCCO)nc56)(CC3)OC4)nc2N1
SPK-0255526,,SPK-0255526-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.500,MIC,Test article,0.828,Visual,6.1,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OCCOCCO)nc56)(CC3)OC4)nc2N1
SPK-0255525,,SPK-0255525-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,2.00,MIC,Test article,3.68,Visual,5.4,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255525,,SPK-0255525-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,4.00,MIC,Test article,7.35,Visual,5.1,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255525,,SPK-0255525-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 14.7,Visual,< 4.8,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255525,,SPK-0255525-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0160,MIC,Test article,0.0294,Visual,7.5,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255525,,SPK-0255525-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 14.7,Visual,< 4.8,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255525,,SPK-0255525-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 14.7,Visual,< 4.8,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255525,,SPK-0255525-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 14.7,Visual,< 4.8,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255525,,SPK-0255525-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0630,MIC,Test article,0.116,Visual,6.9,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255524,,SPK-0255524-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,8.00,MIC,Test article,14.3,Visual,4.8,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CC(C)Oc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255524,,SPK-0255524-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,16.0,MIC,Test article,28.7,Visual,4.5,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CC(C)Oc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255524,,SPK-0255524-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,32.0,MIC,Test article,57.3,Visual,4.2,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CC(C)Oc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255524,,SPK-0255524-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0630,MIC,Test article,0.113,Visual,6.9,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CC(C)Oc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255524,,SPK-0255524-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 57.3,Visual,< 4.2,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CC(C)Oc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255524,,SPK-0255524-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 57.3,Visual,< 4.2,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CC(C)Oc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255524,,SPK-0255524-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 57.3,Visual,< 4.2,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CC(C)Oc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255524,,SPK-0255524-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.250,MIC,Test article,0.448,Visual,6.3,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CC(C)Oc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255523,,SPK-0255523-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,8.00,MIC,Test article,13.5,Visual,4.9,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OC[C@@H]7C[C@@H](O)[C@@H](O)C7)nc56)(CC3)OC4)nc2N1
SPK-0255523,,SPK-0255523-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,16.0,MIC,Test article,27.0,Visual,4.6,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OC[C@@H]7C[C@@H](O)[C@@H](O)C7)nc56)(CC3)OC4)nc2N1
SPK-0255523,,SPK-0255523-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 53.9,Visual,< 4.3,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OC[C@@H]7C[C@@H](O)[C@@H](O)C7)nc56)(CC3)OC4)nc2N1
SPK-0255523,,SPK-0255523-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0630,MIC,Test article,0.106,Visual,7.0,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OC[C@@H]7C[C@@H](O)[C@@H](O)C7)nc56)(CC3)OC4)nc2N1
SPK-0255523,,SPK-0255523-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 53.9,Visual,< 4.3,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OC[C@@H]7C[C@@H](O)[C@@H](O)C7)nc56)(CC3)OC4)nc2N1
SPK-0255523,,SPK-0255523-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 53.9,Visual,< 4.3,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OC[C@@H]7C[C@@H](O)[C@@H](O)C7)nc56)(CC3)OC4)nc2N1
SPK-0255523,,SPK-0255523-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 53.9,Visual,< 4.3,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OC[C@@H]7C[C@@H](O)[C@@H](O)C7)nc56)(CC3)OC4)nc2N1
SPK-0255523,,SPK-0255523-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.250,MIC,Test article,0.421,Visual,6.4,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OC[C@@H]7C[C@@H](O)[C@@H](O)C7)nc56)(CC3)OC4)nc2N1
SPK-0255522,,SPK-0255522-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,4.00,MIC,Test article,7.34,Visual,5.1,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N#Cc1cnc2ccc(OCCCO)nc2c1CCC12CCC(NCc3ccc4c(n3)NC(=O)CO4)(CC1)CO2
SPK-0255522,,SPK-0255522-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,8.00,MIC,Test article,14.7,Visual,4.8,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N#Cc1cnc2ccc(OCCCO)nc2c1CCC12CCC(NCc3ccc4c(n3)NC(=O)CO4)(CC1)CO2
SPK-0255522,,SPK-0255522-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,16.0,MIC,Test article,29.4,Visual,4.5,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N#Cc1cnc2ccc(OCCCO)nc2c1CCC12CCC(NCc3ccc4c(n3)NC(=O)CO4)(CC1)CO2
SPK-0255522,,SPK-0255522-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,8.00E-03,MIC,Test article,0.0147,Visual,7.8,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N#Cc1cnc2ccc(OCCCO)nc2c1CCC12CCC(NCc3ccc4c(n3)NC(=O)CO4)(CC1)CO2
SPK-0255522,,SPK-0255522-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 29.4,Visual,< 4.5,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N#Cc1cnc2ccc(OCCCO)nc2c1CCC12CCC(NCc3ccc4c(n3)NC(=O)CO4)(CC1)CO2
SPK-0255522,,SPK-0255522-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 29.4,Visual,< 4.5,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N#Cc1cnc2ccc(OCCCO)nc2c1CCC12CCC(NCc3ccc4c(n3)NC(=O)CO4)(CC1)CO2
SPK-0255522,,SPK-0255522-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 29.4,Visual,< 4.5,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N#Cc1cnc2ccc(OCCCO)nc2c1CCC12CCC(NCc3ccc4c(n3)NC(=O)CO4)(CC1)CO2
SPK-0255522,,SPK-0255522-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.125,MIC,Test article,0.230,Visual,6.6,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N#Cc1cnc2ccc(OCCCO)nc2c1CCC12CCC(NCc3ccc4c(n3)NC(=O)CO4)(CC1)CO2
SPK-0255521,,SPK-0255521-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,2.00,MIC,Test article,3.77,Visual,5.4,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N#Cc1cnc2ccc(OCCO)nc2c1CCC12CCC(NCc3ccc4c(n3)NC(=O)CO4)(CC1)CO2
SPK-0255521,,SPK-0255521-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,4.00,MIC,Test article,7.54,Visual,5.1,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N#Cc1cnc2ccc(OCCO)nc2c1CCC12CCC(NCc3ccc4c(n3)NC(=O)CO4)(CC1)CO2
SPK-0255521,,SPK-0255521-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,16.0,MIC,Test article,30.2,Visual,4.5,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N#Cc1cnc2ccc(OCCO)nc2c1CCC12CCC(NCc3ccc4c(n3)NC(=O)CO4)(CC1)CO2
SPK-0255521,,SPK-0255521-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0160,MIC,Test article,0.0302,Visual,7.5,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N#Cc1cnc2ccc(OCCO)nc2c1CCC12CCC(NCc3ccc4c(n3)NC(=O)CO4)(CC1)CO2
SPK-0255521,,SPK-0255521-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 30.2,Visual,< 4.5,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N#Cc1cnc2ccc(OCCO)nc2c1CCC12CCC(NCc3ccc4c(n3)NC(=O)CO4)(CC1)CO2
SPK-0255521,,SPK-0255521-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 30.2,Visual,< 4.5,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N#Cc1cnc2ccc(OCCO)nc2c1CCC12CCC(NCc3ccc4c(n3)NC(=O)CO4)(CC1)CO2
SPK-0255521,,SPK-0255521-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 30.2,Visual,< 4.5,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N#Cc1cnc2ccc(OCCO)nc2c1CCC12CCC(NCc3ccc4c(n3)NC(=O)CO4)(CC1)CO2
SPK-0255521,,SPK-0255521-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.125,MIC,Test article,0.236,Visual,6.6,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N#Cc1cnc2ccc(OCCO)nc2c1CCC12CCC(NCc3ccc4c(n3)NC(=O)CO4)(CC1)CO2
SPK-0255519,,SPK-0255519-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 14.8,Visual,< 4.8,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1cc(CCC23CCC(NCc4ccc5c(n4)NC(=O)CO5)(CC2)CO3)c2nc(OC)ccc2n1
SPK-0255519,,SPK-0255519-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 14.8,Visual,< 4.8,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1cc(CCC23CCC(NCc4ccc5c(n4)NC(=O)CO5)(CC2)CO3)c2nc(OC)ccc2n1
SPK-0255519,,SPK-0255519-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 14.8,Visual,< 4.8,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1cc(CCC23CCC(NCc4ccc5c(n4)NC(=O)CO5)(CC2)CO3)c2nc(OC)ccc2n1
SPK-0255519,,SPK-0255519-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,1.00,MIC,Test article,1.84,Visual,5.7,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1cc(CCC23CCC(NCc4ccc5c(n4)NC(=O)CO5)(CC2)CO3)c2nc(OC)ccc2n1
SPK-0255519,,SPK-0255519-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 14.8,Visual,< 4.8,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1cc(CCC23CCC(NCc4ccc5c(n4)NC(=O)CO5)(CC2)CO3)c2nc(OC)ccc2n1
SPK-0255519,,SPK-0255519-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 14.8,Visual,< 4.8,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1cc(CCC23CCC(NCc4ccc5c(n4)NC(=O)CO5)(CC2)CO3)c2nc(OC)ccc2n1
SPK-0255519,,SPK-0255519-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 14.8,Visual,< 4.8,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1cc(CCC23CCC(NCc4ccc5c(n4)NC(=O)CO5)(CC2)CO3)c2nc(OC)ccc2n1
SPK-0255519,,SPK-0255519-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,4.00,MIC,Test article,7.38,Visual,5.1,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1cc(CCC23CCC(NCc4ccc5c(n4)NC(=O)CO5)(CC2)CO3)c2nc(OC)ccc2n1
SPK-0255518,,SPK-0255518-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 54.5,Visual,< 4.3,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(NC(C)=O)C34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255518,,SPK-0255518-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 54.5,Visual,< 4.3,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(NC(C)=O)C34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255518,,SPK-0255518-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 54.5,Visual,< 4.3,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(NC(C)=O)C34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255518,,SPK-0255518-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.500,MIC,Test article,0.852,Visual,6.1,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(NC(C)=O)C34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255518,,SPK-0255518-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 54.5,Visual,< 4.3,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(NC(C)=O)C34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255518,,SPK-0255518-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 54.5,Visual,< 4.3,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(NC(C)=O)C34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255518,,SPK-0255518-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 54.5,Visual,< 4.3,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(NC(C)=O)C34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255518,,SPK-0255518-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,4.00,MIC,Test article,6.81,Visual,5.2,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(NC(C)=O)C34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255516,,SPK-0255516-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 14.8,Visual,< 4.8,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5nc6cccnc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255516,,SPK-0255516-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 14.8,Visual,< 4.8,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5nc6cccnc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255516,,SPK-0255516-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 14.8,Visual,< 4.8,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5nc6cccnc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255516,,SPK-0255516-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 14.8,Visual,< 4.8,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5nc6cccnc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255516,,SPK-0255516-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 14.8,Visual,< 4.8,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5nc6cccnc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255516,,SPK-0255516-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 14.8,Visual,< 4.8,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5nc6cccnc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255516,,SPK-0255516-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 14.8,Visual,< 4.8,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5nc6cccnc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255516,,SPK-0255516-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 14.8,Visual,< 4.8,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5nc6cccnc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255515,,SPK-0255515-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 59.6,Visual,< 4.2,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6c(Cl)cccc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255515,,SPK-0255515-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 59.6,Visual,< 4.2,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6c(Cl)cccc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255515,,SPK-0255515-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 59.6,Visual,< 4.2,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6c(Cl)cccc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255515,,SPK-0255515-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,2.00,MIC,Test article,3.72,Visual,5.4,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6c(Cl)cccc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255515,,SPK-0255515-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 59.6,Visual,< 4.2,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6c(Cl)cccc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255515,,SPK-0255515-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 59.6,Visual,< 4.2,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6c(Cl)cccc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255515,,SPK-0255515-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 59.6,Visual,< 4.2,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6c(Cl)cccc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255515,,SPK-0255515-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,1.00,MIC,Test article,1.86,Visual,5.7,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6c(Cl)cccc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255514,,SPK-0255514-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 66.7,Visual,< 4.2,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6oc(=O)[nH]c6n5)(CC3)CO4)c2n1
SPK-0255514,,SPK-0255514-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 66.7,Visual,< 4.2,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6oc(=O)[nH]c6n5)(CC3)CO4)c2n1
SPK-0255514,,SPK-0255514-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 66.7,Visual,< 4.2,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6oc(=O)[nH]c6n5)(CC3)CO4)c2n1
SPK-0255514,,SPK-0255514-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 66.7,Visual,< 4.2,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6oc(=O)[nH]c6n5)(CC3)CO4)c2n1
SPK-0255514,,SPK-0255514-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 66.7,Visual,< 4.2,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6oc(=O)[nH]c6n5)(CC3)CO4)c2n1
SPK-0255514,,SPK-0255514-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 66.7,Visual,< 4.2,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6oc(=O)[nH]c6n5)(CC3)CO4)c2n1
SPK-0255514,,SPK-0255514-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 66.7,Visual,< 4.2,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6oc(=O)[nH]c6n5)(CC3)CO4)c2n1
SPK-0255514,,SPK-0255514-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 66.7,Visual,< 4.2,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6oc(=O)[nH]c6n5)(CC3)CO4)c2n1
SPK-0255513,,SPK-0255513-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 30.0,Visual,< 4.5,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2cc(CNC34CCC(CCc5c(F)cnc6ccc(OC)nc56)(CC3)OC4)c(=O)n(C)c2c1
SPK-0255513,,SPK-0255513-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 30.0,Visual,< 4.5,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2cc(CNC34CCC(CCc5c(F)cnc6ccc(OC)nc56)(CC3)OC4)c(=O)n(C)c2c1
SPK-0255513,,SPK-0255513-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 30.0,Visual,< 4.5,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2cc(CNC34CCC(CCc5c(F)cnc6ccc(OC)nc56)(CC3)OC4)c(=O)n(C)c2c1
SPK-0255513,,SPK-0255513-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 30.0,Visual,< 4.5,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2cc(CNC34CCC(CCc5c(F)cnc6ccc(OC)nc56)(CC3)OC4)c(=O)n(C)c2c1
SPK-0255513,,SPK-0255513-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 30.0,Visual,< 4.5,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2cc(CNC34CCC(CCc5c(F)cnc6ccc(OC)nc56)(CC3)OC4)c(=O)n(C)c2c1
SPK-0255513,,SPK-0255513-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 30.0,Visual,< 4.5,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2cc(CNC34CCC(CCc5c(F)cnc6ccc(OC)nc56)(CC3)OC4)c(=O)n(C)c2c1
SPK-0255513,,SPK-0255513-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 30.0,Visual,< 4.5,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2cc(CNC34CCC(CCc5c(F)cnc6ccc(OC)nc56)(CC3)OC4)c(=O)n(C)c2c1
SPK-0255513,,SPK-0255513-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 30.0,Visual,< 4.5,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2cc(CNC34CCC(CCc5c(F)cnc6ccc(OC)nc56)(CC3)OC4)c(=O)n(C)c2c1
SPK-0255512,,SPK-0255512-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 4.00,MIC,Test article,> 7.68,Visual,< 5.1,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6ccc(F)cc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255512,,SPK-0255512-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 4.00,MIC,Test article,> 7.68,Visual,< 5.1,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6ccc(F)cc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255512,,SPK-0255512-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 4.00,MIC,Test article,> 7.68,Visual,< 5.1,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6ccc(F)cc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255512,,SPK-0255512-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 4.00,MIC,Test article,> 7.68,Visual,< 5.1,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6ccc(F)cc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255512,,SPK-0255512-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 4.00,MIC,Test article,> 7.68,Visual,< 5.1,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6ccc(F)cc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255512,,SPK-0255512-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 4.00,MIC,Test article,> 7.68,Visual,< 5.1,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6ccc(F)cc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255512,,SPK-0255512-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 4.00,MIC,Test article,> 7.68,Visual,< 5.1,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6ccc(F)cc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255512,,SPK-0255512-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,4.00,MIC,Test article,7.68,Visual,5.1,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6ccc(F)cc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255510,,SPK-0255510-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,64.0,MIC,Test article,124,Visual,3.9,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ncc6c(n5)OCCO6)(CC3)CO4)c2n1
SPK-0255510,,SPK-0255510-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 124,Visual,< 3.9,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ncc6c(n5)OCCO6)(CC3)CO4)c2n1
SPK-0255510,,SPK-0255510-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 124,Visual,< 3.9,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ncc6c(n5)OCCO6)(CC3)CO4)c2n1
SPK-0255510,,SPK-0255510-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,1.00,MIC,Test article,1.93,Visual,5.7,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ncc6c(n5)OCCO6)(CC3)CO4)c2n1
SPK-0255510,,SPK-0255510-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 124,Visual,< 3.9,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ncc6c(n5)OCCO6)(CC3)CO4)c2n1
SPK-0255510,,SPK-0255510-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 124,Visual,< 3.9,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ncc6c(n5)OCCO6)(CC3)CO4)c2n1
SPK-0255510,,SPK-0255510-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 124,Visual,< 3.9,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ncc6c(n5)OCCO6)(CC3)CO4)c2n1
SPK-0255510,,SPK-0255510-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.250,MIC,Test article,0.483,Visual,6.3,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ncc6c(n5)OCCO6)(CC3)CO4)c2n1
SPK-0255509,,SPK-0255509-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 14.9,Visual,< 4.8,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6ccc(Cl)cc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255509,,SPK-0255509-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 14.9,Visual,< 4.8,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6ccc(Cl)cc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255509,,SPK-0255509-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 14.9,Visual,< 4.8,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6ccc(Cl)cc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255509,,SPK-0255509-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 14.9,Visual,< 4.8,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6ccc(Cl)cc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255509,,SPK-0255509-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 14.9,Visual,< 4.8,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6ccc(Cl)cc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255509,,SPK-0255509-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 14.9,Visual,< 4.8,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6ccc(Cl)cc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255509,,SPK-0255509-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 14.9,Visual,< 4.8,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6ccc(Cl)cc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255509,,SPK-0255509-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 14.9,Visual,< 4.8,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6ccc(Cl)cc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255508,,SPK-0255508-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 60.1,Visual,< 4.2,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5c(OC)c6ccccc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255508,,SPK-0255508-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 60.1,Visual,< 4.2,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5c(OC)c6ccccc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255508,,SPK-0255508-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 60.1,Visual,< 4.2,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5c(OC)c6ccccc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255508,,SPK-0255508-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,16.0,MIC,Test article,30.0,Visual,4.5,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5c(OC)c6ccccc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255508,,SPK-0255508-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 60.1,Visual,< 4.2,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5c(OC)c6ccccc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255508,,SPK-0255508-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 60.1,Visual,< 4.2,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5c(OC)c6ccccc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255508,,SPK-0255508-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 60.1,Visual,< 4.2,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5c(OC)c6ccccc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255508,,SPK-0255508-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,8.00,MIC,Test article,15.0,Visual,4.8,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5c(OC)c6ccccc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255507,,SPK-0255507-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 28.4,Visual,< 4.5,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6cc(OC)c(OC)cc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255507,,SPK-0255507-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 28.4,Visual,< 4.5,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6cc(OC)c(OC)cc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255507,,SPK-0255507-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 28.4,Visual,< 4.5,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6cc(OC)c(OC)cc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255507,,SPK-0255507-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 28.4,Visual,< 4.5,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6cc(OC)c(OC)cc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255507,,SPK-0255507-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 28.4,Visual,< 4.5,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6cc(OC)c(OC)cc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255507,,SPK-0255507-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 28.4,Visual,< 4.5,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6cc(OC)c(OC)cc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255507,,SPK-0255507-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 28.4,Visual,< 4.5,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6cc(OC)c(OC)cc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255507,,SPK-0255507-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 28.4,Visual,< 4.5,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6cc(OC)c(OC)cc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255506,,SPK-0255506-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 30.0,Visual,< 4.5,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2c(c1)cc(CNC13CCC(CCc4c(F)cnc5ccc(OC)nc45)(CC1)OC3)c(=O)n2C
SPK-0255506,,SPK-0255506-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 30.0,Visual,< 4.5,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2c(c1)cc(CNC13CCC(CCc4c(F)cnc5ccc(OC)nc45)(CC1)OC3)c(=O)n2C
SPK-0255506,,SPK-0255506-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 30.0,Visual,< 4.5,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2c(c1)cc(CNC13CCC(CCc4c(F)cnc5ccc(OC)nc45)(CC1)OC3)c(=O)n2C
SPK-0255506,,SPK-0255506-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,8.00,MIC,Test article,15.0,Visual,4.8,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2c(c1)cc(CNC13CCC(CCc4c(F)cnc5ccc(OC)nc45)(CC1)OC3)c(=O)n2C
SPK-0255506,,SPK-0255506-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 30.0,Visual,< 4.5,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2c(c1)cc(CNC13CCC(CCc4c(F)cnc5ccc(OC)nc45)(CC1)OC3)c(=O)n2C
SPK-0255506,,SPK-0255506-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 30.0,Visual,< 4.5,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2c(c1)cc(CNC13CCC(CCc4c(F)cnc5ccc(OC)nc45)(CC1)OC3)c(=O)n2C
SPK-0255506,,SPK-0255506-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 30.0,Visual,< 4.5,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2c(c1)cc(CNC13CCC(CCc4c(F)cnc5ccc(OC)nc45)(CC1)OC3)c(=O)n2C
SPK-0255506,,SPK-0255506-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 30.0,Visual,< 4.5,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2c(c1)cc(CNC13CCC(CCc4c(F)cnc5ccc(OC)nc45)(CC1)OC3)c(=O)n2C
SPK-0255505,,SPK-0255505-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 29.8,Visual,< 4.5,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6cc(Cl)ccc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255505,,SPK-0255505-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 29.8,Visual,< 4.5,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6cc(Cl)ccc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255505,,SPK-0255505-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 29.8,Visual,< 4.5,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6cc(Cl)ccc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255505,,SPK-0255505-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 29.8,Visual,< 4.5,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6cc(Cl)ccc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255505,,SPK-0255505-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 29.8,Visual,< 4.5,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6cc(Cl)ccc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255505,,SPK-0255505-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 29.8,Visual,< 4.5,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6cc(Cl)ccc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255505,,SPK-0255505-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 29.8,Visual,< 4.5,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6cc(Cl)ccc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255505,,SPK-0255505-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 29.8,Visual,< 4.5,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6cc(Cl)ccc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255504,,SPK-0255504-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 30.7,Visual,< 4.5,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6cc(F)ccc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255504,,SPK-0255504-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 30.7,Visual,< 4.5,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6cc(F)ccc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255504,,SPK-0255504-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 30.7,Visual,< 4.5,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6cc(F)ccc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255504,,SPK-0255504-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,1.00,MIC,Test article,1.92,Visual,5.7,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6cc(F)ccc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255504,,SPK-0255504-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 30.7,Visual,< 4.5,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6cc(F)ccc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255504,,SPK-0255504-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 30.7,Visual,< 4.5,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6cc(F)ccc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255504,,SPK-0255504-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 30.7,Visual,< 4.5,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6cc(F)ccc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255504,,SPK-0255504-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,2.00,MIC,Test article,3.84,Visual,5.4,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6cc(F)ccc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255503,,SPK-0255503-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,4.00,MIC,Test article,7.11,Visual,5.1,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,NCC1(COc2ccc3ncc(F)c(CCC45CCC(NCc6ccc7c(n6)NC(=O)CO7)(CC4)CO5)c3n2)CC1
SPK-0255503,,SPK-0255503-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,8.00,MIC,Test article,14.2,Visual,4.8,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,NCC1(COc2ccc3ncc(F)c(CCC45CCC(NCc6ccc7c(n6)NC(=O)CO7)(CC4)CO5)c3n2)CC1
SPK-0255503,,SPK-0255503-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,32.0,MIC,Test article,56.9,Visual,4.2,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,NCC1(COc2ccc3ncc(F)c(CCC45CCC(NCc6ccc7c(n6)NC(=O)CO7)(CC4)CO5)c3n2)CC1
SPK-0255503,,SPK-0255503-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0630,MIC,Test article,0.112,Visual,7.0,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,NCC1(COc2ccc3ncc(F)c(CCC45CCC(NCc6ccc7c(n6)NC(=O)CO7)(CC4)CO5)c3n2)CC1
SPK-0255503,,SPK-0255503-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 128,MIC,Test article,> 227,Visual,< 3.6,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,NCC1(COc2ccc3ncc(F)c(CCC45CCC(NCc6ccc7c(n6)NC(=O)CO7)(CC4)CO5)c3n2)CC1
SPK-0255503,,SPK-0255503-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,128,MIC,Test article,227,Visual,3.6,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,NCC1(COc2ccc3ncc(F)c(CCC45CCC(NCc6ccc7c(n6)NC(=O)CO7)(CC4)CO5)c3n2)CC1
SPK-0255503,,SPK-0255503-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,128,MIC,Test article,227,Visual,3.6,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,NCC1(COc2ccc3ncc(F)c(CCC45CCC(NCc6ccc7c(n6)NC(=O)CO7)(CC4)CO5)c3n2)CC1
SPK-0255503,,SPK-0255503-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,1.00,MIC,Test article,1.78,Visual,5.8,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,NCC1(COc2ccc3ncc(F)c(CCC45CCC(NCc6ccc7c(n6)NC(=O)CO7)(CC4)CO5)c3n2)CC1
SPK-0255502,,SPK-0255502-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,4.00,MIC,Test article,7.33,Visual,5.1,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(O)C34CCC(NCc5cc6c(cn5)OCC(=O)N6)(CC3)CO4)c2n1
SPK-0255502,,SPK-0255502-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,8.00,MIC,Test article,14.7,Visual,4.8,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(O)C34CCC(NCc5cc6c(cn5)OCC(=O)N6)(CC3)CO4)c2n1
SPK-0255502,,SPK-0255502-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,32.0,MIC,Test article,58.6,Visual,4.2,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(O)C34CCC(NCc5cc6c(cn5)OCC(=O)N6)(CC3)CO4)c2n1
SPK-0255502,,SPK-0255502-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0310,MIC,Test article,0.0568,Visual,7.2,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(O)C34CCC(NCc5cc6c(cn5)OCC(=O)N6)(CC3)CO4)c2n1
SPK-0255502,,SPK-0255502-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 117,Visual,< 3.9,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(O)C34CCC(NCc5cc6c(cn5)OCC(=O)N6)(CC3)CO4)c2n1
SPK-0255502,,SPK-0255502-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 117,Visual,< 3.9,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(O)C34CCC(NCc5cc6c(cn5)OCC(=O)N6)(CC3)CO4)c2n1
SPK-0255502,,SPK-0255502-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 117,Visual,< 3.9,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(O)C34CCC(NCc5cc6c(cn5)OCC(=O)N6)(CC3)CO4)c2n1
SPK-0255502,,SPK-0255502-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.500,MIC,Test article,0.916,Visual,6.0,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(O)C34CCC(NCc5cc6c(cn5)OCC(=O)N6)(CC3)CO4)c2n1
SPK-0255502,,SPK-0255502-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,2.00,MIC,Test article,3.93,Visual,5.4,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(O)C34CCC(NCc5cc6c(cn5)OCC(=O)N6)(CC3)CO4)c2n1
SPK-0255502,,SPK-0255502-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,4.00,MIC,Test article,7.85,Visual,5.1,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(O)C34CCC(NCc5cc6c(cn5)OCC(=O)N6)(CC3)CO4)c2n1
SPK-0255502,,SPK-0255502-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,16.0,MIC,Test article,31.4,Visual,4.5,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(O)C34CCC(NCc5cc6c(cn5)OCC(=O)N6)(CC3)CO4)c2n1
SPK-0255502,,SPK-0255502-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0160,MIC,Test article,0.0314,Visual,7.5,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(O)C34CCC(NCc5cc6c(cn5)OCC(=O)N6)(CC3)CO4)c2n1
SPK-0255502,,SPK-0255502-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,64.0,MIC,Test article,126,Visual,3.9,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(O)C34CCC(NCc5cc6c(cn5)OCC(=O)N6)(CC3)CO4)c2n1
SPK-0255502,,SPK-0255502-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,64.0,MIC,Test article,126,Visual,3.9,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(O)C34CCC(NCc5cc6c(cn5)OCC(=O)N6)(CC3)CO4)c2n1
SPK-0255502,,SPK-0255502-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,64.0,MIC,Test article,126,Visual,3.9,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(O)C34CCC(NCc5cc6c(cn5)OCC(=O)N6)(CC3)CO4)c2n1
SPK-0255502,,SPK-0255502-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.125,MIC,Test article,0.245,Visual,6.6,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(O)C34CCC(NCc5cc6c(cn5)OCC(=O)N6)(CC3)CO4)c2n1
SPK-0255501,,SPK-0255501-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,32.0,MIC,Test article,60.0,Visual,4.2,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(O)C34CCC(NCc5ccc6c(n5)OCCO6)(CC3)CO4)c2n1
SPK-0255501,,SPK-0255501-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 60.0,Visual,< 4.2,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(O)C34CCC(NCc5ccc6c(n5)OCCO6)(CC3)CO4)c2n1
SPK-0255501,,SPK-0255501-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 60.0,Visual,< 4.2,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(O)C34CCC(NCc5ccc6c(n5)OCCO6)(CC3)CO4)c2n1
SPK-0255501,,SPK-0255501-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,1.00,MIC,Test article,1.88,Visual,5.7,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(O)C34CCC(NCc5ccc6c(n5)OCCO6)(CC3)CO4)c2n1
SPK-0255501,,SPK-0255501-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 60.0,Visual,< 4.2,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(O)C34CCC(NCc5ccc6c(n5)OCCO6)(CC3)CO4)c2n1
SPK-0255501,,SPK-0255501-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 60.0,Visual,< 4.2,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(O)C34CCC(NCc5ccc6c(n5)OCCO6)(CC3)CO4)c2n1
SPK-0255501,,SPK-0255501-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 60.0,Visual,< 4.2,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(O)C34CCC(NCc5ccc6c(n5)OCCO6)(CC3)CO4)c2n1
SPK-0255501,,SPK-0255501-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.250,MIC,Test article,0.469,Visual,6.3,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(O)C34CCC(NCc5ccc6c(n5)OCCO6)(CC3)CO4)c2n1
SPK-0255500,,SPK-0255500-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 15.7,Visual,< 4.8,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)N/C(=N\O)CO6)(CC3)CO4)c2n1
SPK-0255500,,SPK-0255500-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 15.7,Visual,< 4.8,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)N/C(=N\O)CO6)(CC3)CO4)c2n1
SPK-0255500,,SPK-0255500-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 15.7,Visual,< 4.8,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)N/C(=N\O)CO6)(CC3)CO4)c2n1
SPK-0255500,,SPK-0255500-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,1.00,MIC,Test article,1.97,Visual,5.7,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)N/C(=N\O)CO6)(CC3)CO4)c2n1
SPK-0255500,,SPK-0255500-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 15.7,Visual,< 4.8,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)N/C(=N\O)CO6)(CC3)CO4)c2n1
SPK-0255500,,SPK-0255500-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 15.7,Visual,< 4.8,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)N/C(=N\O)CO6)(CC3)CO4)c2n1
SPK-0255500,,SPK-0255500-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 15.7,Visual,< 4.8,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)N/C(=N\O)CO6)(CC3)CO4)c2n1
SPK-0255500,,SPK-0255500-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,2.00,MIC,Test article,3.93,Visual,5.4,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)N/C(=N\O)CO6)(CC3)CO4)c2n1
SPK-0255498,,SPK-0255498-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 30.9,Visual,< 4.5,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6c(nn5)OCCO6)(CC3)CO4)c2n1
SPK-0255498,,SPK-0255498-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 30.9,Visual,< 4.5,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6c(nn5)OCCO6)(CC3)CO4)c2n1
SPK-0255498,,SPK-0255498-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 30.9,Visual,< 4.5,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6c(nn5)OCCO6)(CC3)CO4)c2n1
SPK-0255498,,SPK-0255498-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.250,MIC,Test article,0.483,Visual,6.3,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6c(nn5)OCCO6)(CC3)CO4)c2n1
SPK-0255498,,SPK-0255498-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 30.9,Visual,< 4.5,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6c(nn5)OCCO6)(CC3)CO4)c2n1
SPK-0255498,,SPK-0255498-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 30.9,Visual,< 4.5,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6c(nn5)OCCO6)(CC3)CO4)c2n1
SPK-0255498,,SPK-0255498-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 30.9,Visual,< 4.5,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6c(nn5)OCCO6)(CC3)CO4)c2n1
SPK-0255498,,SPK-0255498-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.250,MIC,Test article,0.483,Visual,6.3,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6c(nn5)OCCO6)(CC3)CO4)c2n1
SPK-0255497,,SPK-0255497-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,8.00,MIC,Test article,14.8,Visual,4.8,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1cc(OC)c2nccc(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255497,,SPK-0255497-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,32.0,MIC,Test article,59.0,Visual,4.2,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1cc(OC)c2nccc(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255497,,SPK-0255497-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 118,Visual,< 3.9,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1cc(OC)c2nccc(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255497,,SPK-0255497-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.125,MIC,Test article,0.231,Visual,6.6,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1cc(OC)c2nccc(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255497,,SPK-0255497-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 118,Visual,< 3.9,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1cc(OC)c2nccc(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255497,,SPK-0255497-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 118,Visual,< 3.9,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1cc(OC)c2nccc(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255497,,SPK-0255497-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 118,Visual,< 3.9,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1cc(OC)c2nccc(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255497,,SPK-0255497-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,1.00,MIC,Test article,1.84,Visual,5.7,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1cc(OC)c2nccc(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255496,,SPK-0255496-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,32.0,MIC,Test article,61.9,Visual,4.2,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)OCCO6)(CC3)CO4)c2n1
SPK-0255496,,SPK-0255496-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 124,Visual,< 3.9,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)OCCO6)(CC3)CO4)c2n1
SPK-0255496,,SPK-0255496-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 124,Visual,< 3.9,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)OCCO6)(CC3)CO4)c2n1
SPK-0255496,,SPK-0255496-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.500,MIC,Test article,0.967,Visual,6.0,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)OCCO6)(CC3)CO4)c2n1
SPK-0255496,,SPK-0255496-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 124,Visual,< 3.9,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)OCCO6)(CC3)CO4)c2n1
SPK-0255496,,SPK-0255496-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 124,Visual,< 3.9,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)OCCO6)(CC3)CO4)c2n1
SPK-0255496,,SPK-0255496-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 124,Visual,< 3.9,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)OCCO6)(CC3)CO4)c2n1
SPK-0255496,,SPK-0255496-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.125,MIC,Test article,0.242,Visual,6.6,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)OCCO6)(CC3)CO4)c2n1
SPK-0255495,,SPK-0255495-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 29.3,Visual,< 4.5,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(C#N)c(CCC34CCC(NCc5cc6ccccc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255495,,SPK-0255495-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 29.3,Visual,< 4.5,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(C#N)c(CCC34CCC(NCc5cc6ccccc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255495,,SPK-0255495-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 29.3,Visual,< 4.5,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(C#N)c(CCC34CCC(NCc5cc6ccccc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255495,,SPK-0255495-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,2.00,MIC,Test article,3.66,Visual,5.4,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(C#N)c(CCC34CCC(NCc5cc6ccccc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255495,,SPK-0255495-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 29.3,Visual,< 4.5,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(C#N)c(CCC34CCC(NCc5cc6ccccc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255495,,SPK-0255495-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 29.3,Visual,< 4.5,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(C#N)c(CCC34CCC(NCc5cc6ccccc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255495,,SPK-0255495-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 29.3,Visual,< 4.5,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(C#N)c(CCC34CCC(NCc5cc6ccccc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255495,,SPK-0255495-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,2.00,MIC,Test article,3.66,Visual,5.4,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(C#N)c(CCC34CCC(NCc5cc6ccccc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255494,,SPK-0255494-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,8.00,MIC,Test article,15.3,Visual,4.8,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(C#N)c(CCC34CCC(NCc5cc6c(cn5)OCCO6)(CC3)CO4)c2n1
SPK-0255494,,SPK-0255494-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,16.0,MIC,Test article,30.5,Visual,4.5,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(C#N)c(CCC34CCC(NCc5cc6c(cn5)OCCO6)(CC3)CO4)c2n1
SPK-0255494,,SPK-0255494-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 30.5,Visual,< 4.5,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(C#N)c(CCC34CCC(NCc5cc6c(cn5)OCCO6)(CC3)CO4)c2n1
SPK-0255494,,SPK-0255494-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.125,MIC,Test article,0.239,Visual,6.6,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(C#N)c(CCC34CCC(NCc5cc6c(cn5)OCCO6)(CC3)CO4)c2n1
SPK-0255494,,SPK-0255494-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 30.5,Visual,< 4.5,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(C#N)c(CCC34CCC(NCc5cc6c(cn5)OCCO6)(CC3)CO4)c2n1
SPK-0255494,,SPK-0255494-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 30.5,Visual,< 4.5,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(C#N)c(CCC34CCC(NCc5cc6c(cn5)OCCO6)(CC3)CO4)c2n1
SPK-0255494,,SPK-0255494-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 30.5,Visual,< 4.5,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(C#N)c(CCC34CCC(NCc5cc6c(cn5)OCCO6)(CC3)CO4)c2n1
SPK-0255494,,SPK-0255494-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0630,MIC,Test article,0.120,Visual,6.9,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(C#N)c(CCC34CCC(NCc5cc6c(cn5)OCCO6)(CC3)CO4)c2n1
SPK-0255493,,SPK-0255493-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 30.6,Visual,< 4.5,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CO/N=C1\COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OC)nc56)(CC3)OC4)nc2N1
SPK-0255493,,SPK-0255493-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 30.6,Visual,< 4.5,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CO/N=C1\COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OC)nc56)(CC3)OC4)nc2N1
SPK-0255493,,SPK-0255493-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 30.6,Visual,< 4.5,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CO/N=C1\COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OC)nc56)(CC3)OC4)nc2N1
SPK-0255493,,SPK-0255493-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,2.00,MIC,Test article,3.83,Visual,5.4,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CO/N=C1\COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OC)nc56)(CC3)OC4)nc2N1
SPK-0255493,,SPK-0255493-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 30.6,Visual,< 4.5,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CO/N=C1\COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OC)nc56)(CC3)OC4)nc2N1
SPK-0255493,,SPK-0255493-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 30.6,Visual,< 4.5,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CO/N=C1\COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OC)nc56)(CC3)OC4)nc2N1
SPK-0255493,,SPK-0255493-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 30.6,Visual,< 4.5,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CO/N=C1\COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OC)nc56)(CC3)OC4)nc2N1
SPK-0255493,,SPK-0255493-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,2.00,MIC,Test article,3.83,Visual,5.4,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CO/N=C1\COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OC)nc56)(CC3)OC4)nc2N1
SPK-0255492,,SPK-0255492-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,4.00,MIC,Test article,7.10,Visual,5.1,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OCC7(CO)CC7)nc56)(CC3)OC4)nc2N1
SPK-0255492,,SPK-0255492-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,16.0,MIC,Test article,28.4,Visual,4.5,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OCC7(CO)CC7)nc56)(CC3)OC4)nc2N1
SPK-0255492,,SPK-0255492-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 56.8,Visual,< 4.2,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OCC7(CO)CC7)nc56)(CC3)OC4)nc2N1
SPK-0255492,,SPK-0255492-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0630,MIC,Test article,0.112,Visual,7.0,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OCC7(CO)CC7)nc56)(CC3)OC4)nc2N1
SPK-0255492,,SPK-0255492-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 56.8,Visual,< 4.2,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OCC7(CO)CC7)nc56)(CC3)OC4)nc2N1
SPK-0255492,,SPK-0255492-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 56.8,Visual,< 4.2,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OCC7(CO)CC7)nc56)(CC3)OC4)nc2N1
SPK-0255492,,SPK-0255492-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 56.8,Visual,< 4.2,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OCC7(CO)CC7)nc56)(CC3)OC4)nc2N1
SPK-0255492,,SPK-0255492-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.125,MIC,Test article,0.222,Visual,6.7,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OCC7(CO)CC7)nc56)(CC3)OC4)nc2N1
SPK-0255491,,SPK-0255491-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.500,MIC,Test article,0.942,Visual,6.0,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ncc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255491,,SPK-0255491-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,4.00,MIC,Test article,7.53,Visual,5.1,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ncc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255491,,SPK-0255491-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,8.00,MIC,Test article,15.1,Visual,4.8,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ncc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255491,,SPK-0255491-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0310,MIC,Test article,0.0584,Visual,7.2,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ncc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255491,,SPK-0255491-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,32.0,MIC,Test article,60.3,Visual,4.2,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ncc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255491,,SPK-0255491-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,32.0,MIC,Test article,60.3,Visual,4.2,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ncc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255491,,SPK-0255491-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,32.0,MIC,Test article,60.3,Visual,4.2,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ncc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255491,,SPK-0255491-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0310,MIC,Test article,0.0584,Visual,7.2,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ncc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255490,,SPK-0255490-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,16.0,MIC,Test article,27.8,Visual,4.6,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(O)C34CCC(NCc5nc6c(cc5OC)OCC(=O)N6)(CC3)CO4)c2n1
SPK-0255490,,SPK-0255490-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 27.8,Visual,< 4.6,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(O)C34CCC(NCc5nc6c(cc5OC)OCC(=O)N6)(CC3)CO4)c2n1
SPK-0255490,,SPK-0255490-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 27.8,Visual,< 4.6,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(O)C34CCC(NCc5nc6c(cc5OC)OCC(=O)N6)(CC3)CO4)c2n1
SPK-0255490,,SPK-0255490-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.250,MIC,Test article,0.434,Visual,6.4,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(O)C34CCC(NCc5nc6c(cc5OC)OCC(=O)N6)(CC3)CO4)c2n1
SPK-0255490,,SPK-0255490-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 27.8,Visual,< 4.6,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(O)C34CCC(NCc5nc6c(cc5OC)OCC(=O)N6)(CC3)CO4)c2n1
SPK-0255490,,SPK-0255490-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 27.8,Visual,< 4.6,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(O)C34CCC(NCc5nc6c(cc5OC)OCC(=O)N6)(CC3)CO4)c2n1
SPK-0255490,,SPK-0255490-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 27.8,Visual,< 4.6,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(O)C34CCC(NCc5nc6c(cc5OC)OCC(=O)N6)(CC3)CO4)c2n1
SPK-0255490,,SPK-0255490-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 27.8,Visual,< 4.6,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(O)C34CCC(NCc5nc6c(cc5OC)OCC(=O)N6)(CC3)CO4)c2n1
SPK-0255489,,SPK-0255489-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,2.00,MIC,Test article,4.18,Visual,5.4,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,Nc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255489,,SPK-0255489-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,8.00,MIC,Test article,16.7,Visual,4.8,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,Nc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255489,,SPK-0255489-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 33.4,Visual,< 4.5,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,Nc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255489,,SPK-0255489-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.125,MIC,Test article,0.261,Visual,6.6,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,Nc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255489,,SPK-0255489-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 33.4,Visual,< 4.5,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,Nc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255489,,SPK-0255489-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 33.4,Visual,< 4.5,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,Nc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255489,,SPK-0255489-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 33.4,Visual,< 4.5,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,Nc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255489,,SPK-0255489-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,2.00,MIC,Test article,4.18,Visual,5.4,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,Nc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255488,,SPK-0255488-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,8.00,MIC,Test article,14.3,Visual,4.8,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(OC)C34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255488,,SPK-0255488-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,16.0,MIC,Test article,28.6,Visual,4.5,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(OC)C34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255488,,SPK-0255488-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 28.6,Visual,< 4.5,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(OC)C34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255488,,SPK-0255488-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0630,MIC,Test article,0.112,Visual,6.9,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(OC)C34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255488,,SPK-0255488-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 28.6,Visual,< 4.5,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(OC)C34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255488,,SPK-0255488-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 28.6,Visual,< 4.5,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(OC)C34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255488,,SPK-0255488-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 28.6,Visual,< 4.5,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(OC)C34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255488,,SPK-0255488-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.250,MIC,Test article,0.446,Visual,6.4,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(OC)C34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255487,,SPK-0255487-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,4.00,MIC,Test article,7.08,Visual,5.1,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,NCCCCCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255487,,SPK-0255487-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,4.00,MIC,Test article,7.08,Visual,5.1,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,NCCCCCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255487,,SPK-0255487-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 28.3,Visual,< 4.5,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,NCCCCCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255487,,SPK-0255487-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0310,MIC,Test article,0.0549,Visual,7.3,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,NCCCCCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255487,,SPK-0255487-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 28.3,Visual,< 4.5,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,NCCCCCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255487,,SPK-0255487-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 28.3,Visual,< 4.5,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,NCCCCCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255487,,SPK-0255487-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 28.3,Visual,< 4.5,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,NCCCCCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255487,,SPK-0255487-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,1.00,MIC,Test article,1.77,Visual,5.8,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,NCCCCCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255486,,SPK-0255486-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,1.00,MIC,Test article,2.05,Visual,5.7,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N#Cc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255486,,SPK-0255486-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,2.00,MIC,Test article,4.09,Visual,5.4,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N#Cc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255486,,SPK-0255486-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,8.00,MIC,Test article,16.4,Visual,4.8,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N#Cc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255486,,SPK-0255486-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,8.00E-03,MIC,Test article,0.0164,Visual,7.8,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N#Cc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255486,,SPK-0255486-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 32.8,Visual,< 4.5,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N#Cc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255486,,SPK-0255486-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 32.8,Visual,< 4.5,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N#Cc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255486,,SPK-0255486-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 32.8,Visual,< 4.5,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N#Cc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255486,,SPK-0255486-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.125,MIC,Test article,0.256,Visual,6.6,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N#Cc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255485,,SPK-0255485-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,64.0,MIC,Test article,123,Visual,3.9,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(O)C34CCC(NCc5cc6ccccc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255485,,SPK-0255485-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 128,MIC,Test article,> 247,Visual,< 3.6,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(O)C34CCC(NCc5cc6ccccc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255485,,SPK-0255485-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 128,MIC,Test article,> 247,Visual,< 3.6,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(O)C34CCC(NCc5cc6ccccc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255485,,SPK-0255485-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,1.00,MIC,Test article,1.93,Visual,5.7,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(O)C34CCC(NCc5cc6ccccc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255485,,SPK-0255485-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 128,MIC,Test article,> 247,Visual,< 3.6,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(O)C34CCC(NCc5cc6ccccc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255485,,SPK-0255485-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 128,MIC,Test article,> 247,Visual,< 3.6,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(O)C34CCC(NCc5cc6ccccc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255485,,SPK-0255485-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 128,MIC,Test article,> 247,Visual,< 3.6,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(O)C34CCC(NCc5cc6ccccc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255485,,SPK-0255485-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,2.00,MIC,Test article,3.86,Visual,5.4,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(O)C34CCC(NCc5cc6ccccc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255484,,SPK-0255484-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,8.00,MIC,Test article,15.8,Visual,4.8,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CN(C)c1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255484,,SPK-0255484-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 15.8,Visual,< 4.8,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CN(C)c1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255484,,SPK-0255484-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 15.8,Visual,< 4.8,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CN(C)c1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255484,,SPK-0255484-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0310,MIC,Test article,0.0612,Visual,7.2,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CN(C)c1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255484,,SPK-0255484-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 15.8,Visual,< 4.8,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CN(C)c1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255484,,SPK-0255484-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 15.8,Visual,< 4.8,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CN(C)c1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255484,,SPK-0255484-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 15.8,Visual,< 4.8,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CN(C)c1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255484,,SPK-0255484-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.250,MIC,Test article,0.494,Visual,6.3,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CN(C)c1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255483,,SPK-0255483-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,16.0,MIC,Test article,29.2,Visual,4.5,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(N7CCOCC7)nc56)(CC3)OC4)nc2N1
SPK-0255483,,SPK-0255483-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 29.2,Visual,< 4.5,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(N7CCOCC7)nc56)(CC3)OC4)nc2N1
SPK-0255483,,SPK-0255483-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 29.2,Visual,< 4.5,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(N7CCOCC7)nc56)(CC3)OC4)nc2N1
SPK-0255483,,SPK-0255483-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.125,MIC,Test article,0.228,Visual,6.6,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(N7CCOCC7)nc56)(CC3)OC4)nc2N1
SPK-0255483,,SPK-0255483-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 29.2,Visual,< 4.5,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(N7CCOCC7)nc56)(CC3)OC4)nc2N1
SPK-0255483,,SPK-0255483-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 29.2,Visual,< 4.5,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(N7CCOCC7)nc56)(CC3)OC4)nc2N1
SPK-0255483,,SPK-0255483-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 29.2,Visual,< 4.5,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(N7CCOCC7)nc56)(CC3)OC4)nc2N1
SPK-0255483,,SPK-0255483-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.500,MIC,Test article,0.911,Visual,6.0,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(N7CCOCC7)nc56)(CC3)OC4)nc2N1
SPK-0255482,,SPK-0255482-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,2.00,MIC,Test article,4.03,Visual,5.4,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(O)C34CCC(NCc5cc6c(cn5)OCCO6)(CC3)CO4)c2n1
SPK-0255482,,SPK-0255482-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,16.0,MIC,Test article,32.2,Visual,4.5,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(O)C34CCC(NCc5cc6c(cn5)OCCO6)(CC3)CO4)c2n1
SPK-0255482,,SPK-0255482-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,64.0,MIC,Test article,129,Visual,3.9,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(O)C34CCC(NCc5cc6c(cn5)OCCO6)(CC3)CO4)c2n1
SPK-0255482,,SPK-0255482-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0310,MIC,Test article,0.0624,Visual,7.2,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(O)C34CCC(NCc5cc6c(cn5)OCCO6)(CC3)CO4)c2n1
SPK-0255482,,SPK-0255482-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 128,MIC,Test article,> 258,Visual,< 3.6,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(O)C34CCC(NCc5cc6c(cn5)OCCO6)(CC3)CO4)c2n1
SPK-0255482,,SPK-0255482-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 128,MIC,Test article,> 258,Visual,< 3.6,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(O)C34CCC(NCc5cc6c(cn5)OCCO6)(CC3)CO4)c2n1
SPK-0255482,,SPK-0255482-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 128,MIC,Test article,> 258,Visual,< 3.6,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(O)C34CCC(NCc5cc6c(cn5)OCCO6)(CC3)CO4)c2n1
SPK-0255482,,SPK-0255482-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0630,MIC,Test article,0.127,Visual,6.9,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(O)C34CCC(NCc5cc6c(cn5)OCCO6)(CC3)CO4)c2n1
SPK-0255481,,SPK-0255481-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,8.00,MIC,Test article,14.5,Visual,4.8,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,NCCCCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255481,,SPK-0255481-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,4.00,MIC,Test article,7.26,Visual,5.1,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,NCCCCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255481,,SPK-0255481-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,16.0,MIC,Test article,29.1,Visual,4.5,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,NCCCCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255481,,SPK-0255481-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0310,MIC,Test article,0.0563,Visual,7.2,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,NCCCCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255481,,SPK-0255481-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 29.1,Visual,< 4.5,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,NCCCCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255481,,SPK-0255481-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 29.1,Visual,< 4.5,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,NCCCCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255481,,SPK-0255481-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 29.1,Visual,< 4.5,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,NCCCCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255481,,SPK-0255481-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,1.00,MIC,Test article,1.82,Visual,5.7,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,NCCCCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255480,,SPK-0255480-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,8.00,MIC,Test article,14.1,Visual,4.8,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OCCCCCO)nc56)(CC3)OC4)nc2N1
SPK-0255480,,SPK-0255480-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 14.1,Visual,< 4.8,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OCCCCCO)nc56)(CC3)OC4)nc2N1
SPK-0255480,,SPK-0255480-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 14.1,Visual,< 4.8,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OCCCCCO)nc56)(CC3)OC4)nc2N1
SPK-0255480,,SPK-0255480-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0310,MIC,Test article,0.0548,Visual,7.3,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OCCCCCO)nc56)(CC3)OC4)nc2N1
SPK-0255480,,SPK-0255480-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 14.1,Visual,< 4.8,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OCCCCCO)nc56)(CC3)OC4)nc2N1
SPK-0255480,,SPK-0255480-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 14.1,Visual,< 4.8,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OCCCCCO)nc56)(CC3)OC4)nc2N1
SPK-0255480,,SPK-0255480-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 14.1,Visual,< 4.8,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OCCCCCO)nc56)(CC3)OC4)nc2N1
SPK-0255480,,SPK-0255480-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.125,MIC,Test article,0.221,Visual,6.7,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OCCCCCO)nc56)(CC3)OC4)nc2N1
SPK-0255479,,SPK-0255479-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 4.00,MIC,Test article,> 8.17,Visual,< 5.1,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5nc6ccccc6[nH]c5=O)(CC3)CO4)c2n1
SPK-0255479,,SPK-0255479-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 4.00,MIC,Test article,> 8.17,Visual,< 5.1,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5nc6ccccc6[nH]c5=O)(CC3)CO4)c2n1
SPK-0255479,,SPK-0255479-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 4.00,MIC,Test article,> 8.17,Visual,< 5.1,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5nc6ccccc6[nH]c5=O)(CC3)CO4)c2n1
SPK-0255479,,SPK-0255479-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 4.00,MIC,Test article,> 8.17,Visual,< 5.1,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5nc6ccccc6[nH]c5=O)(CC3)CO4)c2n1
SPK-0255479,,SPK-0255479-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 4.00,MIC,Test article,> 8.17,Visual,< 5.1,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5nc6ccccc6[nH]c5=O)(CC3)CO4)c2n1
SPK-0255479,,SPK-0255479-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 4.00,MIC,Test article,> 8.17,Visual,< 5.1,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5nc6ccccc6[nH]c5=O)(CC3)CO4)c2n1
SPK-0255479,,SPK-0255479-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 4.00,MIC,Test article,> 8.17,Visual,< 5.1,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5nc6ccccc6[nH]c5=O)(CC3)CO4)c2n1
SPK-0255479,,SPK-0255479-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,1.00,MIC,Test article,2.04,Visual,5.7,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5nc6ccccc6[nH]c5=O)(CC3)CO4)c2n1
SPK-0255478,,SPK-0255478-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 28.8,Visual,< 4.5,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1cc2nccc(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2nc1C(=O)O
SPK-0255478,,SPK-0255478-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 28.8,Visual,< 4.5,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1cc2nccc(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2nc1C(=O)O
SPK-0255478,,SPK-0255478-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 28.8,Visual,< 4.5,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1cc2nccc(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2nc1C(=O)O
SPK-0255478,,SPK-0255478-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,16.0,MIC,Test article,28.8,Visual,4.5,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1cc2nccc(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2nc1C(=O)O
SPK-0255478,,SPK-0255478-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 28.8,Visual,< 4.5,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1cc2nccc(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2nc1C(=O)O
SPK-0255478,,SPK-0255478-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 28.8,Visual,< 4.5,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1cc2nccc(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2nc1C(=O)O
SPK-0255478,,SPK-0255478-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 28.8,Visual,< 4.5,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1cc2nccc(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2nc1C(=O)O
SPK-0255478,,SPK-0255478-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 28.8,Visual,< 4.5,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1cc2nccc(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2nc1C(=O)O
SPK-0255477,,SPK-0255477-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,4.00,MIC,Test article,7.12,Visual,5.1,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(O)C34CCC(NCc5ccc6c(n5)NC(=O)CS6)(CC3)CO4)c2n1
SPK-0255477,,SPK-0255477-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,8.00,MIC,Test article,14.2,Visual,4.8,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(O)C34CCC(NCc5ccc6c(n5)NC(=O)CS6)(CC3)CO4)c2n1
SPK-0255477,,SPK-0255477-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,32.0,MIC,Test article,56.9,Visual,4.2,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(O)C34CCC(NCc5ccc6c(n5)NC(=O)CS6)(CC3)CO4)c2n1
SPK-0255477,,SPK-0255477-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0160,MIC,Test article,0.0285,Visual,7.5,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(O)C34CCC(NCc5ccc6c(n5)NC(=O)CS6)(CC3)CO4)c2n1
SPK-0255477,,SPK-0255477-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 56.9,Visual,< 4.2,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(O)C34CCC(NCc5ccc6c(n5)NC(=O)CS6)(CC3)CO4)c2n1
SPK-0255477,,SPK-0255477-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 56.9,Visual,< 4.2,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(O)C34CCC(NCc5ccc6c(n5)NC(=O)CS6)(CC3)CO4)c2n1
SPK-0255477,,SPK-0255477-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 56.9,Visual,< 4.2,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(O)C34CCC(NCc5ccc6c(n5)NC(=O)CS6)(CC3)CO4)c2n1
SPK-0255477,,SPK-0255477-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.125,MIC,Test article,0.222,Visual,6.7,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(O)C34CCC(NCc5ccc6c(n5)NC(=O)CS6)(CC3)CO4)c2n1
SPK-0255476,,SPK-0255476-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,32.0,MIC,Test article,59.6,Visual,4.2,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1cc2nccc(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2nc1C#N
SPK-0255476,,SPK-0255476-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 59.6,Visual,< 4.2,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1cc2nccc(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2nc1C#N
SPK-0255476,,SPK-0255476-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 59.6,Visual,< 4.2,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1cc2nccc(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2nc1C#N
SPK-0255476,,SPK-0255476-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.500,MIC,Test article,0.931,Visual,6.0,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1cc2nccc(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2nc1C#N
SPK-0255476,,SPK-0255476-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 59.6,Visual,< 4.2,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1cc2nccc(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2nc1C#N
SPK-0255476,,SPK-0255476-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 59.6,Visual,< 4.2,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1cc2nccc(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2nc1C#N
SPK-0255476,,SPK-0255476-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 59.6,Visual,< 4.2,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1cc2nccc(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2nc1C#N
SPK-0255476,,SPK-0255476-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,8.00,MIC,Test article,14.9,Visual,4.8,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1cc2nccc(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2nc1C#N
SPK-0255475,,SPK-0255475-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,2.00,MIC,Test article,3.89,Visual,5.4,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,Cc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255475,,SPK-0255475-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,8.00,MIC,Test article,15.6,Visual,4.8,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,Cc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255475,,SPK-0255475-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 31.1,Visual,< 4.5,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,Cc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255475,,SPK-0255475-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0310,MIC,Test article,0.0603,Visual,7.2,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,Cc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255475,,SPK-0255475-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 31.1,Visual,< 4.5,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,Cc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255475,,SPK-0255475-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 31.1,Visual,< 4.5,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,Cc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255475,,SPK-0255475-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 31.1,Visual,< 4.5,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,Cc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255475,,SPK-0255475-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.250,MIC,Test article,0.486,Visual,6.3,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,Cc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255474,,SPK-0255474-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 28.2,Visual,< 4.6,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6cc(C(F)(F)F)cnc56)(CC3)OC4)nc2N1
SPK-0255474,,SPK-0255474-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 28.2,Visual,< 4.6,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6cc(C(F)(F)F)cnc56)(CC3)OC4)nc2N1
SPK-0255474,,SPK-0255474-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 28.2,Visual,< 4.6,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6cc(C(F)(F)F)cnc56)(CC3)OC4)nc2N1
SPK-0255474,,SPK-0255474-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 28.2,Visual,< 4.6,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6cc(C(F)(F)F)cnc56)(CC3)OC4)nc2N1
SPK-0255474,,SPK-0255474-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 28.2,Visual,< 4.6,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6cc(C(F)(F)F)cnc56)(CC3)OC4)nc2N1
SPK-0255474,,SPK-0255474-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 28.2,Visual,< 4.6,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6cc(C(F)(F)F)cnc56)(CC3)OC4)nc2N1
SPK-0255474,,SPK-0255474-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 28.2,Visual,< 4.6,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6cc(C(F)(F)F)cnc56)(CC3)OC4)nc2N1
SPK-0255474,,SPK-0255474-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 28.2,Visual,< 4.6,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6cc(C(F)(F)F)cnc56)(CC3)OC4)nc2N1
SPK-0255473,,SPK-0255473-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,2.00,MIC,Test article,3.63,Visual,5.4,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OCCCCO)nc56)(CC3)OC4)nc2N1
SPK-0255473,,SPK-0255473-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,8.00,MIC,Test article,14.5,Visual,4.8,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OCCCCO)nc56)(CC3)OC4)nc2N1
SPK-0255473,,SPK-0255473-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,16.0,MIC,Test article,29.0,Visual,4.5,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OCCCCO)nc56)(CC3)OC4)nc2N1
SPK-0255473,,SPK-0255473-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,8.00E-03,MIC,Test article,0.0145,Visual,7.8,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OCCCCO)nc56)(CC3)OC4)nc2N1
SPK-0255473,,SPK-0255473-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 29.0,Visual,< 4.5,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OCCCCO)nc56)(CC3)OC4)nc2N1
SPK-0255473,,SPK-0255473-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 29.0,Visual,< 4.5,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OCCCCO)nc56)(CC3)OC4)nc2N1
SPK-0255473,,SPK-0255473-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 29.0,Visual,< 4.5,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OCCCCO)nc56)(CC3)OC4)nc2N1
SPK-0255473,,SPK-0255473-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0630,MIC,Test article,0.114,Visual,6.9,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OCCCCO)nc56)(CC3)OC4)nc2N1
SPK-0255472,,SPK-0255472-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,1.00,MIC,Test article,2.03,Visual,5.7,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6c(cn5)OCC(=O)N6)(CC3)CO4)c2n1
SPK-0255472,,SPK-0255472-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,4.00,MIC,Test article,8.10,Visual,5.1,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6c(cn5)OCC(=O)N6)(CC3)CO4)c2n1
SPK-0255472,,SPK-0255472-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,8.00,MIC,Test article,16.2,Visual,4.8,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6c(cn5)OCC(=O)N6)(CC3)CO4)c2n1
SPK-0255472,,SPK-0255472-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,8.00E-03,MIC,Test article,0.0162,Visual,7.8,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6c(cn5)OCC(=O)N6)(CC3)CO4)c2n1
SPK-0255472,,SPK-0255472-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,32.0,MIC,Test article,64.8,Visual,4.2,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6c(cn5)OCC(=O)N6)(CC3)CO4)c2n1
SPK-0255472,,SPK-0255472-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,32.0,MIC,Test article,64.8,Visual,4.2,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6c(cn5)OCC(=O)N6)(CC3)CO4)c2n1
SPK-0255472,,SPK-0255472-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,32.0,MIC,Test article,64.8,Visual,4.2,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6c(cn5)OCC(=O)N6)(CC3)CO4)c2n1
SPK-0255472,,SPK-0255472-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0630,MIC,Test article,0.128,Visual,6.9,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6c(cn5)OCC(=O)N6)(CC3)CO4)c2n1
SPK-0255471,,SPK-0255471-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 4.00,MIC,Test article,> 7.94,Visual,< 5.1,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5nc6ccccc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255471,,SPK-0255471-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 4.00,MIC,Test article,> 7.94,Visual,< 5.1,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5nc6ccccc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255471,,SPK-0255471-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 4.00,MIC,Test article,> 7.94,Visual,< 5.1,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5nc6ccccc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255471,,SPK-0255471-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,4.00,MIC,Test article,7.94,Visual,5.1,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5nc6ccccc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255471,,SPK-0255471-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 4.00,MIC,Test article,> 7.94,Visual,< 5.1,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5nc6ccccc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255471,,SPK-0255471-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 4.00,MIC,Test article,> 7.94,Visual,< 5.1,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5nc6ccccc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255471,,SPK-0255471-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 4.00,MIC,Test article,> 7.94,Visual,< 5.1,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5nc6ccccc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255471,,SPK-0255471-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,4.00,MIC,Test article,7.94,Visual,5.1,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5nc6ccccc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255470,,SPK-0255470-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 4.00,MIC,Test article,> 7.73,Visual,< 5.1,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc(OC(F)F)c(OC)c5)(CC3)CO4)c2n1
SPK-0255470,,SPK-0255470-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 4.00,MIC,Test article,> 7.73,Visual,< 5.1,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc(OC(F)F)c(OC)c5)(CC3)CO4)c2n1
SPK-0255470,,SPK-0255470-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 4.00,MIC,Test article,> 7.73,Visual,< 5.1,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc(OC(F)F)c(OC)c5)(CC3)CO4)c2n1
SPK-0255470,,SPK-0255470-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 4.00,MIC,Test article,> 7.73,Visual,< 5.1,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc(OC(F)F)c(OC)c5)(CC3)CO4)c2n1
SPK-0255470,,SPK-0255470-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 4.00,MIC,Test article,> 7.73,Visual,< 5.1,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc(OC(F)F)c(OC)c5)(CC3)CO4)c2n1
SPK-0255470,,SPK-0255470-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 4.00,MIC,Test article,> 7.73,Visual,< 5.1,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc(OC(F)F)c(OC)c5)(CC3)CO4)c2n1
SPK-0255470,,SPK-0255470-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 4.00,MIC,Test article,> 7.73,Visual,< 5.1,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc(OC(F)F)c(OC)c5)(CC3)CO4)c2n1
SPK-0255470,,SPK-0255470-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,1.00,MIC,Test article,1.93,Visual,5.7,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc(OC(F)F)c(OC)c5)(CC3)CO4)c2n1
SPK-0255469,,SPK-0255469-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 33.1,Visual,< 4.5,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cn(C)c(=O)n(C)c5=O)(CC3)CO4)c2n1
SPK-0255469,,SPK-0255469-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 33.1,Visual,< 4.5,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cn(C)c(=O)n(C)c5=O)(CC3)CO4)c2n1
SPK-0255469,,SPK-0255469-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 33.1,Visual,< 4.5,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cn(C)c(=O)n(C)c5=O)(CC3)CO4)c2n1
SPK-0255469,,SPK-0255469-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,8.00,MIC,Test article,16.5,Visual,4.8,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cn(C)c(=O)n(C)c5=O)(CC3)CO4)c2n1
SPK-0255469,,SPK-0255469-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 33.1,Visual,< 4.5,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cn(C)c(=O)n(C)c5=O)(CC3)CO4)c2n1
SPK-0255469,,SPK-0255469-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 33.1,Visual,< 4.5,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cn(C)c(=O)n(C)c5=O)(CC3)CO4)c2n1
SPK-0255469,,SPK-0255469-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 33.1,Visual,< 4.5,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cn(C)c(=O)n(C)c5=O)(CC3)CO4)c2n1
SPK-0255469,,SPK-0255469-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 33.1,Visual,< 4.5,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cn(C)c(=O)n(C)c5=O)(CC3)CO4)c2n1
SPK-0255468,,SPK-0255468-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 69.6,Visual,< 4.2,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5nn(C)cc5Cl)(CC3)CO4)c2n1
SPK-0255468,,SPK-0255468-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 69.6,Visual,< 4.2,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5nn(C)cc5Cl)(CC3)CO4)c2n1
SPK-0255468,,SPK-0255468-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 69.6,Visual,< 4.2,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5nn(C)cc5Cl)(CC3)CO4)c2n1
SPK-0255468,,SPK-0255468-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 69.6,Visual,< 4.2,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5nn(C)cc5Cl)(CC3)CO4)c2n1
SPK-0255468,,SPK-0255468-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 69.6,Visual,< 4.2,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5nn(C)cc5Cl)(CC3)CO4)c2n1
SPK-0255468,,SPK-0255468-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 69.6,Visual,< 4.2,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5nn(C)cc5Cl)(CC3)CO4)c2n1
SPK-0255468,,SPK-0255468-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 69.6,Visual,< 4.2,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5nn(C)cc5Cl)(CC3)CO4)c2n1
SPK-0255468,,SPK-0255468-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,16.0,MIC,Test article,34.8,Visual,4.5,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5nn(C)cc5Cl)(CC3)CO4)c2n1
SPK-0255467,,SPK-0255467-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,128,MIC,Test article,269,Visual,3.6,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cnn(CC(F)F)c5)(CC3)CO4)c2n1
SPK-0255467,,SPK-0255467-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,128,MIC,Test article,269,Visual,3.6,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cnn(CC(F)F)c5)(CC3)CO4)c2n1
SPK-0255467,,SPK-0255467-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 128,MIC,Test article,> 269,Visual,< 3.6,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cnn(CC(F)F)c5)(CC3)CO4)c2n1
SPK-0255467,,SPK-0255467-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,1.00,MIC,Test article,2.10,Visual,5.7,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cnn(CC(F)F)c5)(CC3)CO4)c2n1
SPK-0255467,,SPK-0255467-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 128,MIC,Test article,> 269,Visual,< 3.6,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cnn(CC(F)F)c5)(CC3)CO4)c2n1
SPK-0255467,,SPK-0255467-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 128,MIC,Test article,> 269,Visual,< 3.6,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cnn(CC(F)F)c5)(CC3)CO4)c2n1
SPK-0255467,,SPK-0255467-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 128,MIC,Test article,> 269,Visual,< 3.6,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cnn(CC(F)F)c5)(CC3)CO4)c2n1
SPK-0255467,,SPK-0255467-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.250,MIC,Test article,0.526,Visual,6.3,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cnn(CC(F)F)c5)(CC3)CO4)c2n1
SPK-0255466,,SPK-0255466-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 132,Visual,< 3.9,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5c(OC)ncnc5OC)(CC3)CO4)c2n1
SPK-0255466,,SPK-0255466-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 132,Visual,< 3.9,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5c(OC)ncnc5OC)(CC3)CO4)c2n1
SPK-0255466,,SPK-0255466-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 132,Visual,< 3.9,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5c(OC)ncnc5OC)(CC3)CO4)c2n1
SPK-0255466,,SPK-0255466-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 132,Visual,< 3.9,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5c(OC)ncnc5OC)(CC3)CO4)c2n1
SPK-0255466,,SPK-0255466-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 132,Visual,< 3.9,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5c(OC)ncnc5OC)(CC3)CO4)c2n1
SPK-0255466,,SPK-0255466-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 132,Visual,< 3.9,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5c(OC)ncnc5OC)(CC3)CO4)c2n1
SPK-0255466,,SPK-0255466-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 132,Visual,< 3.9,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5c(OC)ncnc5OC)(CC3)CO4)c2n1
SPK-0255466,,SPK-0255466-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 132,Visual,< 3.9,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5c(OC)ncnc5OC)(CC3)CO4)c2n1
SPK-0255465,,SPK-0255465-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 4.00,MIC,Test article,> 7.50,Visual,< 5.1,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COC(=O)c1cc2ncc(CNC34CCC(CCc5c(F)cnc6ccc(OC)nc56)(CC3)OC4)cc2n1C
SPK-0255465,,SPK-0255465-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 4.00,MIC,Test article,> 7.50,Visual,< 5.1,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COC(=O)c1cc2ncc(CNC34CCC(CCc5c(F)cnc6ccc(OC)nc56)(CC3)OC4)cc2n1C
SPK-0255465,,SPK-0255465-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 4.00,MIC,Test article,> 7.50,Visual,< 5.1,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COC(=O)c1cc2ncc(CNC34CCC(CCc5c(F)cnc6ccc(OC)nc56)(CC3)OC4)cc2n1C
SPK-0255465,,SPK-0255465-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 4.00,MIC,Test article,> 7.50,Visual,< 5.1,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COC(=O)c1cc2ncc(CNC34CCC(CCc5c(F)cnc6ccc(OC)nc56)(CC3)OC4)cc2n1C
SPK-0255465,,SPK-0255465-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 4.00,MIC,Test article,> 7.50,Visual,< 5.1,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COC(=O)c1cc2ncc(CNC34CCC(CCc5c(F)cnc6ccc(OC)nc56)(CC3)OC4)cc2n1C
SPK-0255465,,SPK-0255465-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 4.00,MIC,Test article,> 7.50,Visual,< 5.1,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COC(=O)c1cc2ncc(CNC34CCC(CCc5c(F)cnc6ccc(OC)nc56)(CC3)OC4)cc2n1C
SPK-0255465,,SPK-0255465-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 4.00,MIC,Test article,> 7.50,Visual,< 5.1,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COC(=O)c1cc2ncc(CNC34CCC(CCc5c(F)cnc6ccc(OC)nc56)(CC3)OC4)cc2n1C
SPK-0255465,,SPK-0255465-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 4.00,MIC,Test article,> 7.50,Visual,< 5.1,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COC(=O)c1cc2ncc(CNC34CCC(CCc5c(F)cnc6ccc(OC)nc56)(CC3)OC4)cc2n1C
SPK-0255464,,SPK-0255464-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 31.6,Visual,< 4.5,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(c5)n(C)c(=O)n6C)(CC3)CO4)c2n1
SPK-0255464,,SPK-0255464-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 31.6,Visual,< 4.5,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(c5)n(C)c(=O)n6C)(CC3)CO4)c2n1
SPK-0255464,,SPK-0255464-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 31.6,Visual,< 4.5,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(c5)n(C)c(=O)n6C)(CC3)CO4)c2n1
SPK-0255464,,SPK-0255464-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,16.0,MIC,Test article,31.6,Visual,4.5,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(c5)n(C)c(=O)n6C)(CC3)CO4)c2n1
SPK-0255464,,SPK-0255464-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 31.6,Visual,< 4.5,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(c5)n(C)c(=O)n6C)(CC3)CO4)c2n1
SPK-0255464,,SPK-0255464-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 31.6,Visual,< 4.5,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(c5)n(C)c(=O)n6C)(CC3)CO4)c2n1
SPK-0255464,,SPK-0255464-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 31.6,Visual,< 4.5,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(c5)n(C)c(=O)n6C)(CC3)CO4)c2n1
SPK-0255464,,SPK-0255464-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 31.6,Visual,< 4.5,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(c5)n(C)c(=O)n6C)(CC3)CO4)c2n1
SPK-0255463,,SPK-0255463-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 31.9,Visual,< 4.5,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc(Cl)c(O)c(OC)c5)(CC3)CO4)c2n1
SPK-0255463,,SPK-0255463-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 31.9,Visual,< 4.5,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc(Cl)c(O)c(OC)c5)(CC3)CO4)c2n1
SPK-0255463,,SPK-0255463-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 31.9,Visual,< 4.5,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc(Cl)c(O)c(OC)c5)(CC3)CO4)c2n1
SPK-0255463,,SPK-0255463-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 31.9,Visual,< 4.5,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc(Cl)c(O)c(OC)c5)(CC3)CO4)c2n1
SPK-0255463,,SPK-0255463-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 31.9,Visual,< 4.5,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc(Cl)c(O)c(OC)c5)(CC3)CO4)c2n1
SPK-0255463,,SPK-0255463-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 31.9,Visual,< 4.5,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc(Cl)c(O)c(OC)c5)(CC3)CO4)c2n1
SPK-0255463,,SPK-0255463-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 31.9,Visual,< 4.5,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc(Cl)c(O)c(OC)c5)(CC3)CO4)c2n1
SPK-0255463,,SPK-0255463-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 31.9,Visual,< 4.5,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc(Cl)c(O)c(OC)c5)(CC3)CO4)c2n1
SPK-0255462,,SPK-0255462-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 62.5,Visual,< 4.2,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc(OCCO)c(OC)c5)(CC3)CO4)c2n1
SPK-0255462,,SPK-0255462-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 62.5,Visual,< 4.2,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc(OCCO)c(OC)c5)(CC3)CO4)c2n1
SPK-0255462,,SPK-0255462-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 62.5,Visual,< 4.2,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc(OCCO)c(OC)c5)(CC3)CO4)c2n1
SPK-0255462,,SPK-0255462-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 62.5,Visual,< 4.2,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc(OCCO)c(OC)c5)(CC3)CO4)c2n1
SPK-0255462,,SPK-0255462-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 62.5,Visual,< 4.2,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc(OCCO)c(OC)c5)(CC3)CO4)c2n1
SPK-0255462,,SPK-0255462-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 62.5,Visual,< 4.2,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc(OCCO)c(OC)c5)(CC3)CO4)c2n1
SPK-0255462,,SPK-0255462-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 62.5,Visual,< 4.2,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc(OCCO)c(OC)c5)(CC3)CO4)c2n1
SPK-0255462,,SPK-0255462-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 62.5,Visual,< 4.2,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc(OCCO)c(OC)c5)(CC3)CO4)c2n1
SPK-0255461,,SPK-0255461-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 31.9,Visual,< 4.5,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(c5)OC(F)(F)O6)(CC3)CO4)c2n1
SPK-0255461,,SPK-0255461-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 31.9,Visual,< 4.5,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(c5)OC(F)(F)O6)(CC3)CO4)c2n1
SPK-0255461,,SPK-0255461-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 31.9,Visual,< 4.5,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(c5)OC(F)(F)O6)(CC3)CO4)c2n1
SPK-0255461,,SPK-0255461-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 31.9,Visual,< 4.5,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(c5)OC(F)(F)O6)(CC3)CO4)c2n1
SPK-0255461,,SPK-0255461-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 31.9,Visual,< 4.5,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(c5)OC(F)(F)O6)(CC3)CO4)c2n1
SPK-0255461,,SPK-0255461-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 31.9,Visual,< 4.5,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(c5)OC(F)(F)O6)(CC3)CO4)c2n1
SPK-0255461,,SPK-0255461-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 31.9,Visual,< 4.5,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(c5)OC(F)(F)O6)(CC3)CO4)c2n1
SPK-0255461,,SPK-0255461-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.250,MIC,Test article,0.498,Visual,6.3,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(c5)OC(F)(F)O6)(CC3)CO4)c2n1
SPK-0255460,,SPK-0255460-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 32.4,Visual,< 4.5,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cnc6c(c5)OCCN6C)(CC3)CO4)c2n1
SPK-0255460,,SPK-0255460-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 32.4,Visual,< 4.5,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cnc6c(c5)OCCN6C)(CC3)CO4)c2n1
SPK-0255460,,SPK-0255460-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 32.4,Visual,< 4.5,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cnc6c(c5)OCCN6C)(CC3)CO4)c2n1
SPK-0255460,,SPK-0255460-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.500,MIC,Test article,1.01,Visual,6.0,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cnc6c(c5)OCCN6C)(CC3)CO4)c2n1
SPK-0255460,,SPK-0255460-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 32.4,Visual,< 4.5,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cnc6c(c5)OCCN6C)(CC3)CO4)c2n1
SPK-0255460,,SPK-0255460-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 32.4,Visual,< 4.5,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cnc6c(c5)OCCN6C)(CC3)CO4)c2n1
SPK-0255460,,SPK-0255460-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 32.4,Visual,< 4.5,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cnc6c(c5)OCCN6C)(CC3)CO4)c2n1
SPK-0255460,,SPK-0255460-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.250,MIC,Test article,0.507,Visual,6.3,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cnc6c(c5)OCCN6C)(CC3)CO4)c2n1
SPK-0255459,,SPK-0255459-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,1.00,MIC,Test article,2.00,Visual,5.7,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(C#N)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255459,,SPK-0255459-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,2.00,MIC,Test article,4.00,Visual,5.4,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(C#N)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255459,,SPK-0255459-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 4.00,MIC,Test article,> 7.99,Visual,< 5.1,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(C#N)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255459,,SPK-0255459-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,8.00E-03,MIC,Test article,0.0160,Visual,7.8,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(C#N)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255459,,SPK-0255459-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 4.00,MIC,Test article,> 7.99,Visual,< 5.1,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(C#N)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255459,,SPK-0255459-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 4.00,MIC,Test article,> 7.99,Visual,< 5.1,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(C#N)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255459,,SPK-0255459-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 4.00,MIC,Test article,> 7.99,Visual,< 5.1,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(C#N)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255459,,SPK-0255459-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0160,MIC,Test article,0.0320,Visual,7.5,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(C#N)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255458,,SPK-0255458-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,2.00,MIC,Test article,3.73,Visual,5.4,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,NCCCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255458,,SPK-0255458-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,2.00,MIC,Test article,3.73,Visual,5.4,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,NCCCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255458,,SPK-0255458-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,8.00,MIC,Test article,14.9,Visual,4.8,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,NCCCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255458,,SPK-0255458-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0160,MIC,Test article,0.0298,Visual,7.5,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,NCCCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255458,,SPK-0255458-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 29.8,Visual,< 4.5,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,NCCCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255458,,SPK-0255458-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,16.0,MIC,Test article,29.8,Visual,4.5,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,NCCCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255458,,SPK-0255458-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,16.0,MIC,Test article,29.8,Visual,4.5,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,NCCCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255458,,SPK-0255458-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.250,MIC,Test article,0.466,Visual,6.3,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,NCCCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255457,,SPK-0255457-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,2.00,MIC,Test article,3.72,Visual,5.4,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OCCCO)nc56)(CC3)OC4)nc2N1
SPK-0255457,,SPK-0255457-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,4.00,MIC,Test article,7.44,Visual,5.1,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OCCCO)nc56)(CC3)OC4)nc2N1
SPK-0255457,,SPK-0255457-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,16.0,MIC,Test article,29.8,Visual,4.5,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OCCCO)nc56)(CC3)OC4)nc2N1
SPK-0255457,,SPK-0255457-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,8.00E-03,MIC,Test article,0.0149,Visual,7.8,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OCCCO)nc56)(CC3)OC4)nc2N1
SPK-0255457,,SPK-0255457-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 29.8,Visual,< 4.5,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OCCCO)nc56)(CC3)OC4)nc2N1
SPK-0255457,,SPK-0255457-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 29.8,Visual,< 4.5,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OCCCO)nc56)(CC3)OC4)nc2N1
SPK-0255457,,SPK-0255457-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 29.8,Visual,< 4.5,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OCCCO)nc56)(CC3)OC4)nc2N1
SPK-0255457,,SPK-0255457-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0310,MIC,Test article,0.0577,Visual,7.2,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OCCCO)nc56)(CC3)OC4)nc2N1
SPK-0255456,,SPK-0255456-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 30.7,Visual,< 4.5,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,Cc1nc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)ccnc2cc1C#N
SPK-0255456,,SPK-0255456-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 30.7,Visual,< 4.5,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,Cc1nc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)ccnc2cc1C#N
SPK-0255456,,SPK-0255456-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 30.7,Visual,< 4.5,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,Cc1nc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)ccnc2cc1C#N
SPK-0255456,,SPK-0255456-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,8.00,MIC,Test article,15.4,Visual,4.8,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,Cc1nc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)ccnc2cc1C#N
SPK-0255456,,SPK-0255456-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 30.7,Visual,< 4.5,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,Cc1nc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)ccnc2cc1C#N
SPK-0255456,,SPK-0255456-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 30.7,Visual,< 4.5,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,Cc1nc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)ccnc2cc1C#N
SPK-0255456,,SPK-0255456-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 30.7,Visual,< 4.5,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,Cc1nc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)ccnc2cc1C#N
SPK-0255456,,SPK-0255456-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 30.7,Visual,< 4.5,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,Cc1nc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)ccnc2cc1C#N
SPK-0255455,,SPK-0255455-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,64.0,MIC,Test article,119,Visual,3.9,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1nc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)ccnc2cc1C#N
SPK-0255455,,SPK-0255455-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 119,Visual,< 3.9,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1nc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)ccnc2cc1C#N
SPK-0255455,,SPK-0255455-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 119,Visual,< 3.9,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1nc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)ccnc2cc1C#N
SPK-0255455,,SPK-0255455-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.500,MIC,Test article,0.931,Visual,6.0,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1nc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)ccnc2cc1C#N
SPK-0255455,,SPK-0255455-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 119,Visual,< 3.9,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1nc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)ccnc2cc1C#N
SPK-0255455,,SPK-0255455-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 119,Visual,< 3.9,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1nc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)ccnc2cc1C#N
SPK-0255455,,SPK-0255455-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 119,Visual,< 3.9,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1nc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)ccnc2cc1C#N
SPK-0255455,,SPK-0255455-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,16.0,MIC,Test article,29.8,Visual,4.5,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1nc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)ccnc2cc1C#N
SPK-0255454,,SPK-0255454-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,4.00,MIC,Test article,7.68,Visual,5.1,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,Cc1cc(C#N)nc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)ccnc12
SPK-0255454,,SPK-0255454-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,16.0,MIC,Test article,30.7,Visual,4.5,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,Cc1cc(C#N)nc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)ccnc12
SPK-0255454,,SPK-0255454-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,64.0,MIC,Test article,123,Visual,3.9,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,Cc1cc(C#N)nc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)ccnc12
SPK-0255454,,SPK-0255454-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0630,MIC,Test article,0.121,Visual,6.9,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,Cc1cc(C#N)nc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)ccnc12
SPK-0255454,,SPK-0255454-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 123,Visual,< 3.9,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,Cc1cc(C#N)nc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)ccnc12
SPK-0255454,,SPK-0255454-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 123,Visual,< 3.9,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,Cc1cc(C#N)nc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)ccnc12
SPK-0255454,,SPK-0255454-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 123,Visual,< 3.9,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,Cc1cc(C#N)nc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)ccnc12
SPK-0255454,,SPK-0255454-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,1.00,MIC,Test article,1.92,Visual,5.7,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,Cc1cc(C#N)nc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)ccnc12
SPK-0255453,,SPK-0255453-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,16.0,MIC,Test article,29.5,Visual,4.5,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CN(C)c1nc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)ccnc2cc1F
SPK-0255453,,SPK-0255453-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 29.5,Visual,< 4.5,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CN(C)c1nc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)ccnc2cc1F
SPK-0255453,,SPK-0255453-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 29.5,Visual,< 4.5,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CN(C)c1nc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)ccnc2cc1F
SPK-0255453,,SPK-0255453-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.125,MIC,Test article,0.230,Visual,6.6,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CN(C)c1nc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)ccnc2cc1F
SPK-0255453,,SPK-0255453-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 29.5,Visual,< 4.5,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CN(C)c1nc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)ccnc2cc1F
SPK-0255453,,SPK-0255453-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 29.5,Visual,< 4.5,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CN(C)c1nc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)ccnc2cc1F
SPK-0255453,,SPK-0255453-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 29.5,Visual,< 4.5,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CN(C)c1nc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)ccnc2cc1F
SPK-0255453,,SPK-0255453-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,2.00,MIC,Test article,3.68,Visual,5.4,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CN(C)c1nc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)ccnc2cc1F
SPK-0255452,,SPK-0255452-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 116,Visual,< 3.9,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cc(C(F)(F)F)cnc56)(CC3)OC4)nc2N1
SPK-0255452,,SPK-0255452-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 116,Visual,< 3.9,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cc(C(F)(F)F)cnc56)(CC3)OC4)nc2N1
SPK-0255452,,SPK-0255452-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 116,Visual,< 3.9,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cc(C(F)(F)F)cnc56)(CC3)OC4)nc2N1
SPK-0255452,,SPK-0255452-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,64.0,MIC,Test article,116,Visual,3.9,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cc(C(F)(F)F)cnc56)(CC3)OC4)nc2N1
SPK-0255452,,SPK-0255452-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 116,Visual,< 3.9,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cc(C(F)(F)F)cnc56)(CC3)OC4)nc2N1
SPK-0255452,,SPK-0255452-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 116,Visual,< 3.9,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cc(C(F)(F)F)cnc56)(CC3)OC4)nc2N1
SPK-0255452,,SPK-0255452-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 116,Visual,< 3.9,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cc(C(F)(F)F)cnc56)(CC3)OC4)nc2N1
SPK-0255452,,SPK-0255452-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 116,Visual,< 3.9,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cc(C(F)(F)F)cnc56)(CC3)OC4)nc2N1
SPK-0255451,,SPK-0255451-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,64.0,MIC,Test article,113,Visual,3.9,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CCOC(=O)Cc1ccc2nccc(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255451,,SPK-0255451-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 113,Visual,< 3.9,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CCOC(=O)Cc1ccc2nccc(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255451,,SPK-0255451-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 113,Visual,< 3.9,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CCOC(=O)Cc1ccc2nccc(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255451,,SPK-0255451-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,1.00,MIC,Test article,1.76,Visual,5.8,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CCOC(=O)Cc1ccc2nccc(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255451,,SPK-0255451-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 113,Visual,< 3.9,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CCOC(=O)Cc1ccc2nccc(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255451,,SPK-0255451-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 113,Visual,< 3.9,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CCOC(=O)Cc1ccc2nccc(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255451,,SPK-0255451-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 113,Visual,< 3.9,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CCOC(=O)Cc1ccc2nccc(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255451,,SPK-0255451-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,32.0,MIC,Test article,56.3,Visual,4.2,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CCOC(=O)Cc1ccc2nccc(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255450,,SPK-0255450-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.500,MIC,Test article,0.916,Visual,6.0,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CS6)(CC3)CO4)c2n1
SPK-0255450,,SPK-0255450-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,2.00,MIC,Test article,3.66,Visual,5.4,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CS6)(CC3)CO4)c2n1
SPK-0255450,,SPK-0255450-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,8.00,MIC,Test article,14.7,Visual,4.8,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CS6)(CC3)CO4)c2n1
SPK-0255450,,SPK-0255450-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,8.00E-03,MIC,Test article,0.0147,Visual,7.8,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CS6)(CC3)CO4)c2n1
SPK-0255450,,SPK-0255450-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 29.3,Visual,< 4.5,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CS6)(CC3)CO4)c2n1
SPK-0255450,,SPK-0255450-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 29.3,Visual,< 4.5,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CS6)(CC3)CO4)c2n1
SPK-0255450,,SPK-0255450-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 29.3,Visual,< 4.5,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CS6)(CC3)CO4)c2n1
SPK-0255450,,SPK-0255450-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0310,MIC,Test article,0.0568,Visual,7.2,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CS6)(CC3)CO4)c2n1
SPK-0255449,,SPK-0255449-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 13.8,Visual,< 4.9,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NS(=O)(=O)c5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255449,,SPK-0255449-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 13.8,Visual,< 4.9,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NS(=O)(=O)c5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255449,,SPK-0255449-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 13.8,Visual,< 4.9,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NS(=O)(=O)c5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255449,,SPK-0255449-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.125,MIC,Test article,0.216,Visual,6.7,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NS(=O)(=O)c5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255449,,SPK-0255449-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 13.8,Visual,< 4.9,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NS(=O)(=O)c5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255449,,SPK-0255449-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 13.8,Visual,< 4.9,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NS(=O)(=O)c5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255449,,SPK-0255449-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 13.8,Visual,< 4.9,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NS(=O)(=O)c5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255449,,SPK-0255449-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.125,MIC,Test article,0.216,Visual,6.7,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NS(=O)(=O)c5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255448,,SPK-0255448-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 13.1,Visual,< 4.9,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CN(C)c1nc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c(F)cnc2cc1C(F)(F)F
SPK-0255448,,SPK-0255448-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 13.1,Visual,< 4.9,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CN(C)c1nc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c(F)cnc2cc1C(F)(F)F
SPK-0255448,,SPK-0255448-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 13.1,Visual,< 4.9,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CN(C)c1nc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c(F)cnc2cc1C(F)(F)F
SPK-0255448,,SPK-0255448-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 13.1,Visual,< 4.9,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CN(C)c1nc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c(F)cnc2cc1C(F)(F)F
SPK-0255448,,SPK-0255448-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 13.1,Visual,< 4.9,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CN(C)c1nc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c(F)cnc2cc1C(F)(F)F
SPK-0255448,,SPK-0255448-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 13.1,Visual,< 4.9,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CN(C)c1nc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c(F)cnc2cc1C(F)(F)F
SPK-0255448,,SPK-0255448-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 13.1,Visual,< 4.9,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CN(C)c1nc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c(F)cnc2cc1C(F)(F)F
SPK-0255448,,SPK-0255448-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 13.1,Visual,< 4.9,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CN(C)c1nc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c(F)cnc2cc1C(F)(F)F
SPK-0255447,,SPK-0255447-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,4.00,MIC,Test article,7.09,Visual,5.1,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1nc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c(F)cnc2cc1Cl
SPK-0255447,,SPK-0255447-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 14.2,Visual,< 4.8,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1nc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c(F)cnc2cc1Cl
SPK-0255447,,SPK-0255447-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 14.2,Visual,< 4.8,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1nc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c(F)cnc2cc1Cl
SPK-0255447,,SPK-0255447-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,8.00E-03,MIC,Test article,0.0142,Visual,7.8,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1nc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c(F)cnc2cc1Cl
SPK-0255447,,SPK-0255447-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 14.2,Visual,< 4.8,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1nc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c(F)cnc2cc1Cl
SPK-0255447,,SPK-0255447-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 14.2,Visual,< 4.8,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1nc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c(F)cnc2cc1Cl
SPK-0255447,,SPK-0255447-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 14.2,Visual,< 4.8,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1nc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c(F)cnc2cc1Cl
SPK-0255447,,SPK-0255447-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.250,MIC,Test article,0.443,Visual,6.4,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1nc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c(F)cnc2cc1Cl
SPK-0255446,,SPK-0255446-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,16.0,MIC,Test article,32.0,Visual,4.5,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cc(F)cnc56)(CC3)OC4)nc2N1
SPK-0255446,,SPK-0255446-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 64.0,Visual,< 4.2,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cc(F)cnc56)(CC3)OC4)nc2N1
SPK-0255446,,SPK-0255446-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 64.0,Visual,< 4.2,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cc(F)cnc56)(CC3)OC4)nc2N1
SPK-0255446,,SPK-0255446-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.250,MIC,Test article,0.500,Visual,6.3,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cc(F)cnc56)(CC3)OC4)nc2N1
SPK-0255446,,SPK-0255446-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 64.0,Visual,< 4.2,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cc(F)cnc56)(CC3)OC4)nc2N1
SPK-0255446,,SPK-0255446-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 64.0,Visual,< 4.2,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cc(F)cnc56)(CC3)OC4)nc2N1
SPK-0255446,,SPK-0255446-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 64.0,Visual,< 4.2,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cc(F)cnc56)(CC3)OC4)nc2N1
SPK-0255446,,SPK-0255446-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,8.00,MIC,Test article,16.0,Visual,4.8,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cc(F)cnc56)(CC3)OC4)nc2N1
SPK-0255445,,SPK-0255445-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 27.4,Visual,< 4.6,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CCOC(=O)c1c(OC)cnc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)ccnc12
SPK-0255445,,SPK-0255445-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 27.4,Visual,< 4.6,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CCOC(=O)c1c(OC)cnc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)ccnc12
SPK-0255445,,SPK-0255445-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 27.4,Visual,< 4.6,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CCOC(=O)c1c(OC)cnc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)ccnc12
SPK-0255445,,SPK-0255445-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 27.4,Visual,< 4.6,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CCOC(=O)c1c(OC)cnc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)ccnc12
SPK-0255445,,SPK-0255445-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 27.4,Visual,< 4.6,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CCOC(=O)c1c(OC)cnc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)ccnc12
SPK-0255445,,SPK-0255445-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 27.4,Visual,< 4.6,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CCOC(=O)c1c(OC)cnc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)ccnc12
SPK-0255445,,SPK-0255445-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 27.4,Visual,< 4.6,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CCOC(=O)c1c(OC)cnc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)ccnc12
SPK-0255445,,SPK-0255445-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 27.4,Visual,< 4.6,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CCOC(=O)c1c(OC)cnc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)ccnc12
SPK-0255444,,SPK-0255444-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,2.00,MIC,Test article,3.77,Visual,5.4,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1nc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)ccnc2cc1F
SPK-0255444,,SPK-0255444-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,4.00,MIC,Test article,7.55,Visual,5.1,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1nc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)ccnc2cc1F
SPK-0255444,,SPK-0255444-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 30.2,Visual,< 4.5,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1nc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)ccnc2cc1F
SPK-0255444,,SPK-0255444-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0160,MIC,Test article,0.0302,Visual,7.5,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1nc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)ccnc2cc1F
SPK-0255444,,SPK-0255444-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 30.2,Visual,< 4.5,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1nc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)ccnc2cc1F
SPK-0255444,,SPK-0255444-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 30.2,Visual,< 4.5,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1nc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)ccnc2cc1F
SPK-0255444,,SPK-0255444-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 30.2,Visual,< 4.5,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1nc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)ccnc2cc1F
SPK-0255444,,SPK-0255444-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.250,MIC,Test article,0.472,Visual,6.3,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1nc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)ccnc2cc1F
SPK-0255443,,SPK-0255443-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,4.00,MIC,Test article,7.17,Visual,5.1,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CCOc1cc(C)c2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255443,,SPK-0255443-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,8.00,MIC,Test article,14.3,Visual,4.8,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CCOc1cc(C)c2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255443,,SPK-0255443-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,32.0,MIC,Test article,57.3,Visual,4.2,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CCOc1cc(C)c2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255443,,SPK-0255443-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0310,MIC,Test article,0.0556,Visual,7.3,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CCOc1cc(C)c2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255443,,SPK-0255443-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 57.3,Visual,< 4.2,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CCOc1cc(C)c2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255443,,SPK-0255443-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 57.3,Visual,< 4.2,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CCOc1cc(C)c2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255443,,SPK-0255443-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 57.3,Visual,< 4.2,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CCOc1cc(C)c2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255443,,SPK-0255443-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.125,MIC,Test article,0.224,Visual,6.6,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CCOc1cc(C)c2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255442,,SPK-0255442-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,2.00,MIC,Test article,3.38,Visual,5.5,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,Cc1cc(S(C)(=O)=O)nc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c(F)cnc12
SPK-0255442,,SPK-0255442-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,8.00,MIC,Test article,13.5,Visual,4.9,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,Cc1cc(S(C)(=O)=O)nc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c(F)cnc12
SPK-0255442,,SPK-0255442-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,32.0,MIC,Test article,54.0,Visual,4.3,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,Cc1cc(S(C)(=O)=O)nc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c(F)cnc12
SPK-0255442,,SPK-0255442-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0160,MIC,Test article,0.0270,Visual,7.6,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,Cc1cc(S(C)(=O)=O)nc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c(F)cnc12
SPK-0255442,,SPK-0255442-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 108,Visual,< 4.0,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,Cc1cc(S(C)(=O)=O)nc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c(F)cnc12
SPK-0255442,,SPK-0255442-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 108,Visual,< 4.0,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,Cc1cc(S(C)(=O)=O)nc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c(F)cnc12
SPK-0255442,,SPK-0255442-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,64.0,MIC,Test article,108,Visual,4.0,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,Cc1cc(S(C)(=O)=O)nc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c(F)cnc12
SPK-0255442,,SPK-0255442-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.250,MIC,Test article,0.422,Visual,6.4,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,Cc1cc(S(C)(=O)=O)nc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c(F)cnc12
SPK-0255441,,SPK-0255441-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 13.5,Visual,< 4.9,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CN(C)c1nc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)ccnc2cc1C(F)(F)F
SPK-0255441,,SPK-0255441-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 13.5,Visual,< 4.9,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CN(C)c1nc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)ccnc2cc1C(F)(F)F
SPK-0255441,,SPK-0255441-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 13.5,Visual,< 4.9,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CN(C)c1nc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)ccnc2cc1C(F)(F)F
SPK-0255441,,SPK-0255441-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 13.5,Visual,< 4.9,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CN(C)c1nc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)ccnc2cc1C(F)(F)F
SPK-0255441,,SPK-0255441-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 13.5,Visual,< 4.9,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CN(C)c1nc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)ccnc2cc1C(F)(F)F
SPK-0255441,,SPK-0255441-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 13.5,Visual,< 4.9,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CN(C)c1nc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)ccnc2cc1C(F)(F)F
SPK-0255441,,SPK-0255441-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 13.5,Visual,< 4.9,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CN(C)c1nc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)ccnc2cc1C(F)(F)F
SPK-0255441,,SPK-0255441-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 13.5,Visual,< 4.9,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CN(C)c1nc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)ccnc2cc1C(F)(F)F
SPK-0255440,,SPK-0255440-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,8.00,MIC,Test article,14.5,Visual,4.8,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5ccnc6ccc(C(F)(F)F)nc56)(CC3)OC4)nc2N1
SPK-0255440,,SPK-0255440-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,32.0,MIC,Test article,58.2,Visual,4.2,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5ccnc6ccc(C(F)(F)F)nc56)(CC3)OC4)nc2N1
SPK-0255440,,SPK-0255440-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 116,Visual,< 3.9,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5ccnc6ccc(C(F)(F)F)nc56)(CC3)OC4)nc2N1
SPK-0255440,,SPK-0255440-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.250,MIC,Test article,0.455,Visual,6.3,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5ccnc6ccc(C(F)(F)F)nc56)(CC3)OC4)nc2N1
SPK-0255440,,SPK-0255440-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 116,Visual,< 3.9,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5ccnc6ccc(C(F)(F)F)nc56)(CC3)OC4)nc2N1
SPK-0255440,,SPK-0255440-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 116,Visual,< 3.9,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5ccnc6ccc(C(F)(F)F)nc56)(CC3)OC4)nc2N1
SPK-0255440,,SPK-0255440-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 116,Visual,< 3.9,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5ccnc6ccc(C(F)(F)F)nc56)(CC3)OC4)nc2N1
SPK-0255440,,SPK-0255440-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,2.00,MIC,Test article,3.64,Visual,5.4,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5ccnc6ccc(C(F)(F)F)nc56)(CC3)OC4)nc2N1
SPK-0255439,,SPK-0255439-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,16.0,MIC,Test article,27.9,Visual,4.6,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,Cc1cc(S(C)(=O)=O)nc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)ccnc12
SPK-0255439,,SPK-0255439-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,32.0,MIC,Test article,55.7,Visual,4.3,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,Cc1cc(S(C)(=O)=O)nc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)ccnc12
SPK-0255439,,SPK-0255439-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 55.7,Visual,< 4.3,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,Cc1cc(S(C)(=O)=O)nc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)ccnc12
SPK-0255439,,SPK-0255439-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0630,MIC,Test article,0.110,Visual,7.0,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,Cc1cc(S(C)(=O)=O)nc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)ccnc12
SPK-0255439,,SPK-0255439-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 55.7,Visual,< 4.3,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,Cc1cc(S(C)(=O)=O)nc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)ccnc12
SPK-0255439,,SPK-0255439-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 55.7,Visual,< 4.3,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,Cc1cc(S(C)(=O)=O)nc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)ccnc12
SPK-0255439,,SPK-0255439-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 55.7,Visual,< 4.3,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,Cc1cc(S(C)(=O)=O)nc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)ccnc12
SPK-0255439,,SPK-0255439-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,1.00,MIC,Test article,1.74,Visual,5.8,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,Cc1cc(S(C)(=O)=O)nc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)ccnc12
SPK-0255438,,SPK-0255438-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 106,Visual,< 4.0,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N#Cc1cc2nccc(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2nc1OCC(F)(F)F
SPK-0255438,,SPK-0255438-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 106,Visual,< 4.0,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N#Cc1cc2nccc(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2nc1OCC(F)(F)F
SPK-0255438,,SPK-0255438-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 106,Visual,< 4.0,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N#Cc1cc2nccc(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2nc1OCC(F)(F)F
SPK-0255438,,SPK-0255438-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,2.00,MIC,Test article,3.31,Visual,5.5,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N#Cc1cc2nccc(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2nc1OCC(F)(F)F
SPK-0255438,,SPK-0255438-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 106,Visual,< 4.0,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N#Cc1cc2nccc(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2nc1OCC(F)(F)F
SPK-0255438,,SPK-0255438-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 106,Visual,< 4.0,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N#Cc1cc2nccc(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2nc1OCC(F)(F)F
SPK-0255438,,SPK-0255438-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 106,Visual,< 4.0,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N#Cc1cc2nccc(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2nc1OCC(F)(F)F
SPK-0255438,,SPK-0255438-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 106,Visual,< 4.0,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,N#Cc1cc2nccc(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2nc1OCC(F)(F)F
SPK-0255437,,SPK-0255437-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 30.5,Visual,< 4.5,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CN(C)c1cnc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)ccnc2c1
SPK-0255437,,SPK-0255437-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 30.5,Visual,< 4.5,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CN(C)c1cnc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)ccnc2c1
SPK-0255437,,SPK-0255437-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 30.5,Visual,< 4.5,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CN(C)c1cnc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)ccnc2c1
SPK-0255437,,SPK-0255437-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 30.5,Visual,< 4.5,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CN(C)c1cnc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)ccnc2c1
SPK-0255437,,SPK-0255437-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 30.5,Visual,< 4.5,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CN(C)c1cnc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)ccnc2c1
SPK-0255437,,SPK-0255437-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 30.5,Visual,< 4.5,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CN(C)c1cnc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)ccnc2c1
SPK-0255437,,SPK-0255437-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 30.5,Visual,< 4.5,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CN(C)c1cnc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)ccnc2c1
SPK-0255437,,SPK-0255437-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 30.5,Visual,< 4.5,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CN(C)c1cnc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)ccnc2c1
SPK-0255436,,SPK-0255436-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,2.00,MIC,Test article,3.68,Visual,5.4,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1cc(C)c2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255436,,SPK-0255436-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,4.00,MIC,Test article,7.35,Visual,5.1,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1cc(C)c2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255436,,SPK-0255436-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,16.0,MIC,Test article,29.4,Visual,4.5,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1cc(C)c2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255436,,SPK-0255436-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,8.00E-03,MIC,Test article,0.0147,Visual,7.8,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1cc(C)c2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255436,,SPK-0255436-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 29.4,Visual,< 4.5,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1cc(C)c2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255436,,SPK-0255436-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,16.0,MIC,Test article,29.4,Visual,4.5,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1cc(C)c2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255436,,SPK-0255436-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 29.4,Visual,< 4.5,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1cc(C)c2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255436,,SPK-0255436-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0310,MIC,Test article,0.0570,Visual,7.2,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1cc(C)c2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255435,,SPK-0255435-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 128,MIC,Test article,> 251,Visual,< 3.6,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5nc(C(=O)O)cs5)(CC3)CO4)c2n1
SPK-0255435,,SPK-0255435-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 128,MIC,Test article,> 251,Visual,< 3.6,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5nc(C(=O)O)cs5)(CC3)CO4)c2n1
SPK-0255435,,SPK-0255435-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 128,MIC,Test article,> 251,Visual,< 3.6,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5nc(C(=O)O)cs5)(CC3)CO4)c2n1
SPK-0255435,,SPK-0255435-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 128,MIC,Test article,> 251,Visual,< 3.6,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5nc(C(=O)O)cs5)(CC3)CO4)c2n1
SPK-0255435,,SPK-0255435-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 128,MIC,Test article,> 251,Visual,< 3.6,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5nc(C(=O)O)cs5)(CC3)CO4)c2n1
SPK-0255435,,SPK-0255435-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 128,MIC,Test article,> 251,Visual,< 3.6,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5nc(C(=O)O)cs5)(CC3)CO4)c2n1
SPK-0255435,,SPK-0255435-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 128,MIC,Test article,> 251,Visual,< 3.6,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5nc(C(=O)O)cs5)(CC3)CO4)c2n1
SPK-0255435,,SPK-0255435-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,64.0,MIC,Test article,126,Visual,3.9,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5nc(C(=O)O)cs5)(CC3)CO4)c2n1
SPK-0255434,,SPK-0255434-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,16.0,MIC,Test article,30.8,Visual,4.5,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6c(cc5F)OCO6)(CC3)CO4)c2n1
SPK-0255434,,SPK-0255434-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 30.8,Visual,< 4.5,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6c(cc5F)OCO6)(CC3)CO4)c2n1
SPK-0255434,,SPK-0255434-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 30.8,Visual,< 4.5,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6c(cc5F)OCO6)(CC3)CO4)c2n1
SPK-0255434,,SPK-0255434-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.500,MIC,Test article,0.962,Visual,6.0,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6c(cc5F)OCO6)(CC3)CO4)c2n1
SPK-0255434,,SPK-0255434-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 30.8,Visual,< 4.5,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6c(cc5F)OCO6)(CC3)CO4)c2n1
SPK-0255434,,SPK-0255434-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 30.8,Visual,< 4.5,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6c(cc5F)OCO6)(CC3)CO4)c2n1
SPK-0255434,,SPK-0255434-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 30.8,Visual,< 4.5,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6c(cc5F)OCO6)(CC3)CO4)c2n1
SPK-0255434,,SPK-0255434-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0630,MIC,Test article,0.121,Visual,6.9,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6c(cc5F)OCO6)(CC3)CO4)c2n1
SPK-0255433,,SPK-0255433-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 32.0,Visual,< 4.5,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CCOC(=O)c1csc(CNC23CCC(CCc4c(F)cnc5ccc(OC)nc45)(CC2)OC3)n1
SPK-0255433,,SPK-0255433-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 32.0,Visual,< 4.5,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CCOC(=O)c1csc(CNC23CCC(CCc4c(F)cnc5ccc(OC)nc45)(CC2)OC3)n1
SPK-0255433,,SPK-0255433-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 32.0,Visual,< 4.5,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CCOC(=O)c1csc(CNC23CCC(CCc4c(F)cnc5ccc(OC)nc45)(CC2)OC3)n1
SPK-0255433,,SPK-0255433-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 32.0,Visual,< 4.5,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CCOC(=O)c1csc(CNC23CCC(CCc4c(F)cnc5ccc(OC)nc45)(CC2)OC3)n1
SPK-0255433,,SPK-0255433-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 32.0,Visual,< 4.5,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CCOC(=O)c1csc(CNC23CCC(CCc4c(F)cnc5ccc(OC)nc45)(CC2)OC3)n1
SPK-0255433,,SPK-0255433-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 32.0,Visual,< 4.5,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CCOC(=O)c1csc(CNC23CCC(CCc4c(F)cnc5ccc(OC)nc45)(CC2)OC3)n1
SPK-0255433,,SPK-0255433-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 32.0,Visual,< 4.5,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CCOC(=O)c1csc(CNC23CCC(CCc4c(F)cnc5ccc(OC)nc45)(CC2)OC3)n1
SPK-0255433,,SPK-0255433-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,16.0,MIC,Test article,32.0,Visual,4.5,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CCOC(=O)c1csc(CNC23CCC(CCc4c(F)cnc5ccc(OC)nc45)(CC2)OC3)n1
SPK-0255432,,SPK-0255432-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,2.00,MIC,Test article,4.07,Visual,5.4,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(O)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255432,,SPK-0255432-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,4.00,MIC,Test article,8.14,Visual,5.1,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(O)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255432,,SPK-0255432-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,16.0,MIC,Test article,32.6,Visual,4.5,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(O)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255432,,SPK-0255432-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0160,MIC,Test article,0.0326,Visual,7.5,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(O)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255432,,SPK-0255432-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,32.0,MIC,Test article,65.1,Visual,4.2,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(O)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255432,,SPK-0255432-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,32.0,MIC,Test article,65.1,Visual,4.2,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(O)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255432,,SPK-0255432-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,32.0,MIC,Test article,65.1,Visual,4.2,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(O)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255432,,SPK-0255432-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0630,MIC,Test article,0.128,Visual,6.9,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(O)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255431,,SPK-0255431-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 29.8,Visual,< 4.5,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C(O)COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255431,,SPK-0255431-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 29.8,Visual,< 4.5,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C(O)COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255431,,SPK-0255431-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 29.8,Visual,< 4.5,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C(O)COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255431,,SPK-0255431-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,8.00,MIC,Test article,14.9,Visual,4.8,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C(O)COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255431,,SPK-0255431-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 29.8,Visual,< 4.5,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C(O)COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255431,,SPK-0255431-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 29.8,Visual,< 4.5,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C(O)COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255431,,SPK-0255431-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 29.8,Visual,< 4.5,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C(O)COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255431,,SPK-0255431-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 29.8,Visual,< 4.5,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C(O)COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255430,,SPK-0255430-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,1.00,MIC,Test article,1.91,Visual,5.7,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,NCCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255430,,SPK-0255430-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,1.00,MIC,Test article,1.91,Visual,5.7,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,NCCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255430,,SPK-0255430-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,4.00,MIC,Test article,7.65,Visual,5.1,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,NCCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255430,,SPK-0255430-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0160,MIC,Test article,0.0306,Visual,7.5,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,NCCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255430,,SPK-0255430-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,64.0,MIC,Test article,122,Visual,3.9,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,NCCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255430,,SPK-0255430-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,32.0,MIC,Test article,61.2,Visual,4.2,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,NCCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255430,,SPK-0255430-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,16.0,MIC,Test article,30.6,Visual,4.5,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,NCCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255430,,SPK-0255430-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.250,MIC,Test article,0.478,Visual,6.3,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,NCCOc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255429,,SPK-0255429-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,1.00,MIC,Test article,1.91,Visual,5.7,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OCCO)nc56)(CC3)OC4)nc2N1
SPK-0255429,,SPK-0255429-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,4.00,MIC,Test article,7.64,Visual,5.1,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OCCO)nc56)(CC3)OC4)nc2N1
SPK-0255429,,SPK-0255429-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,8.00,MIC,Test article,15.3,Visual,4.8,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OCCO)nc56)(CC3)OC4)nc2N1
SPK-0255429,,SPK-0255429-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,8.00E-03,MIC,Test article,0.0153,Visual,7.8,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OCCO)nc56)(CC3)OC4)nc2N1
SPK-0255429,,SPK-0255429-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 61.1,Visual,< 4.2,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OCCO)nc56)(CC3)OC4)nc2N1
SPK-0255429,,SPK-0255429-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,32.0,MIC,Test article,61.1,Visual,4.2,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OCCO)nc56)(CC3)OC4)nc2N1
SPK-0255429,,SPK-0255429-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 61.1,Visual,< 4.2,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OCCO)nc56)(CC3)OC4)nc2N1
SPK-0255429,,SPK-0255429-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0630,MIC,Test article,0.120,Visual,6.9,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6ccc(OCCO)nc56)(CC3)OC4)nc2N1
SPK-0255428,,SPK-0255428-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,8.00,MIC,Test article,14.1,Visual,4.8,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CCOC(=O)COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255428,,SPK-0255428-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,16.0,MIC,Test article,28.3,Visual,4.5,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CCOC(=O)COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255428,,SPK-0255428-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 28.3,Visual,< 4.5,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CCOC(=O)COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255428,,SPK-0255428-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0630,MIC,Test article,0.111,Visual,7.0,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CCOC(=O)COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255428,,SPK-0255428-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 28.3,Visual,< 4.5,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CCOC(=O)COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255428,,SPK-0255428-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 28.3,Visual,< 4.5,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CCOC(=O)COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255428,,SPK-0255428-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 28.3,Visual,< 4.5,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CCOC(=O)COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255428,,SPK-0255428-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.250,MIC,Test article,0.442,Visual,6.4,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CCOC(=O)COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255427,,SPK-0255427-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,32.0,MIC,Test article,58.6,Visual,4.2,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1nc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)ccnc2cc1Cl
SPK-0255427,,SPK-0255427-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,32.0,MIC,Test article,58.6,Visual,4.2,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1nc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)ccnc2cc1Cl
SPK-0255427,,SPK-0255427-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 58.6,Visual,< 4.2,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1nc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)ccnc2cc1Cl
SPK-0255427,,SPK-0255427-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.125,MIC,Test article,0.229,Visual,6.6,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1nc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)ccnc2cc1Cl
SPK-0255427,,SPK-0255427-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 58.6,Visual,< 4.2,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1nc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)ccnc2cc1Cl
SPK-0255427,,SPK-0255427-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 58.6,Visual,< 4.2,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1nc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)ccnc2cc1Cl
SPK-0255427,,SPK-0255427-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 58.6,Visual,< 4.2,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1nc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)ccnc2cc1Cl
SPK-0255427,,SPK-0255427-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,1.00,MIC,Test article,1.83,Visual,5.7,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1nc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)ccnc2cc1Cl
SPK-0255426,,SPK-0255426-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 59.9,Visual,< 4.2,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6cc(Cl)cnc56)(CC3)OC4)nc2N1
SPK-0255426,,SPK-0255426-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 59.9,Visual,< 4.2,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6cc(Cl)cnc56)(CC3)OC4)nc2N1
SPK-0255426,,SPK-0255426-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 59.9,Visual,< 4.2,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6cc(Cl)cnc56)(CC3)OC4)nc2N1
SPK-0255426,,SPK-0255426-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.250,MIC,Test article,0.468,Visual,6.3,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6cc(Cl)cnc56)(CC3)OC4)nc2N1
SPK-0255426,,SPK-0255426-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 59.9,Visual,< 4.2,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6cc(Cl)cnc56)(CC3)OC4)nc2N1
SPK-0255426,,SPK-0255426-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 59.9,Visual,< 4.2,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6cc(Cl)cnc56)(CC3)OC4)nc2N1
SPK-0255426,,SPK-0255426-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 59.9,Visual,< 4.2,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6cc(Cl)cnc56)(CC3)OC4)nc2N1
SPK-0255426,,SPK-0255426-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,8.00,MIC,Test article,15.0,Visual,4.8,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5c(F)cnc6cc(Cl)cnc56)(CC3)OC4)nc2N1
SPK-0255425,,SPK-0255425-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,8.00,MIC,Test article,15.2,Visual,4.8,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1cc(C)c2nccc(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255425,,SPK-0255425-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,8.00,MIC,Test article,15.2,Visual,4.8,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1cc(C)c2nccc(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255425,,SPK-0255425-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 60.8,Visual,< 4.2,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1cc(C)c2nccc(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255425,,SPK-0255425-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0160,MIC,Test article,0.0304,Visual,7.5,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1cc(C)c2nccc(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255425,,SPK-0255425-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 60.8,Visual,< 4.2,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1cc(C)c2nccc(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255425,,SPK-0255425-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 60.8,Visual,< 4.2,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1cc(C)c2nccc(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255425,,SPK-0255425-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 60.8,Visual,< 4.2,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1cc(C)c2nccc(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255425,,SPK-0255425-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.250,MIC,Test article,0.475,Visual,6.3,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1cc(C)c2nccc(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255424,,SPK-0255424-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 124,Visual,< 3.9,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cc(Cl)cnc56)(CC3)OC4)nc2N1
SPK-0255424,,SPK-0255424-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 124,Visual,< 3.9,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cc(Cl)cnc56)(CC3)OC4)nc2N1
SPK-0255424,,SPK-0255424-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 124,Visual,< 3.9,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cc(Cl)cnc56)(CC3)OC4)nc2N1
SPK-0255424,,SPK-0255424-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,2.00,MIC,Test article,3.87,Visual,5.4,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cc(Cl)cnc56)(CC3)OC4)nc2N1
SPK-0255424,,SPK-0255424-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 124,Visual,< 3.9,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cc(Cl)cnc56)(CC3)OC4)nc2N1
SPK-0255424,,SPK-0255424-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 124,Visual,< 3.9,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cc(Cl)cnc56)(CC3)OC4)nc2N1
SPK-0255424,,SPK-0255424-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 124,Visual,< 3.9,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cc(Cl)cnc56)(CC3)OC4)nc2N1
SPK-0255424,,SPK-0255424-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 124,Visual,< 3.9,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,O=C1COc2ccc(CNC34CCC(CCc5ccnc6cc(Cl)cnc56)(CC3)OC4)nc2N1
SPK-0255423,,SPK-0255423-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 125,Visual,< 3.9,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1cnc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)ccnc2c1
SPK-0255423,,SPK-0255423-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 125,Visual,< 3.9,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1cnc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)ccnc2c1
SPK-0255423,,SPK-0255423-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 125,Visual,< 3.9,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1cnc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)ccnc2c1
SPK-0255423,,SPK-0255423-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,1.00,MIC,Test article,1.95,Visual,5.7,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1cnc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)ccnc2c1
SPK-0255423,,SPK-0255423-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 125,Visual,< 3.9,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1cnc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)ccnc2c1
SPK-0255423,,SPK-0255423-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 125,Visual,< 3.9,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1cnc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)ccnc2c1
SPK-0255423,,SPK-0255423-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 125,Visual,< 3.9,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1cnc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)ccnc2c1
SPK-0255423,,SPK-0255423-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,32.0,MIC,Test article,62.5,Visual,4.2,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1cnc2c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)ccnc2c1
SPK-0255422,,SPK-0255422-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,8.00,MIC,Test article,15.8,Visual,4.8,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(OC)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255422,,SPK-0255422-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,16.0,MIC,Test article,31.6,Visual,4.5,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(OC)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255422,,SPK-0255422-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 127,Visual,< 3.9,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(OC)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255422,,SPK-0255422-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0630,MIC,Test article,0.125,Visual,6.9,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(OC)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255422,,SPK-0255422-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 127,Visual,< 3.9,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(OC)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255422,,SPK-0255422-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 127,Visual,< 3.9,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(OC)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255422,,SPK-0255422-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 127,Visual,< 3.9,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(OC)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255422,,SPK-0255422-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.125,MIC,Test article,0.247,Visual,6.6,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(OC)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255421,,SPK-0255421-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 16.5,Visual,< 4.8,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc(F)c(O)c(OC)c5)(CC3)CO4)c2n1
SPK-0255421,,SPK-0255421-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 16.5,Visual,< 4.8,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc(F)c(O)c(OC)c5)(CC3)CO4)c2n1
SPK-0255421,,SPK-0255421-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 16.5,Visual,< 4.8,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc(F)c(O)c(OC)c5)(CC3)CO4)c2n1
SPK-0255421,,SPK-0255421-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,8.00,MIC,Test article,16.5,Visual,4.8,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc(F)c(O)c(OC)c5)(CC3)CO4)c2n1
SPK-0255421,,SPK-0255421-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 16.5,Visual,< 4.8,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc(F)c(O)c(OC)c5)(CC3)CO4)c2n1
SPK-0255421,,SPK-0255421-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 16.5,Visual,< 4.8,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc(F)c(O)c(OC)c5)(CC3)CO4)c2n1
SPK-0255421,,SPK-0255421-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 16.5,Visual,< 4.8,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc(F)c(O)c(OC)c5)(CC3)CO4)c2n1
SPK-0255421,,SPK-0255421-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 16.5,Visual,< 4.8,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc(F)c(O)c(OC)c5)(CC3)CO4)c2n1
SPK-0255420,,SPK-0255420-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 34.3,Visual,< 4.5,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cnc(N(C)C)nc5)(CC3)CO4)c2n1
SPK-0255420,,SPK-0255420-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 34.3,Visual,< 4.5,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cnc(N(C)C)nc5)(CC3)CO4)c2n1
SPK-0255420,,SPK-0255420-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 34.3,Visual,< 4.5,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cnc(N(C)C)nc5)(CC3)CO4)c2n1
SPK-0255420,,SPK-0255420-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,1.00,MIC,Test article,2.14,Visual,5.7,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cnc(N(C)C)nc5)(CC3)CO4)c2n1
SPK-0255420,,SPK-0255420-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 34.3,Visual,< 4.5,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cnc(N(C)C)nc5)(CC3)CO4)c2n1
SPK-0255420,,SPK-0255420-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 34.3,Visual,< 4.5,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cnc(N(C)C)nc5)(CC3)CO4)c2n1
SPK-0255420,,SPK-0255420-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 34.3,Visual,< 4.5,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cnc(N(C)C)nc5)(CC3)CO4)c2n1
SPK-0255420,,SPK-0255420-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.250,MIC,Test article,0.536,Visual,6.3,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cnc(N(C)C)nc5)(CC3)CO4)c2n1
SPK-0255419,,SPK-0255419-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 31.6,Visual,< 4.5,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc(N6CCCCC6)nc5)(CC3)CO4)c2n1
SPK-0255419,,SPK-0255419-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 31.6,Visual,< 4.5,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc(N6CCCCC6)nc5)(CC3)CO4)c2n1
SPK-0255419,,SPK-0255419-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 31.6,Visual,< 4.5,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc(N6CCCCC6)nc5)(CC3)CO4)c2n1
SPK-0255419,,SPK-0255419-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,4.00,MIC,Test article,7.91,Visual,5.1,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc(N6CCCCC6)nc5)(CC3)CO4)c2n1
SPK-0255419,,SPK-0255419-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 31.6,Visual,< 4.5,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc(N6CCCCC6)nc5)(CC3)CO4)c2n1
SPK-0255419,,SPK-0255419-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 31.6,Visual,< 4.5,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc(N6CCCCC6)nc5)(CC3)CO4)c2n1
SPK-0255419,,SPK-0255419-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 31.6,Visual,< 4.5,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc(N6CCCCC6)nc5)(CC3)CO4)c2n1
SPK-0255419,,SPK-0255419-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.250,MIC,Test article,0.494,Visual,6.3,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc(N6CCCCC6)nc5)(CC3)CO4)c2n1
SPK-0255418,,SPK-0255418-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 16.3,Visual,< 4.8,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6ccc(=O)[nH]c6n5)(CC3)CO4)c2n1
SPK-0255418,,SPK-0255418-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 16.3,Visual,< 4.8,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6ccc(=O)[nH]c6n5)(CC3)CO4)c2n1
SPK-0255418,,SPK-0255418-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 16.3,Visual,< 4.8,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6ccc(=O)[nH]c6n5)(CC3)CO4)c2n1
SPK-0255418,,SPK-0255418-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.250,MIC,Test article,0.511,Visual,6.3,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6ccc(=O)[nH]c6n5)(CC3)CO4)c2n1
SPK-0255418,,SPK-0255418-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 16.3,Visual,< 4.8,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6ccc(=O)[nH]c6n5)(CC3)CO4)c2n1
SPK-0255418,,SPK-0255418-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 16.3,Visual,< 4.8,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6ccc(=O)[nH]c6n5)(CC3)CO4)c2n1
SPK-0255418,,SPK-0255418-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 16.3,Visual,< 4.8,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6ccc(=O)[nH]c6n5)(CC3)CO4)c2n1
SPK-0255418,,SPK-0255418-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,2.00,MIC,Test article,4.09,Visual,5.4,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6ccc(=O)[nH]c6n5)(CC3)CO4)c2n1
SPK-0255417,,SPK-0255417-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 121,Visual,< 3.9,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)OCC(=O)N6)(CC3)CO4)c2n1
SPK-0255417,,SPK-0255417-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 121,Visual,< 3.9,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)OCC(=O)N6)(CC3)CO4)c2n1
SPK-0255417,,SPK-0255417-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 121,Visual,< 3.9,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)OCC(=O)N6)(CC3)CO4)c2n1
SPK-0255417,,SPK-0255417-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 121,Visual,< 3.9,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)OCC(=O)N6)(CC3)CO4)c2n1
SPK-0255417,,SPK-0255417-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 121,Visual,< 3.9,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)OCC(=O)N6)(CC3)CO4)c2n1
SPK-0255417,,SPK-0255417-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 121,Visual,< 3.9,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)OCC(=O)N6)(CC3)CO4)c2n1
SPK-0255417,,SPK-0255417-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 121,Visual,< 3.9,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)OCC(=O)N6)(CC3)CO4)c2n1
SPK-0255417,,SPK-0255417-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 121,Visual,< 3.9,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)OCC(=O)N6)(CC3)CO4)c2n1
SPK-0255416,,SPK-0255416-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 32.5,Visual,< 4.5,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc(N6CCCC6)nc5)(CC3)CO4)c2n1
SPK-0255416,,SPK-0255416-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 32.5,Visual,< 4.5,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc(N6CCCC6)nc5)(CC3)CO4)c2n1
SPK-0255416,,SPK-0255416-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 32.5,Visual,< 4.5,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc(N6CCCC6)nc5)(CC3)CO4)c2n1
SPK-0255416,,SPK-0255416-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,4.00,MIC,Test article,8.14,Visual,5.1,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc(N6CCCC6)nc5)(CC3)CO4)c2n1
SPK-0255416,,SPK-0255416-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 32.5,Visual,< 4.5,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc(N6CCCC6)nc5)(CC3)CO4)c2n1
SPK-0255416,,SPK-0255416-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 32.5,Visual,< 4.5,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc(N6CCCC6)nc5)(CC3)CO4)c2n1
SPK-0255416,,SPK-0255416-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 32.5,Visual,< 4.5,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc(N6CCCC6)nc5)(CC3)CO4)c2n1
SPK-0255416,,SPK-0255416-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.250,MIC,Test article,0.509,Visual,6.3,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc(N6CCCC6)nc5)(CC3)CO4)c2n1
SPK-0255415,,SPK-0255415-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 34.7,Visual,< 4.5,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cnc6[nH]ccc6c5)(CC3)CO4)c2n1
SPK-0255415,,SPK-0255415-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 34.7,Visual,< 4.5,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cnc6[nH]ccc6c5)(CC3)CO4)c2n1
SPK-0255415,,SPK-0255415-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 34.7,Visual,< 4.5,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cnc6[nH]ccc6c5)(CC3)CO4)c2n1
SPK-0255415,,SPK-0255415-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,4.00,MIC,Test article,8.67,Visual,5.1,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cnc6[nH]ccc6c5)(CC3)CO4)c2n1
SPK-0255415,,SPK-0255415-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 34.7,Visual,< 4.5,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cnc6[nH]ccc6c5)(CC3)CO4)c2n1
SPK-0255415,,SPK-0255415-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 34.7,Visual,< 4.5,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cnc6[nH]ccc6c5)(CC3)CO4)c2n1
SPK-0255415,,SPK-0255415-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 34.7,Visual,< 4.5,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cnc6[nH]ccc6c5)(CC3)CO4)c2n1
SPK-0255415,,SPK-0255415-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,1.00,MIC,Test article,2.17,Visual,5.7,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cnc6[nH]ccc6c5)(CC3)CO4)c2n1
SPK-0255414,,SPK-0255414-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 34.7,Visual,< 4.5,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6cc[nH]c6n5)(CC3)CO4)c2n1
SPK-0255414,,SPK-0255414-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 34.7,Visual,< 4.5,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6cc[nH]c6n5)(CC3)CO4)c2n1
SPK-0255414,,SPK-0255414-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 34.7,Visual,< 4.5,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6cc[nH]c6n5)(CC3)CO4)c2n1
SPK-0255414,,SPK-0255414-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,1.00,MIC,Test article,2.17,Visual,5.7,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6cc[nH]c6n5)(CC3)CO4)c2n1
SPK-0255414,,SPK-0255414-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 34.7,Visual,< 4.5,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6cc[nH]c6n5)(CC3)CO4)c2n1
SPK-0255414,,SPK-0255414-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 34.7,Visual,< 4.5,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6cc[nH]c6n5)(CC3)CO4)c2n1
SPK-0255414,,SPK-0255414-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 34.7,Visual,< 4.5,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6cc[nH]c6n5)(CC3)CO4)c2n1
SPK-0255414,,SPK-0255414-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.125,MIC,Test article,0.271,Visual,6.6,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6cc[nH]c6n5)(CC3)CO4)c2n1
SPK-0255413,,SPK-0255413-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 15.9,Visual,< 4.8,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6ccccc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255413,,SPK-0255413-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 15.9,Visual,< 4.8,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6ccccc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255413,,SPK-0255413-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 15.9,Visual,< 4.8,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6ccccc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255413,,SPK-0255413-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,2.00,MIC,Test article,3.98,Visual,5.4,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6ccccc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255413,,SPK-0255413-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 15.9,Visual,< 4.8,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6ccccc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255413,,SPK-0255413-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 15.9,Visual,< 4.8,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6ccccc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255413,,SPK-0255413-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 15.9,Visual,< 4.8,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6ccccc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255413,,SPK-0255413-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,1.00,MIC,Test article,1.99,Visual,5.7,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6ccccc6n(C)c5=O)(CC3)CO4)c2n1
SPK-0255412,,SPK-0255412-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 4.00,MIC,Test article,> 8.12,Visual,< 5.1,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cnc(N6CCCC6)nc5)(CC3)CO4)c2n1
SPK-0255412,,SPK-0255412-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 4.00,MIC,Test article,> 8.12,Visual,< 5.1,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cnc(N6CCCC6)nc5)(CC3)CO4)c2n1
SPK-0255412,,SPK-0255412-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 4.00,MIC,Test article,> 8.12,Visual,< 5.1,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cnc(N6CCCC6)nc5)(CC3)CO4)c2n1
SPK-0255412,,SPK-0255412-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,2.00,MIC,Test article,4.06,Visual,5.4,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cnc(N6CCCC6)nc5)(CC3)CO4)c2n1
SPK-0255412,,SPK-0255412-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 4.00,MIC,Test article,> 8.12,Visual,< 5.1,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cnc(N6CCCC6)nc5)(CC3)CO4)c2n1
SPK-0255412,,SPK-0255412-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 4.00,MIC,Test article,> 8.12,Visual,< 5.1,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cnc(N6CCCC6)nc5)(CC3)CO4)c2n1
SPK-0255412,,SPK-0255412-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 4.00,MIC,Test article,> 8.12,Visual,< 5.1,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cnc(N6CCCC6)nc5)(CC3)CO4)c2n1
SPK-0255412,,SPK-0255412-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.250,MIC,Test article,0.508,Visual,6.3,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cnc(N6CCCC6)nc5)(CC3)CO4)c2n1
SPK-0255411,,SPK-0255411-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 16.7,Visual,< 4.8,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6cccnc6s5)(CC3)CO4)c2n1
SPK-0255411,,SPK-0255411-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 16.7,Visual,< 4.8,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6cccnc6s5)(CC3)CO4)c2n1
SPK-0255411,,SPK-0255411-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 16.7,Visual,< 4.8,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6cccnc6s5)(CC3)CO4)c2n1
SPK-0255411,,SPK-0255411-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,4.00,MIC,Test article,8.36,Visual,5.1,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6cccnc6s5)(CC3)CO4)c2n1
SPK-0255411,,SPK-0255411-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 16.7,Visual,< 4.8,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6cccnc6s5)(CC3)CO4)c2n1
SPK-0255411,,SPK-0255411-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 16.7,Visual,< 4.8,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6cccnc6s5)(CC3)CO4)c2n1
SPK-0255411,,SPK-0255411-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 16.7,Visual,< 4.8,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6cccnc6s5)(CC3)CO4)c2n1
SPK-0255411,,SPK-0255411-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.250,MIC,Test article,0.522,Visual,6.3,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6cccnc6s5)(CC3)CO4)c2n1
SPK-0255410,,SPK-0255410-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 65.4,Visual,< 4.2,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cn(-c6ncccn6)cn5)(CC3)CO4)c2n1
SPK-0255410,,SPK-0255410-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 65.4,Visual,< 4.2,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cn(-c6ncccn6)cn5)(CC3)CO4)c2n1
SPK-0255410,,SPK-0255410-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 65.4,Visual,< 4.2,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cn(-c6ncccn6)cn5)(CC3)CO4)c2n1
SPK-0255410,,SPK-0255410-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,1.00,MIC,Test article,2.04,Visual,5.7,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cn(-c6ncccn6)cn5)(CC3)CO4)c2n1
SPK-0255410,,SPK-0255410-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 65.4,Visual,< 4.2,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cn(-c6ncccn6)cn5)(CC3)CO4)c2n1
SPK-0255410,,SPK-0255410-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 65.4,Visual,< 4.2,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cn(-c6ncccn6)cn5)(CC3)CO4)c2n1
SPK-0255410,,SPK-0255410-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 65.4,Visual,< 4.2,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cn(-c6ncccn6)cn5)(CC3)CO4)c2n1
SPK-0255410,,SPK-0255410-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.250,MIC,Test article,0.511,Visual,6.3,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cn(-c6ncccn6)cn5)(CC3)CO4)c2n1
SPK-0255409,,SPK-0255409-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 4.00,MIC,Test article,> 7.91,Visual,< 5.1,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5csc(-c6ccccn6)n5)(CC3)CO4)c2n1
SPK-0255409,,SPK-0255409-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 4.00,MIC,Test article,> 7.91,Visual,< 5.1,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5csc(-c6ccccn6)n5)(CC3)CO4)c2n1
SPK-0255409,,SPK-0255409-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 4.00,MIC,Test article,> 7.91,Visual,< 5.1,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5csc(-c6ccccn6)n5)(CC3)CO4)c2n1
SPK-0255409,,SPK-0255409-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 4.00,MIC,Test article,> 7.91,Visual,< 5.1,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5csc(-c6ccccn6)n5)(CC3)CO4)c2n1
SPK-0255409,,SPK-0255409-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 4.00,MIC,Test article,> 7.91,Visual,< 5.1,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5csc(-c6ccccn6)n5)(CC3)CO4)c2n1
SPK-0255409,,SPK-0255409-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 4.00,MIC,Test article,> 7.91,Visual,< 5.1,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5csc(-c6ccccn6)n5)(CC3)CO4)c2n1
SPK-0255409,,SPK-0255409-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 4.00,MIC,Test article,> 7.91,Visual,< 5.1,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5csc(-c6ccccn6)n5)(CC3)CO4)c2n1
SPK-0255409,,SPK-0255409-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,4.00,MIC,Test article,7.91,Visual,5.1,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5csc(-c6ccccn6)n5)(CC3)CO4)c2n1
SPK-0255408,,SPK-0255408-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 32.7,Visual,< 4.5,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cnn(-c6ccccn6)c5)(CC3)CO4)c2n1
SPK-0255408,,SPK-0255408-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 32.7,Visual,< 4.5,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cnn(-c6ccccn6)c5)(CC3)CO4)c2n1
SPK-0255408,,SPK-0255408-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 32.7,Visual,< 4.5,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cnn(-c6ccccn6)c5)(CC3)CO4)c2n1
SPK-0255408,,SPK-0255408-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,4.00,MIC,Test article,8.19,Visual,5.1,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cnn(-c6ccccn6)c5)(CC3)CO4)c2n1
SPK-0255408,,SPK-0255408-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 32.7,Visual,< 4.5,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cnn(-c6ccccn6)c5)(CC3)CO4)c2n1
SPK-0255408,,SPK-0255408-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 32.7,Visual,< 4.5,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cnn(-c6ccccn6)c5)(CC3)CO4)c2n1
SPK-0255408,,SPK-0255408-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 32.7,Visual,< 4.5,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cnn(-c6ccccn6)c5)(CC3)CO4)c2n1
SPK-0255408,,SPK-0255408-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.250,MIC,Test article,0.512,Visual,6.3,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cnn(-c6ccccn6)c5)(CC3)CO4)c2n1
SPK-0255407,,SPK-0255407-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 32.4,Visual,< 4.5,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cnc6c(c5)OCC(=O)N6)(CC3)CO4)c2n1
SPK-0255407,,SPK-0255407-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 32.4,Visual,< 4.5,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cnc6c(c5)OCC(=O)N6)(CC3)CO4)c2n1
SPK-0255407,,SPK-0255407-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 32.4,Visual,< 4.5,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cnc6c(c5)OCC(=O)N6)(CC3)CO4)c2n1
SPK-0255407,,SPK-0255407-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 32.4,Visual,< 4.5,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cnc6c(c5)OCC(=O)N6)(CC3)CO4)c2n1
SPK-0255407,,SPK-0255407-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 32.4,Visual,< 4.5,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cnc6c(c5)OCC(=O)N6)(CC3)CO4)c2n1
SPK-0255407,,SPK-0255407-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 32.4,Visual,< 4.5,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cnc6c(c5)OCC(=O)N6)(CC3)CO4)c2n1
SPK-0255407,,SPK-0255407-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 32.4,Visual,< 4.5,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cnc6c(c5)OCC(=O)N6)(CC3)CO4)c2n1
SPK-0255407,,SPK-0255407-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 32.4,Visual,< 4.5,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cnc6c(c5)OCC(=O)N6)(CC3)CO4)c2n1
SPK-0255406,,SPK-0255406-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 32.4,Visual,< 4.5,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc(-c6cccs6)on5)(CC3)CO4)c2n1
SPK-0255406,,SPK-0255406-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 32.4,Visual,< 4.5,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc(-c6cccs6)on5)(CC3)CO4)c2n1
SPK-0255406,,SPK-0255406-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 32.4,Visual,< 4.5,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc(-c6cccs6)on5)(CC3)CO4)c2n1
SPK-0255406,,SPK-0255406-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,1.00,MIC,Test article,2.02,Visual,5.7,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc(-c6cccs6)on5)(CC3)CO4)c2n1
SPK-0255406,,SPK-0255406-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 32.4,Visual,< 4.5,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc(-c6cccs6)on5)(CC3)CO4)c2n1
SPK-0255406,,SPK-0255406-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 32.4,Visual,< 4.5,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc(-c6cccs6)on5)(CC3)CO4)c2n1
SPK-0255406,,SPK-0255406-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 32.4,Visual,< 4.5,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc(-c6cccs6)on5)(CC3)CO4)c2n1
SPK-0255406,,SPK-0255406-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0310,MIC,Test article,0.0627,Visual,7.2,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc(-c6cccs6)on5)(CC3)CO4)c2n1
SPK-0255405,,SPK-0255405-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 32.0,Visual,< 4.5,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc(Cl)c6c(c5)OCO6)(CC3)CO4)c2n1
SPK-0255405,,SPK-0255405-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 32.0,Visual,< 4.5,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc(Cl)c6c(c5)OCO6)(CC3)CO4)c2n1
SPK-0255405,,SPK-0255405-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 32.0,Visual,< 4.5,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc(Cl)c6c(c5)OCO6)(CC3)CO4)c2n1
SPK-0255405,,SPK-0255405-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,1.00,MIC,Test article,2.00,Visual,5.7,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc(Cl)c6c(c5)OCO6)(CC3)CO4)c2n1
SPK-0255405,,SPK-0255405-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 32.0,Visual,< 4.5,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc(Cl)c6c(c5)OCO6)(CC3)CO4)c2n1
SPK-0255405,,SPK-0255405-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 32.0,Visual,< 4.5,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc(Cl)c6c(c5)OCO6)(CC3)CO4)c2n1
SPK-0255405,,SPK-0255405-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 32.0,Visual,< 4.5,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc(Cl)c6c(c5)OCO6)(CC3)CO4)c2n1
SPK-0255405,,SPK-0255405-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.125,MIC,Test article,0.250,Visual,6.6,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc(Cl)c6c(c5)OCO6)(CC3)CO4)c2n1
SPK-0255404,,SPK-0255404-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 31.8,Visual,< 4.5,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NS(=O)(=O)c5ccc(C)c(F)c5)(CC3)CO4)c2n1
SPK-0255404,,SPK-0255404-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 31.8,Visual,< 4.5,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NS(=O)(=O)c5ccc(C)c(F)c5)(CC3)CO4)c2n1
SPK-0255404,,SPK-0255404-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 31.8,Visual,< 4.5,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NS(=O)(=O)c5ccc(C)c(F)c5)(CC3)CO4)c2n1
SPK-0255404,,SPK-0255404-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 31.8,Visual,< 4.5,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NS(=O)(=O)c5ccc(C)c(F)c5)(CC3)CO4)c2n1
SPK-0255404,,SPK-0255404-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 31.8,Visual,< 4.5,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NS(=O)(=O)c5ccc(C)c(F)c5)(CC3)CO4)c2n1
SPK-0255404,,SPK-0255404-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 31.8,Visual,< 4.5,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NS(=O)(=O)c5ccc(C)c(F)c5)(CC3)CO4)c2n1
SPK-0255404,,SPK-0255404-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 31.8,Visual,< 4.5,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NS(=O)(=O)c5ccc(C)c(F)c5)(CC3)CO4)c2n1
SPK-0255404,,SPK-0255404-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,2.00,MIC,Test article,3.97,Visual,5.4,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NS(=O)(=O)c5ccc(C)c(F)c5)(CC3)CO4)c2n1
SPK-0255403,,SPK-0255403-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 37.4,Visual,< 4.4,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCC5CCCCC5)(CC3)CO4)c2n1
SPK-0255403,,SPK-0255403-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 37.4,Visual,< 4.4,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCC5CCCCC5)(CC3)CO4)c2n1
SPK-0255403,,SPK-0255403-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 37.4,Visual,< 4.4,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCC5CCCCC5)(CC3)CO4)c2n1
SPK-0255403,,SPK-0255403-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,4.00,MIC,Test article,9.36,Visual,5.0,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCC5CCCCC5)(CC3)CO4)c2n1
SPK-0255403,,SPK-0255403-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 37.4,Visual,< 4.4,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCC5CCCCC5)(CC3)CO4)c2n1
SPK-0255403,,SPK-0255403-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 37.4,Visual,< 4.4,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCC5CCCCC5)(CC3)CO4)c2n1
SPK-0255403,,SPK-0255403-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 37.4,Visual,< 4.4,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCC5CCCCC5)(CC3)CO4)c2n1
SPK-0255403,,SPK-0255403-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,2.00,MIC,Test article,4.68,Visual,5.3,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCC5CCCCC5)(CC3)CO4)c2n1
SPK-0255402,,SPK-0255402-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,1.00,MIC,Test article,2.09,Visual,5.7,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(c5)OCCO6)(CC3)CO4)c2n1
SPK-0255402,,SPK-0255402-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,8.00,MIC,Test article,16.7,Visual,4.8,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(c5)OCCO6)(CC3)CO4)c2n1
SPK-0255402,,SPK-0255402-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 66.7,Visual,< 4.2,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(c5)OCCO6)(CC3)CO4)c2n1
SPK-0255402,,SPK-0255402-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0310,MIC,Test article,0.0646,Visual,7.2,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(c5)OCCO6)(CC3)CO4)c2n1
SPK-0255402,,SPK-0255402-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 66.7,Visual,< 4.2,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(c5)OCCO6)(CC3)CO4)c2n1
SPK-0255402,,SPK-0255402-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 66.7,Visual,< 4.2,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(c5)OCCO6)(CC3)CO4)c2n1
SPK-0255402,,SPK-0255402-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 66.7,Visual,< 4.2,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(c5)OCCO6)(CC3)CO4)c2n1
SPK-0255402,,SPK-0255402-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0160,MIC,Test article,0.0334,Visual,7.5,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(c5)OCCO6)(CC3)CO4)c2n1
SPK-0255401,,SPK-0255401-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 2.00,MIC,Test article,> 4.28,Visual,< 5.4,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NC(=O)c5ccc(C)c(F)c5)(CC3)CO4)c2n1
SPK-0255401,,SPK-0255401-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 2.00,MIC,Test article,> 4.28,Visual,< 5.4,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NC(=O)c5ccc(C)c(F)c5)(CC3)CO4)c2n1
SPK-0255401,,SPK-0255401-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 2.00,MIC,Test article,> 4.28,Visual,< 5.4,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NC(=O)c5ccc(C)c(F)c5)(CC3)CO4)c2n1
SPK-0255401,,SPK-0255401-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,1.00,MIC,Test article,2.14,Visual,5.7,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NC(=O)c5ccc(C)c(F)c5)(CC3)CO4)c2n1
SPK-0255401,,SPK-0255401-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 2.00,MIC,Test article,> 4.28,Visual,< 5.4,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NC(=O)c5ccc(C)c(F)c5)(CC3)CO4)c2n1
SPK-0255401,,SPK-0255401-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 2.00,MIC,Test article,> 4.28,Visual,< 5.4,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NC(=O)c5ccc(C)c(F)c5)(CC3)CO4)c2n1
SPK-0255401,,SPK-0255401-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 2.00,MIC,Test article,> 4.28,Visual,< 5.4,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NC(=O)c5ccc(C)c(F)c5)(CC3)CO4)c2n1
SPK-0255401,,SPK-0255401-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0630,MIC,Test article,0.135,Visual,6.9,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NC(=O)c5ccc(C)c(F)c5)(CC3)CO4)c2n1
SPK-0255400,,SPK-0255400-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,2.00,MIC,Test article,3.89,Visual,5.4,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc(Cl)c6c(c5)OCCO6)(CC3)CO4)c2n1
SPK-0255400,,SPK-0255400-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,8.00,MIC,Test article,15.6,Visual,4.8,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc(Cl)c6c(c5)OCCO6)(CC3)CO4)c2n1
SPK-0255400,,SPK-0255400-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 31.1,Visual,< 4.5,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc(Cl)c6c(c5)OCCO6)(CC3)CO4)c2n1
SPK-0255400,,SPK-0255400-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0630,MIC,Test article,0.123,Visual,6.9,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc(Cl)c6c(c5)OCCO6)(CC3)CO4)c2n1
SPK-0255400,,SPK-0255400-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 31.1,Visual,< 4.5,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc(Cl)c6c(c5)OCCO6)(CC3)CO4)c2n1
SPK-0255400,,SPK-0255400-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 31.1,Visual,< 4.5,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc(Cl)c6c(c5)OCCO6)(CC3)CO4)c2n1
SPK-0255400,,SPK-0255400-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 31.1,Visual,< 4.5,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc(Cl)c6c(c5)OCCO6)(CC3)CO4)c2n1
SPK-0255400,,SPK-0255400-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0630,MIC,Test article,0.123,Visual,6.9,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc(Cl)c6c(c5)OCCO6)(CC3)CO4)c2n1
SPK-0255399,,SPK-0255399-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 32.5,Visual,< 4.5,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(c5)OCCN6C)(CC3)CO4)c2n1
SPK-0255399,,SPK-0255399-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 32.5,Visual,< 4.5,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(c5)OCCN6C)(CC3)CO4)c2n1
SPK-0255399,,SPK-0255399-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 32.5,Visual,< 4.5,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(c5)OCCN6C)(CC3)CO4)c2n1
SPK-0255399,,SPK-0255399-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,2.00,MIC,Test article,4.06,Visual,5.4,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(c5)OCCN6C)(CC3)CO4)c2n1
SPK-0255399,,SPK-0255399-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 32.5,Visual,< 4.5,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(c5)OCCN6C)(CC3)CO4)c2n1
SPK-0255399,,SPK-0255399-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 32.5,Visual,< 4.5,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(c5)OCCN6C)(CC3)CO4)c2n1
SPK-0255399,,SPK-0255399-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 32.5,Visual,< 4.5,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(c5)OCCN6C)(CC3)CO4)c2n1
SPK-0255399,,SPK-0255399-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.250,MIC,Test article,0.508,Visual,6.3,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(c5)OCCN6C)(CC3)CO4)c2n1
SPK-0255398,,SPK-0255398-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 31.5,Visual,< 4.5,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cnc(N6CCOCC6)nc5)(CC3)CO4)c2n1
SPK-0255398,,SPK-0255398-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 31.5,Visual,< 4.5,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cnc(N6CCOCC6)nc5)(CC3)CO4)c2n1
SPK-0255398,,SPK-0255398-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 31.5,Visual,< 4.5,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cnc(N6CCOCC6)nc5)(CC3)CO4)c2n1
SPK-0255398,,SPK-0255398-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 31.5,Visual,< 4.5,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cnc(N6CCOCC6)nc5)(CC3)CO4)c2n1
SPK-0255398,,SPK-0255398-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 31.5,Visual,< 4.5,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cnc(N6CCOCC6)nc5)(CC3)CO4)c2n1
SPK-0255398,,SPK-0255398-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 31.5,Visual,< 4.5,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cnc(N6CCOCC6)nc5)(CC3)CO4)c2n1
SPK-0255398,,SPK-0255398-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 31.5,Visual,< 4.5,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cnc(N6CCOCC6)nc5)(CC3)CO4)c2n1
SPK-0255398,,SPK-0255398-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,2.00,MIC,Test article,3.93,Visual,5.4,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cnc(N6CCOCC6)nc5)(CC3)CO4)c2n1
SPK-0255397,,SPK-0255397-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 17.6,Visual,< 4.8,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc(=O)c(O)c[nH]5)(CC3)CO4)c2n1
SPK-0255397,,SPK-0255397-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 17.6,Visual,< 4.8,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc(=O)c(O)c[nH]5)(CC3)CO4)c2n1
SPK-0255397,,SPK-0255397-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 17.6,Visual,< 4.8,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc(=O)c(O)c[nH]5)(CC3)CO4)c2n1
SPK-0255397,,SPK-0255397-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 17.6,Visual,< 4.8,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc(=O)c(O)c[nH]5)(CC3)CO4)c2n1
SPK-0255397,,SPK-0255397-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 17.6,Visual,< 4.8,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc(=O)c(O)c[nH]5)(CC3)CO4)c2n1
SPK-0255397,,SPK-0255397-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 17.6,Visual,< 4.8,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc(=O)c(O)c[nH]5)(CC3)CO4)c2n1
SPK-0255397,,SPK-0255397-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 17.6,Visual,< 4.8,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc(=O)c(O)c[nH]5)(CC3)CO4)c2n1
SPK-0255397,,SPK-0255397-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 17.6,Visual,< 4.8,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc(=O)c(O)c[nH]5)(CC3)CO4)c2n1
SPK-0255396,,SPK-0255396-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 15.8,Visual,< 4.8,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc(N6CCOCC6)nc5)(CC3)CO4)c2n1
SPK-0255396,,SPK-0255396-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 15.8,Visual,< 4.8,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc(N6CCOCC6)nc5)(CC3)CO4)c2n1
SPK-0255396,,SPK-0255396-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 15.8,Visual,< 4.8,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc(N6CCOCC6)nc5)(CC3)CO4)c2n1
SPK-0255396,,SPK-0255396-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 15.8,Visual,< 4.8,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc(N6CCOCC6)nc5)(CC3)CO4)c2n1
SPK-0255396,,SPK-0255396-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 15.8,Visual,< 4.8,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc(N6CCOCC6)nc5)(CC3)CO4)c2n1
SPK-0255396,,SPK-0255396-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 15.8,Visual,< 4.8,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc(N6CCOCC6)nc5)(CC3)CO4)c2n1
SPK-0255396,,SPK-0255396-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 15.8,Visual,< 4.8,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc(N6CCOCC6)nc5)(CC3)CO4)c2n1
SPK-0255396,,SPK-0255396-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,4.00,MIC,Test article,7.88,Visual,5.1,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc(N6CCOCC6)nc5)(CC3)CO4)c2n1
SPK-0255395,,SPK-0255395-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 34.1,Visual,< 4.5,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc(OC)c(O)cn5)(CC3)CO4)c2n1
SPK-0255395,,SPK-0255395-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 34.1,Visual,< 4.5,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc(OC)c(O)cn5)(CC3)CO4)c2n1
SPK-0255395,,SPK-0255395-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 34.1,Visual,< 4.5,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc(OC)c(O)cn5)(CC3)CO4)c2n1
SPK-0255395,,SPK-0255395-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 34.1,Visual,< 4.5,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc(OC)c(O)cn5)(CC3)CO4)c2n1
SPK-0255395,,SPK-0255395-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 34.1,Visual,< 4.5,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc(OC)c(O)cn5)(CC3)CO4)c2n1
SPK-0255395,,SPK-0255395-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 34.1,Visual,< 4.5,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc(OC)c(O)cn5)(CC3)CO4)c2n1
SPK-0255395,,SPK-0255395-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 34.1,Visual,< 4.5,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc(OC)c(O)cn5)(CC3)CO4)c2n1
SPK-0255395,,SPK-0255395-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 34.1,Visual,< 4.5,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc(OC)c(O)cn5)(CC3)CO4)c2n1
SPK-0255394,,SPK-0255394-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 137,Visual,< 3.9,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc(=O)c(OC)c[nH]5)(CC3)CO4)c2n1
SPK-0255394,,SPK-0255394-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 137,Visual,< 3.9,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc(=O)c(OC)c[nH]5)(CC3)CO4)c2n1
SPK-0255394,,SPK-0255394-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 137,Visual,< 3.9,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc(=O)c(OC)c[nH]5)(CC3)CO4)c2n1
SPK-0255394,,SPK-0255394-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,16.0,MIC,Test article,34.1,Visual,4.5,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc(=O)c(OC)c[nH]5)(CC3)CO4)c2n1
SPK-0255394,,SPK-0255394-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 137,Visual,< 3.9,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc(=O)c(OC)c[nH]5)(CC3)CO4)c2n1
SPK-0255394,,SPK-0255394-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 137,Visual,< 3.9,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc(=O)c(OC)c[nH]5)(CC3)CO4)c2n1
SPK-0255394,,SPK-0255394-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 137,Visual,< 3.9,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc(=O)c(OC)c[nH]5)(CC3)CO4)c2n1
SPK-0255394,,SPK-0255394-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 137,Visual,< 3.9,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc(=O)c(OC)c[nH]5)(CC3)CO4)c2n1
SPK-0255393,,SPK-0255393-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 130,Visual,< 3.9,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc(N6CCCC6)cn5)(CC3)CO4)c2n1
SPK-0255393,,SPK-0255393-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 130,Visual,< 3.9,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc(N6CCCC6)cn5)(CC3)CO4)c2n1
SPK-0255393,,SPK-0255393-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 130,Visual,< 3.9,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc(N6CCCC6)cn5)(CC3)CO4)c2n1
SPK-0255393,,SPK-0255393-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,4.00,MIC,Test article,8.14,Visual,5.1,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc(N6CCCC6)cn5)(CC3)CO4)c2n1
SPK-0255393,,SPK-0255393-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 130,Visual,< 3.9,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc(N6CCCC6)cn5)(CC3)CO4)c2n1
SPK-0255393,,SPK-0255393-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 130,Visual,< 3.9,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc(N6CCCC6)cn5)(CC3)CO4)c2n1
SPK-0255393,,SPK-0255393-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 130,Visual,< 3.9,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc(N6CCCC6)cn5)(CC3)CO4)c2n1
SPK-0255393,,SPK-0255393-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.250,MIC,Test article,0.509,Visual,6.3,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc(N6CCCC6)cn5)(CC3)CO4)c2n1
SPK-0255392,,SPK-0255392-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 128,MIC,Test article,> 292,Visual,< 3.5,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc[nH]c5=O)(CC3)CO4)c2n1
SPK-0255392,,SPK-0255392-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 128,MIC,Test article,> 292,Visual,< 3.5,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc[nH]c5=O)(CC3)CO4)c2n1
SPK-0255392,,SPK-0255392-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 128,MIC,Test article,> 292,Visual,< 3.5,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc[nH]c5=O)(CC3)CO4)c2n1
SPK-0255392,,SPK-0255392-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,32.0,MIC,Test article,73.0,Visual,4.1,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc[nH]c5=O)(CC3)CO4)c2n1
SPK-0255392,,SPK-0255392-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 128,MIC,Test article,> 292,Visual,< 3.5,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc[nH]c5=O)(CC3)CO4)c2n1
SPK-0255392,,SPK-0255392-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 128,MIC,Test article,> 292,Visual,< 3.5,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc[nH]c5=O)(CC3)CO4)c2n1
SPK-0255392,,SPK-0255392-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 128,MIC,Test article,> 292,Visual,< 3.5,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc[nH]c5=O)(CC3)CO4)c2n1
SPK-0255392,,SPK-0255392-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 128,MIC,Test article,> 292,Visual,< 3.5,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc[nH]c5=O)(CC3)CO4)c2n1
SPK-0255391,,SPK-0255391-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 146,Visual,< 3.8,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc(=O)[nH]c5)(CC3)CO4)c2n1
SPK-0255391,,SPK-0255391-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 146,Visual,< 3.8,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc(=O)[nH]c5)(CC3)CO4)c2n1
SPK-0255391,,SPK-0255391-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 146,Visual,< 3.8,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc(=O)[nH]c5)(CC3)CO4)c2n1
SPK-0255391,,SPK-0255391-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 146,Visual,< 3.8,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc(=O)[nH]c5)(CC3)CO4)c2n1
SPK-0255391,,SPK-0255391-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 146,Visual,< 3.8,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc(=O)[nH]c5)(CC3)CO4)c2n1
SPK-0255391,,SPK-0255391-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 146,Visual,< 3.8,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc(=O)[nH]c5)(CC3)CO4)c2n1
SPK-0255391,,SPK-0255391-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 146,Visual,< 3.8,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc(=O)[nH]c5)(CC3)CO4)c2n1
SPK-0255391,,SPK-0255391-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 146,Visual,< 3.8,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc(=O)[nH]c5)(CC3)CO4)c2n1
SPK-0255390,,SPK-0255390-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 33.2,Visual,< 4.5,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc(OC)c(OC)cn5)(CC3)CO4)c2n1
SPK-0255390,,SPK-0255390-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 33.2,Visual,< 4.5,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc(OC)c(OC)cn5)(CC3)CO4)c2n1
SPK-0255390,,SPK-0255390-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 33.2,Visual,< 4.5,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc(OC)c(OC)cn5)(CC3)CO4)c2n1
SPK-0255390,,SPK-0255390-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,16.0,MIC,Test article,33.2,Visual,4.5,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc(OC)c(OC)cn5)(CC3)CO4)c2n1
SPK-0255390,,SPK-0255390-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 33.2,Visual,< 4.5,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc(OC)c(OC)cn5)(CC3)CO4)c2n1
SPK-0255390,,SPK-0255390-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 33.2,Visual,< 4.5,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc(OC)c(OC)cn5)(CC3)CO4)c2n1
SPK-0255390,,SPK-0255390-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 33.2,Visual,< 4.5,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc(OC)c(OC)cn5)(CC3)CO4)c2n1
SPK-0255390,,SPK-0255390-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,4.00,MIC,Test article,8.29,Visual,5.1,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc(OC)c(OC)cn5)(CC3)CO4)c2n1
SPK-0255389,,SPK-0255389-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,8.00,MIC,Test article,16.6,Visual,4.8,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6c(cn5)OCCO6)(CC3)CO4)c2n1
SPK-0255389,,SPK-0255389-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,16.0,MIC,Test article,33.3,Visual,4.5,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6c(cn5)OCCO6)(CC3)CO4)c2n1
SPK-0255389,,SPK-0255389-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 66.6,Visual,< 4.2,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6c(cn5)OCCO6)(CC3)CO4)c2n1
SPK-0255389,,SPK-0255389-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0630,MIC,Test article,0.131,Visual,6.9,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6c(cn5)OCCO6)(CC3)CO4)c2n1
SPK-0255389,,SPK-0255389-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 66.6,Visual,< 4.2,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6c(cn5)OCCO6)(CC3)CO4)c2n1
SPK-0255389,,SPK-0255389-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 66.6,Visual,< 4.2,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6c(cn5)OCCO6)(CC3)CO4)c2n1
SPK-0255389,,SPK-0255389-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 66.6,Visual,< 4.2,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6c(cn5)OCCO6)(CC3)CO4)c2n1
SPK-0255389,,SPK-0255389-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0310,MIC,Test article,0.0645,Visual,7.2,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cc6c(cn5)OCCO6)(CC3)CO4)c2n1
SPK-0255388,,SPK-0255388-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 35.8,Visual,< 4.4,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cccc(C#N)n5)(CC3)CO4)c2n1
SPK-0255388,,SPK-0255388-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 35.8,Visual,< 4.4,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cccc(C#N)n5)(CC3)CO4)c2n1
SPK-0255388,,SPK-0255388-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 35.8,Visual,< 4.4,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cccc(C#N)n5)(CC3)CO4)c2n1
SPK-0255388,,SPK-0255388-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 35.8,Visual,< 4.4,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cccc(C#N)n5)(CC3)CO4)c2n1
SPK-0255388,,SPK-0255388-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 35.8,Visual,< 4.4,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cccc(C#N)n5)(CC3)CO4)c2n1
SPK-0255388,,SPK-0255388-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 35.8,Visual,< 4.4,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cccc(C#N)n5)(CC3)CO4)c2n1
SPK-0255388,,SPK-0255388-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 35.8,Visual,< 4.4,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cccc(C#N)n5)(CC3)CO4)c2n1
SPK-0255388,,SPK-0255388-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,8.00,MIC,Test article,17.9,Visual,4.7,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5cccc(C#N)n5)(CC3)CO4)c2n1
SPK-0255387,,SPK-0255387-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 35.3,Visual,< 4.5,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc(C)c(F)c5)(CC3)CO4)c2n1
SPK-0255387,,SPK-0255387-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 35.3,Visual,< 4.5,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc(C)c(F)c5)(CC3)CO4)c2n1
SPK-0255387,,SPK-0255387-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 35.3,Visual,< 4.5,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc(C)c(F)c5)(CC3)CO4)c2n1
SPK-0255387,,SPK-0255387-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.500,MIC,Test article,1.10,Visual,6.0,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc(C)c(F)c5)(CC3)CO4)c2n1
SPK-0255387,,SPK-0255387-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 35.3,Visual,< 4.5,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc(C)c(F)c5)(CC3)CO4)c2n1
SPK-0255387,,SPK-0255387-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 35.3,Visual,< 4.5,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc(C)c(F)c5)(CC3)CO4)c2n1
SPK-0255387,,SPK-0255387-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 35.3,Visual,< 4.5,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc(C)c(F)c5)(CC3)CO4)c2n1
SPK-0255387,,SPK-0255387-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0310,MIC,Test article,0.0684,Visual,7.2,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc(C)c(F)c5)(CC3)CO4)c2n1
SPK-0255386,,SPK-0255386-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,2.00,MIC,Test article,4.14,Visual,5.4,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NC/C=C/c5cc(F)ccc5F)(CC3)CO4)c2n1
SPK-0255386,,SPK-0255386-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,2.00,MIC,Test article,4.14,Visual,5.4,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NC/C=C/c5cc(F)ccc5F)(CC3)CO4)c2n1
SPK-0255386,,SPK-0255386-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 66.2,Visual,< 4.2,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NC/C=C/c5cc(F)ccc5F)(CC3)CO4)c2n1
SPK-0255386,,SPK-0255386-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.125,MIC,Test article,0.259,Visual,6.6,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NC/C=C/c5cc(F)ccc5F)(CC3)CO4)c2n1
SPK-0255386,,SPK-0255386-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 66.2,Visual,< 4.2,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NC/C=C/c5cc(F)ccc5F)(CC3)CO4)c2n1
SPK-0255386,,SPK-0255386-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 66.2,Visual,< 4.2,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NC/C=C/c5cc(F)ccc5F)(CC3)CO4)c2n1
SPK-0255386,,SPK-0255386-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 66.2,Visual,< 4.2,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NC/C=C/c5cc(F)ccc5F)(CC3)CO4)c2n1
SPK-0255386,,SPK-0255386-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0310,MIC,Test article,0.0641,Visual,7.2,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NC/C=C/c5cc(F)ccc5F)(CC3)CO4)c2n1
SPK-0255385,,SPK-0255385-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.500,MIC,Test article,1.05,Visual,6.0,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2nccc(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255385,,SPK-0255385-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,2.00,MIC,Test article,4.21,Visual,5.4,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2nccc(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255385,,SPK-0255385-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,8.00,MIC,Test article,16.8,Visual,4.8,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2nccc(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255385,,SPK-0255385-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,8.00E-03,MIC,Test article,0.0168,Visual,7.8,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2nccc(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255385,,SPK-0255385-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 67.3,Visual,< 4.2,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2nccc(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255385,,SPK-0255385-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,16.0,MIC,Test article,33.6,Visual,4.5,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2nccc(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255385,,SPK-0255385-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,32.0,MIC,Test article,67.3,Visual,4.2,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2nccc(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255385,,SPK-0255385-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0630,MIC,Test article,0.132,Visual,6.9,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2nccc(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255385,,SPK-0255385-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,2.00,MIC,Test article,3.91,Visual,5.4,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2nccc(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255385,,SPK-0255385-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,2.00,MIC,Test article,3.91,Visual,5.4,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2nccc(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255385,,SPK-0255385-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,8.00,MIC,Test article,15.6,Visual,4.8,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2nccc(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255385,,SPK-0255385-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,8.00E-03,MIC,Test article,0.0156,Visual,7.8,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2nccc(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255385,,SPK-0255385-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 31.2,Visual,< 4.5,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2nccc(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255385,,SPK-0255385-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 31.2,Visual,< 4.5,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2nccc(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255385,,SPK-0255385-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 31.2,Visual,< 4.5,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2nccc(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255385,,SPK-0255385-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0630,MIC,Test article,0.123,Visual,6.9,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2nccc(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255384,,SPK-0255384-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,1.00,MIC,Test article,1.96,Visual,5.7,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(Cl)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255384,,SPK-0255384-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,2.00,MIC,Test article,3.92,Visual,5.4,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(Cl)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255384,,SPK-0255384-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,8.00,MIC,Test article,15.7,Visual,4.8,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(Cl)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255384,,SPK-0255384-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,8.00E-03,MIC,Test article,0.0157,Visual,7.8,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(Cl)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255384,,SPK-0255384-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 15.7,Visual,< 4.8,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(Cl)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255384,,SPK-0255384-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,8.00,MIC,Test article,15.7,Visual,4.8,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(Cl)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255384,,SPK-0255384-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 15.7,Visual,< 4.8,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(Cl)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255384,,SPK-0255384-001,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0160,MIC,Test article,0.0314,Visual,7.5,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(Cl)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255384,,SPK-0255384-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,1.00,MIC,Test article,1.83,Visual,5.7,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(Cl)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255384,,SPK-0255384-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,2.00,MIC,Test article,3.66,Visual,5.4,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(Cl)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255384,,SPK-0255384-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 4.00,MIC,Test article,> 7.32,Visual,< 5.1,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(Cl)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255384,,SPK-0255384-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,8.00E-03,MIC,Test article,0.0146,Visual,7.8,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(Cl)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255384,,SPK-0255384-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 4.00,MIC,Test article,> 7.32,Visual,< 5.1,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(Cl)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255384,,SPK-0255384-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 4.00,MIC,Test article,> 7.32,Visual,< 5.1,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(Cl)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255384,,SPK-0255384-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 4.00,MIC,Test article,> 7.32,Visual,< 5.1,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(Cl)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0255384,,SPK-0255384-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0160,MIC,Test article,0.0293,Visual,7.5,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(Cl)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0108939,,SPK-0108939-001,,,,,,,,,,,,,,,,,,,,,,COc1ccc2ncc(F)c([C@H]3OC(=O)O[C@@H]3C34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0108939,,SPK-0108939-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,16.0,MIC,Test article,27.2,Visual,4.6,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c([C@H]3OC(=O)O[C@@H]3C34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0108939,,SPK-0108939-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 27.2,Visual,< 4.6,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c([C@H]3OC(=O)O[C@@H]3C34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0108939,,SPK-0108939-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 27.2,Visual,< 4.6,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c([C@H]3OC(=O)O[C@@H]3C34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0108939,,SPK-0108939-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0630,MIC,Test article,0.107,Visual,7.0,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c([C@H]3OC(=O)O[C@@H]3C34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0108939,,SPK-0108939-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 27.2,Visual,< 4.6,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c([C@H]3OC(=O)O[C@@H]3C34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0108939,,SPK-0108939-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 27.2,Visual,< 4.6,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c([C@H]3OC(=O)O[C@@H]3C34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0108939,,SPK-0108939-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 27.2,Visual,< 4.6,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c([C@H]3OC(=O)O[C@@H]3C34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0108939,,SPK-0108939-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.250,MIC,Test article,0.425,Visual,6.4,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c([C@H]3OC(=O)O[C@@H]3C34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0108931,,SPK-0108931-001,,,,,,,,,,,,,,,,,,,,,,COc1ccc2ncc(F)c(CC(O)(C(F)(F)F)C34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0108931,,SPK-0108931-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,32.0,MIC,Test article,52.1,Visual,4.3,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(O)(C(F)(F)F)C34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0108931,,SPK-0108931-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 52.1,Visual,< 4.3,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(O)(C(F)(F)F)C34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0108931,,SPK-0108931-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 52.1,Visual,< 4.3,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(O)(C(F)(F)F)C34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0108931,,SPK-0108931-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.250,MIC,Test article,0.407,Visual,6.4,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(O)(C(F)(F)F)C34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0108931,,SPK-0108931-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 52.1,Visual,< 4.3,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(O)(C(F)(F)F)C34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0108931,,SPK-0108931-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 52.1,Visual,< 4.3,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(O)(C(F)(F)F)C34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0108931,,SPK-0108931-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 52.1,Visual,< 4.3,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(O)(C(F)(F)F)C34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0108931,,SPK-0108931-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,1.00,MIC,Test article,1.63,Visual,5.8,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(O)(C(F)(F)F)C34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0108930,,SPK-0108930-001,,,,,,,,,,,,,,,,,,,,,,COc1ccc2ncc(F)c(CC(C)(O)C34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0108930,,SPK-0108930-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,2.00,MIC,Test article,3.57,Visual,5.4,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(C)(O)C34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0108930,,SPK-0108930-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,8.00,MIC,Test article,14.3,Visual,4.8,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(C)(O)C34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0108930,,SPK-0108930-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,32.0,MIC,Test article,57.1,Visual,4.2,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(C)(O)C34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0108930,,SPK-0108930-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0160,MIC,Test article,0.0286,Visual,7.5,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(C)(O)C34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0108930,,SPK-0108930-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 57.1,Visual,< 4.2,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(C)(O)C34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0108930,,SPK-0108930-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 57.1,Visual,< 4.2,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(C)(O)C34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0108930,,SPK-0108930-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 57.1,Visual,< 4.2,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(C)(O)C34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0108930,,SPK-0108930-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.125,MIC,Test article,0.223,Visual,6.7,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(C)(O)C34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0108929,,SPK-0108929-001,,,,,,,,,,,,,,,,,,,,,,CO/N=C(/Cc1c(F)cnc2ccc(OC)nc12)C12CCC(NCc3ccc4c(n3)NC(=O)CO4)(CC1)CO2
SPK-0108929,,SPK-0108929-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 29.8,Visual,< 4.5,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CO/N=C(/Cc1c(F)cnc2ccc(OC)nc12)C12CCC(NCc3ccc4c(n3)NC(=O)CO4)(CC1)CO2
SPK-0108929,,SPK-0108929-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 29.8,Visual,< 4.5,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CO/N=C(/Cc1c(F)cnc2ccc(OC)nc12)C12CCC(NCc3ccc4c(n3)NC(=O)CO4)(CC1)CO2
SPK-0108929,,SPK-0108929-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 29.8,Visual,< 4.5,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CO/N=C(/Cc1c(F)cnc2ccc(OC)nc12)C12CCC(NCc3ccc4c(n3)NC(=O)CO4)(CC1)CO2
SPK-0108929,,SPK-0108929-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 29.8,Visual,< 4.5,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CO/N=C(/Cc1c(F)cnc2ccc(OC)nc12)C12CCC(NCc3ccc4c(n3)NC(=O)CO4)(CC1)CO2
SPK-0108929,,SPK-0108929-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 29.8,Visual,< 4.5,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CO/N=C(/Cc1c(F)cnc2ccc(OC)nc12)C12CCC(NCc3ccc4c(n3)NC(=O)CO4)(CC1)CO2
SPK-0108929,,SPK-0108929-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 29.8,Visual,< 4.5,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CO/N=C(/Cc1c(F)cnc2ccc(OC)nc12)C12CCC(NCc3ccc4c(n3)NC(=O)CO4)(CC1)CO2
SPK-0108929,,SPK-0108929-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 29.8,Visual,< 4.5,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CO/N=C(/Cc1c(F)cnc2ccc(OC)nc12)C12CCC(NCc3ccc4c(n3)NC(=O)CO4)(CC1)CO2
SPK-0108929,,SPK-0108929-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 29.8,Visual,< 4.5,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CO/N=C(/Cc1c(F)cnc2ccc(OC)nc12)C12CCC(NCc3ccc4c(n3)NC(=O)CO4)(CC1)CO2
SPK-0108926,,SPK-0108926-001,,,,,,,,,,,,,,,,,,,,,,COc1ccc2ncc(F)c(CC(NS(C)(=O)=O)C34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0108926,,SPK-0108926-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 51.4,Visual,< 4.3,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(NS(C)(=O)=O)C34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0108926,,SPK-0108926-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 51.4,Visual,< 4.3,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(NS(C)(=O)=O)C34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0108926,,SPK-0108926-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 51.4,Visual,< 4.3,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(NS(C)(=O)=O)C34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0108926,,SPK-0108926-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,4.00,MIC,Test article,6.42,Visual,5.2,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(NS(C)(=O)=O)C34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0108926,,SPK-0108926-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 51.4,Visual,< 4.3,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(NS(C)(=O)=O)C34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0108926,,SPK-0108926-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 51.4,Visual,< 4.3,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(NS(C)(=O)=O)C34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0108926,,SPK-0108926-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 51.4,Visual,< 4.3,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(NS(C)(=O)=O)C34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0108926,,SPK-0108926-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 51.4,Visual,< 4.3,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(NS(C)(=O)=O)C34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0108923,,SPK-0108923-001,,,,,,,,,,,,,,,,,,,,,,COc1ccc2ncc(F)c(CC(F)C34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0108923,,SPK-0108923-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,8.00,MIC,Test article,14.6,Visual,4.8,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(F)C34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0108923,,SPK-0108923-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 14.6,Visual,< 4.8,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(F)C34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0108923,,SPK-0108923-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 14.6,Visual,< 4.8,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(F)C34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0108923,,SPK-0108923-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.125,MIC,Test article,0.228,Visual,6.6,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(F)C34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0108923,,SPK-0108923-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 14.6,Visual,< 4.8,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(F)C34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0108923,,SPK-0108923-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 14.6,Visual,< 4.8,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(F)C34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0108923,,SPK-0108923-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 14.6,Visual,< 4.8,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(F)C34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0108923,,SPK-0108923-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.500,MIC,Test article,0.912,Visual,6.0,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(F)C34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0108921,,SPK-0108921-001,,,,,,,,,,,,,,,,,,,,,,COc1ccc2ncc(F)c(CC(OCCO)C34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0108921,,SPK-0108921-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,32.0,MIC,Test article,54.2,Visual,4.3,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(OCCO)C34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0108921,,SPK-0108921-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 54.2,Visual,< 4.3,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(OCCO)C34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0108921,,SPK-0108921-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 54.2,Visual,< 4.3,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(OCCO)C34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0108921,,SPK-0108921-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.500,MIC,Test article,0.847,Visual,6.1,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(OCCO)C34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0108921,,SPK-0108921-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 54.2,Visual,< 4.3,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(OCCO)C34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0108921,,SPK-0108921-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 54.2,Visual,< 4.3,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(OCCO)C34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0108921,,SPK-0108921-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 54.2,Visual,< 4.3,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(OCCO)C34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0108921,,SPK-0108921-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,4.00,MIC,Test article,6.78,Visual,5.2,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(OCCO)C34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0108919,,SPK-0108919-001,,,,,,,,,,,,,,,,,,,,,,COc1ccc2ncc(F)c(CC(=O)C34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0108919,,SPK-0108919-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,2.00,MIC,Test article,3.94,Visual,5.4,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(=O)C34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0108919,,SPK-0108919-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,16.0,MIC,Test article,31.5,Visual,4.5,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(=O)C34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0108919,,SPK-0108919-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 31.5,Visual,< 4.5,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(=O)C34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0108919,,SPK-0108919-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0310,MIC,Test article,0.0611,Visual,7.2,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(=O)C34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0108919,,SPK-0108919-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 31.5,Visual,< 4.5,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(=O)C34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0108919,,SPK-0108919-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 31.5,Visual,< 4.5,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(=O)C34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0108919,,SPK-0108919-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 31.5,Visual,< 4.5,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(=O)C34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0108919,,SPK-0108919-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.125,MIC,Test article,0.246,Visual,6.6,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CC(=O)C34CCC(NCc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0107470,,SPK-0107470-001,,,,,,,,,,,,,,,,,,,,,,COc1ccc2ncc(F)c(CCC34CCC(NC(=O)c5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0107470,,SPK-0107470-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 15.8,Visual,< 4.8,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NC(=O)c5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0107470,,SPK-0107470-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 15.8,Visual,< 4.8,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NC(=O)c5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0107470,,SPK-0107470-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 15.8,Visual,< 4.8,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NC(=O)c5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0107470,,SPK-0107470-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.125,MIC,Test article,0.246,Visual,6.6,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NC(=O)c5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0107470,,SPK-0107470-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 15.8,Visual,< 4.8,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NC(=O)c5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0107470,,SPK-0107470-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 15.8,Visual,< 4.8,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NC(=O)c5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0107470,,SPK-0107470-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 15.8,Visual,< 4.8,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NC(=O)c5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0107470,,SPK-0107470-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0310,MIC,Test article,0.0611,Visual,7.2,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NC(=O)c5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0107466,,SPK-0107466-001,,,,,,,,,,,,,,,,,,,,,,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)C(C)(C)O6)(CC3)CO4)c2n1
SPK-0107466,,SPK-0107466-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 2.00,MIC,Test article,> 3.58,Visual,< 5.4,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)C(C)(C)O6)(CC3)CO4)c2n1
SPK-0107466,,SPK-0107466-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 2.00,MIC,Test article,> 3.58,Visual,< 5.4,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)C(C)(C)O6)(CC3)CO4)c2n1
SPK-0107466,,SPK-0107466-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 2.00,MIC,Test article,> 3.58,Visual,< 5.4,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)C(C)(C)O6)(CC3)CO4)c2n1
SPK-0107466,,SPK-0107466-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.250,MIC,Test article,0.448,Visual,6.3,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)C(C)(C)O6)(CC3)CO4)c2n1
SPK-0107466,,SPK-0107466-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 2.00,MIC,Test article,> 3.58,Visual,< 5.4,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)C(C)(C)O6)(CC3)CO4)c2n1
SPK-0107466,,SPK-0107466-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 2.00,MIC,Test article,> 3.58,Visual,< 5.4,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)C(C)(C)O6)(CC3)CO4)c2n1
SPK-0107466,,SPK-0107466-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 2.00,MIC,Test article,> 3.58,Visual,< 5.4,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)C(C)(C)O6)(CC3)CO4)c2n1
SPK-0107466,,SPK-0107466-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.500,MIC,Test article,0.896,Visual,6.0,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)NC(=O)C(C)(C)O6)(CC3)CO4)c2n1
SPK-0107461,,SPK-0107461-001,,,,,,,,,,,,,,,,,,,,,,COc1ccc2ncc(F)c(CCC34CCC(NCc5nc6c(cc5OC)OCC(=O)N6)(CC3)CO4)c2n1
SPK-0107461,,SPK-0107461-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,8.00,MIC,Test article,14.3,Visual,4.8,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5nc6c(cc5OC)OCC(=O)N6)(CC3)CO4)c2n1
SPK-0107461,,SPK-0107461-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 14.3,Visual,< 4.8,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5nc6c(cc5OC)OCC(=O)N6)(CC3)CO4)c2n1
SPK-0107461,,SPK-0107461-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 14.3,Visual,< 4.8,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5nc6c(cc5OC)OCC(=O)N6)(CC3)CO4)c2n1
SPK-0107461,,SPK-0107461-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0630,MIC,Test article,0.112,Visual,6.9,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5nc6c(cc5OC)OCC(=O)N6)(CC3)CO4)c2n1
SPK-0107461,,SPK-0107461-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 14.3,Visual,< 4.8,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5nc6c(cc5OC)OCC(=O)N6)(CC3)CO4)c2n1
SPK-0107461,,SPK-0107461-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 14.3,Visual,< 4.8,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5nc6c(cc5OC)OCC(=O)N6)(CC3)CO4)c2n1
SPK-0107461,,SPK-0107461-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 14.3,Visual,< 4.8,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5nc6c(cc5OC)OCC(=O)N6)(CC3)CO4)c2n1
SPK-0107461,,SPK-0107461-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,2.00,MIC,Test article,3.57,Visual,5.4,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5nc6c(cc5OC)OCC(=O)N6)(CC3)CO4)c2n1
SPK-0107460,,SPK-0107460-001,,,,,,,,,,,,,,,,,,,,,,COc1ccc2ncc(F)c(CCC34CCC(NCc5nc6c(cc5Cl)OCC(=O)N6)(CC3)CO4)c2n1
SPK-0107460,,SPK-0107460-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,1.00,MIC,Test article,1.77,Visual,5.8,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5nc6c(cc5Cl)OCC(=O)N6)(CC3)CO4)c2n1
SPK-0107460,,SPK-0107460-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,2.00,MIC,Test article,3.54,Visual,5.5,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5nc6c(cc5Cl)OCC(=O)N6)(CC3)CO4)c2n1
SPK-0107460,,SPK-0107460-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 2.00,MIC,Test article,> 3.54,Visual,< 5.5,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5nc6c(cc5Cl)OCC(=O)N6)(CC3)CO4)c2n1
SPK-0107460,,SPK-0107460-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0160,MIC,Test article,0.0283,Visual,7.5,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5nc6c(cc5Cl)OCC(=O)N6)(CC3)CO4)c2n1
SPK-0107460,,SPK-0107460-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 2.00,MIC,Test article,> 3.54,Visual,< 5.5,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5nc6c(cc5Cl)OCC(=O)N6)(CC3)CO4)c2n1
SPK-0107460,,SPK-0107460-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 2.00,MIC,Test article,> 3.54,Visual,< 5.5,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5nc6c(cc5Cl)OCC(=O)N6)(CC3)CO4)c2n1
SPK-0107460,,SPK-0107460-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 2.00,MIC,Test article,> 3.54,Visual,< 5.5,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5nc6c(cc5Cl)OCC(=O)N6)(CC3)CO4)c2n1
SPK-0107460,,SPK-0107460-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,8.00E-03,MIC,Test article,0.0142,Visual,7.8,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5nc6c(cc5Cl)OCC(=O)N6)(CC3)CO4)c2n1
SPK-0107459,,SPK-0107459-001,,,,,,,,,,,,,,,,,,,,,,COc1ccc2ncc(F)c(CCC34CCC(N(C)Cc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0107459,,SPK-0107459-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,8.00,MIC,Test article,14.7,Visual,4.8,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(N(C)Cc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0107459,,SPK-0107459-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,16.0,MIC,Test article,29.4,Visual,4.5,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(N(C)Cc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0107459,,SPK-0107459-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 58.8,Visual,< 4.2,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(N(C)Cc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0107459,,SPK-0107459-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.125,MIC,Test article,0.230,Visual,6.6,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(N(C)Cc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0107459,,SPK-0107459-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 58.8,Visual,< 4.2,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(N(C)Cc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0107459,,SPK-0107459-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 58.8,Visual,< 4.2,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(N(C)Cc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0107459,,SPK-0107459-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 32.0,MIC,Test article,> 58.8,Visual,< 4.2,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(N(C)Cc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0107459,,SPK-0107459-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.500,MIC,Test article,0.919,Visual,6.0,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(N(C)Cc5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0107456,,SPK-0107456-001,,,,,,,,,,,,,,,,,,,,,,COc1ccc2ncc(F)c(CCC34CCC(N(C)C(=O)c5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0107456,,SPK-0107456-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 4.00,MIC,Test article,> 7.67,Visual,< 5.1,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(N(C)C(=O)c5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0107456,,SPK-0107456-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 4.00,MIC,Test article,> 7.67,Visual,< 5.1,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(N(C)C(=O)c5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0107456,,SPK-0107456-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 4.00,MIC,Test article,> 7.67,Visual,< 5.1,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(N(C)C(=O)c5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0107456,,SPK-0107456-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.125,MIC,Test article,0.240,Visual,6.6,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(N(C)C(=O)c5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0107456,,SPK-0107456-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 4.00,MIC,Test article,> 7.67,Visual,< 5.1,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(N(C)C(=O)c5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0107456,,SPK-0107456-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 4.00,MIC,Test article,> 7.67,Visual,< 5.1,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(N(C)C(=O)c5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0107456,,SPK-0107456-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 4.00,MIC,Test article,> 7.67,Visual,< 5.1,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(N(C)C(=O)c5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0107456,,SPK-0107456-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0630,MIC,Test article,0.121,Visual,6.9,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(N(C)C(=O)c5ccc6c(n5)NC(=O)CO6)(CC3)CO4)c2n1
SPK-0107455,,SPK-0107455-001,,,,,,,,,,,,,,,,,,,,,,COC(=O)N(Cc1ccc2c(n1)NC(=O)CO2)C12CCC(CCc3c(F)cnc4ccc(OC)nc34)(CC1)OC2
SPK-0107455,,SPK-0107455-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 109,Visual,< 4.0,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COC(=O)N(Cc1ccc2c(n1)NC(=O)CO2)C12CCC(CCc3c(F)cnc4ccc(OC)nc34)(CC1)OC2
SPK-0107455,,SPK-0107455-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 109,Visual,< 4.0,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COC(=O)N(Cc1ccc2c(n1)NC(=O)CO2)C12CCC(CCc3c(F)cnc4ccc(OC)nc34)(CC1)OC2
SPK-0107455,,SPK-0107455-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 109,Visual,< 4.0,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COC(=O)N(Cc1ccc2c(n1)NC(=O)CO2)C12CCC(CCc3c(F)cnc4ccc(OC)nc34)(CC1)OC2
SPK-0107455,,SPK-0107455-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,16.0,MIC,Test article,27.2,Visual,4.6,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COC(=O)N(Cc1ccc2c(n1)NC(=O)CO2)C12CCC(CCc3c(F)cnc4ccc(OC)nc34)(CC1)OC2
SPK-0107455,,SPK-0107455-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 109,Visual,< 4.0,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COC(=O)N(Cc1ccc2c(n1)NC(=O)CO2)C12CCC(CCc3c(F)cnc4ccc(OC)nc34)(CC1)OC2
SPK-0107455,,SPK-0107455-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 109,Visual,< 4.0,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COC(=O)N(Cc1ccc2c(n1)NC(=O)CO2)C12CCC(CCc3c(F)cnc4ccc(OC)nc34)(CC1)OC2
SPK-0107455,,SPK-0107455-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 64.0,MIC,Test article,> 109,Visual,< 4.0,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COC(=O)N(Cc1ccc2c(n1)NC(=O)CO2)C12CCC(CCc3c(F)cnc4ccc(OC)nc34)(CC1)OC2
SPK-0107455,,SPK-0107455-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,32.0,MIC,Test article,54.4,Visual,4.3,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COC(=O)N(Cc1ccc2c(n1)NC(=O)CO2)C12CCC(CCc3c(F)cnc4ccc(OC)nc34)(CC1)OC2
SPK-0107454,,SPK-0107454-001,,,,,,,,,,,,,,,,,,,,,,COc1ccc2ncc(F)c(CCC34CCC(NCc5nc6c(cc5F)OCC(=O)N6)(CC3)CO4)c2n1
SPK-0107454,,SPK-0107454-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.500,MIC,Test article,0.977,Visual,6.0,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5nc6c(cc5F)OCC(=O)N6)(CC3)CO4)c2n1
SPK-0107454,,SPK-0107454-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,2.00,MIC,Test article,3.91,Visual,5.4,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5nc6c(cc5F)OCC(=O)N6)(CC3)CO4)c2n1
SPK-0107454,,SPK-0107454-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,8.00,MIC,Test article,15.6,Visual,4.8,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5nc6c(cc5F)OCC(=O)N6)(CC3)CO4)c2n1
SPK-0107454,,SPK-0107454-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0160,MIC,Test article,0.0313,Visual,7.5,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5nc6c(cc5F)OCC(=O)N6)(CC3)CO4)c2n1
SPK-0107454,,SPK-0107454-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 15.6,Visual,< 4.8,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5nc6c(cc5F)OCC(=O)N6)(CC3)CO4)c2n1
SPK-0107454,,SPK-0107454-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 15.6,Visual,< 4.8,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5nc6c(cc5F)OCC(=O)N6)(CC3)CO4)c2n1
SPK-0107454,,SPK-0107454-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 8.00,MIC,Test article,> 15.6,Visual,< 4.8,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5nc6c(cc5F)OCC(=O)N6)(CC3)CO4)c2n1
SPK-0107454,,SPK-0107454-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,0.0310,MIC,Test article,0.0606,Visual,7.2,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5nc6c(cc5F)OCC(=O)N6)(CC3)CO4)c2n1
SPK-0107451,,SPK-0107451-001,,,,,,,,,,,,,,,,,,,,,,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)N(C)C(=O)CO6)(CC3)CO4)c2n1
SPK-0107451,,SPK-0107451-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 31.5,Visual,< 4.5,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)N(C)C(=O)CO6)(CC3)CO4)c2n1
SPK-0107451,,SPK-0107451-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 31.5,Visual,< 4.5,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)N(C)C(=O)CO6)(CC3)CO4)c2n1
SPK-0107451,,SPK-0107451-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 31.5,Visual,< 4.5,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)N(C)C(=O)CO6)(CC3)CO4)c2n1
SPK-0107451,,SPK-0107451-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,1.00,MIC,Test article,1.97,Visual,5.7,Escherichia coli,KAM3,,Efflux deficient,TG1 ΔacrAB supE hsdD5 thi (Δlac-proAB)/F′ [traD36 proAB+ lacIq lac ΔZM15],Efflux deficient (acrAB) mutant derived from TG1,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)N(C)C(=O)CO6)(CC3)CO4)c2n1
SPK-0107451,,SPK-0107451-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 31.5,Visual,< 4.5,Pseudomonas aeruginosa,KH4013e,,Efflux overexpressor,"nfxB, MecCD OprJ overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)N(C)C(=O)CO6)(CC3)CO4)c2n1
SPK-0107451,,SPK-0107451-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 31.5,Visual,< 4.5,Pseudomonas aeruginosa,KH4014a,,Efflux overexpressor,"nfxC, MexEF OprN overexpressor (derived from PAO4009)",Generated in Merck's Kyorin labs through spontaneous mutagenesis (Reference: Tan et al. Antimicrob Agents Chemother. 2016 Aug; 60(8): 4830–4839.),DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)N(C)C(=O)CO6)(CC3)CO4)c2n1
SPK-0107451,,SPK-0107451-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Test article,> 31.5,Visual,< 4.5,Pseudomonas aeruginosa,PAO6006,,Efflux overexpressor,"nalB, MexAB OprM overexpressor (derived from PAO969 proC130)","From Dieter Haas lab Mikrobiologisches Institut in Switzerland (Reference: Rella M, Haas D. Antimicrob Agents Chemother. 1982 Aug; 22(2):242-9.)",DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)N(C)C(=O)CO6)(CC3)CO4)c2n1
SPK-0107451,,SPK-0107451-002,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,2.00,MIC,Test article,3.94,Visual,5.4,Staphylococcus aureus,RN4220,NR-45946 (BEI Resources); NRS144,NA / Gram Positive,"Negative for mec, rsbU and agr; MLST sequence type (ST) 8; eGenomic spa type 59, eGenomic spa repeats YHGGFMBQBLO; Ridom spa type t211.",Derived from NCTC8325; whole genome sequenced; used as a cloning host due to mutation that makes it restriction deficient,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,COc1ccc2ncc(F)c(CCC34CCC(NCc5ccc6c(n5)N(C)C(=O)CO6)(CC3)CO4)c2n1
SPK-0002337,"C000001294, Levofloxacin, SPK-0125752",SPK-0002337-001,,,,,,,,,,,,,,,,,,,,,,C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23
SPK-0002337,"C000001294, Levofloxacin, SPK-0125752",SPK-0002337-005,,,,,,,,,,,,,,,,,,,,,,C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23
SPK-0002337,"C000001294, Levofloxacin, SPK-0125752",SPK-0002337-006,,,,,,,,,,,,,,,,,,,,,,C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23
SPK-0002337,"C000001294, Levofloxacin, SPK-0125752",SPK-0002337-007,,,,,,,,,,,,,,,,,,,,,,C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23
SPK-0002337,"C000001294, Levofloxacin, SPK-0125752",SPK-0002337-009,,,,,,,,,,,,,,,,,,,,,,C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23
SPK-0002337,"C000001294, Levofloxacin, SPK-0125752",SPK-0002337-010,,,,,,,,,,,,,,,,,,,,,,C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23
SPK-0002337,"C000001294, Levofloxacin, SPK-0125752",SPK-0002337-013,,,,,,,,,,,,,,,,,,,,,,C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23
SPK-0002337,"C000001294, Levofloxacin, SPK-0125752",SPK-0002337-014,,,,,,,,,,,,,,,,,,,,,,C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23
SPK-0002337,"C000001294, Levofloxacin, SPK-0125752",SPK-0002337-015,,,,,,,,,,,,,,,,,,,,,,C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23
SPK-0002337,"C000001294, Levofloxacin, SPK-0125752",SPK-0002337-018,,,,,,,,,,,,,,,,,,,,,,C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23
SPK-0002337,"C000001294, Levofloxacin, SPK-0125752",SPK-0002337-019,,,,,,,,,,,,,,,,,,,,,,C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23
SPK-0002337,"C000001294, Levofloxacin, SPK-0125752",SPK-0002337-020,,,,,,,,,,,,,,,,,,,,,,C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23
SPK-0002337,"C000001294, Levofloxacin, SPK-0125752",SPK-0002337-021,,,,,,,,,,,,,,,,,,,,,,C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23
SPK-0002337,"C000001294, Levofloxacin, SPK-0125752",SPK-0002337-022,,,,,,,,,,,,,,,,,,,,,,C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23
SPK-0002337,"C000001294, Levofloxacin, SPK-0125752",SPK-0002337-023,,,,,,,,,,,,,,,,,,,,,,C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23
SPK-0002337,"C000001294, Levofloxacin, SPK-0125752",SPK-0002337-024,,,,,,,,,,,,,,,,,,,,,,C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23
SPK-0002337,"C000001294, Levofloxacin, SPK-0125752",SPK-0002337-025,,,,,,,,,,,,,,,,,,,,,,C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23
SPK-0002337,"C000001294, Levofloxacin, SPK-0125752",SPK-0002337-026,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 0.0612,MIC,Control / Reference compound,> 0.169,Visual,< 6.8,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23
SPK-0002337,"C000001294, Levofloxacin, SPK-0125752",SPK-0002337-026,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 0.0350,MIC,Control / Reference compound,> 0.0969,Visual,< 7.0,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23
SPK-0002337,"C000001294, Levofloxacin, SPK-0125752",SPK-0002337-026,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 0.340,MIC,Control / Reference compound,> 0.940,Visual,< 6.0,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23
SPK-0002337,"C000001294, Levofloxacin, SPK-0125752",SPK-0002337-027,,,,,,,,,,,,,,,,,,,,,,C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23
SPK-0002337,"C000001294, Levofloxacin, SPK-0125752",SPK-0002337-028,,,,,,,,,,,,,,,,,,,,,,C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23
SPK-0002337,"C000001294, Levofloxacin, SPK-0125752",SPK-0002337-029,,,,,,,,,,,,,,,,,,,,,,C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23
SPK-0002308,Linezolid,SPK-0002308-001,,,,,,,,,,,,,,,,,,,,,,CC(=O)NC[C@H]1CN(c2ccc(N3CCOCC3)c(F)c2)C(=O)O1
SPK-0002308,Linezolid,SPK-0002308-004,,,,,,,,,,,,,,,,,,,,,,CC(=O)NC[C@H]1CN(c2ccc(N3CCOCC3)c(F)c2)C(=O)O1
SPK-0002308,Linezolid,SPK-0002308-005,,,,,,,,,,,,,,,,,,,,,,CC(=O)NC[C@H]1CN(c2ccc(N3CCOCC3)c(F)c2)C(=O)O1
SPK-0002308,Linezolid,SPK-0002308-006,,,,,,,,,,,,,,,,,,,,,,CC(=O)NC[C@H]1CN(c2ccc(N3CCOCC3)c(F)c2)C(=O)O1
SPK-0002308,Linezolid,SPK-0002308-008,,,,,,,,,,,,,,,,,,,,,,CC(=O)NC[C@H]1CN(c2ccc(N3CCOCC3)c(F)c2)C(=O)O1
SPK-0002308,Linezolid,SPK-0002308-009,,,,,,,,,,,,,,,,,,,,,,CC(=O)NC[C@H]1CN(c2ccc(N3CCOCC3)c(F)c2)C(=O)O1
SPK-0002308,Linezolid,SPK-0002308-010,,,,,,,,,,,,,,,,,,,,,,CC(=O)NC[C@H]1CN(c2ccc(N3CCOCC3)c(F)c2)C(=O)O1
SPK-0002308,Linezolid,SPK-0002308-011,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Control / Reference compound,> 47.4,Visual,< 4.3,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CC(=O)NC[C@H]1CN(c2ccc(N3CCOCC3)c(F)c2)C(=O)O1
SPK-0002308,Linezolid,SPK-0002308-011,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Control / Reference compound,> 47.4,Visual,< 4.3,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CC(=O)NC[C@H]1CN(c2ccc(N3CCOCC3)c(F)c2)C(=O)O1
SPK-0002308,Linezolid,SPK-0002308-011,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Control / Reference compound,> 47.4,Visual,< 4.3,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CC(=O)NC[C@H]1CN(c2ccc(N3CCOCC3)c(F)c2)C(=O)O1
SPK-0002308,Linezolid,SPK-0002308-012,,,,,,,,,,,,,,,,,,,,,,CC(=O)NC[C@H]1CN(c2ccc(N3CCOCC3)c(F)c2)C(=O)O1
SPK-0002308,Linezolid,SPK-0002308-013,,,,,,,,,,,,,,,,,,,,,,CC(=O)NC[C@H]1CN(c2ccc(N3CCOCC3)c(F)c2)C(=O)O1
SPK-0002308,Linezolid,SPK-0002308-014,,,,,,,,,,,,,,,,,,,,,,CC(=O)NC[C@H]1CN(c2ccc(N3CCOCC3)c(F)c2)C(=O)O1
SPK-0002308,Linezolid,SPK-0002308-015,,,,,,,,,,,,,,,,,,,,,,CC(=O)NC[C@H]1CN(c2ccc(N3CCOCC3)c(F)c2)C(=O)O1
SPK-0002308,Linezolid,SPK-0002308-016,,,,,,,,,,,,,,,,,,,,,,CC(=O)NC[C@H]1CN(c2ccc(N3CCOCC3)c(F)c2)C(=O)O1
SPK-0002308,Linezolid,SPK-0002308-017,,,,,,,,,,,,,,,,,,,,,,CC(=O)NC[C@H]1CN(c2ccc(N3CCOCC3)c(F)c2)C(=O)O1
SPK-0002308,Linezolid,SPK-0002308-018,,,,,,,,,,,,,,,,,,,,,,CC(=O)NC[C@H]1CN(c2ccc(N3CCOCC3)c(F)c2)C(=O)O1
SPK-0000144,Vancomycin,SPK-0000144-001,,,,,,,,,,,,,,,,,,,,,,CN[C@H](CC(C)C)C(=O)N[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]2C(=O)N[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)O)c4cc(O)cc(O)c4-c4cc3ccc4O)[C@H](O)c3ccc(c(Cl)c3)Oc3cc2cc(c3O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O[C@H]2C[C@](C)(N)[C@H](O)[C@H](C)O2)Oc2ccc(cc2Cl)[C@H]1O
SPK-0000144,Vancomycin,SPK-0000144-003,,,,,,,,,,,,,,,,,,,,,,CN[C@H](CC(C)C)C(=O)N[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]2C(=O)N[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)O)c4cc(O)cc(O)c4-c4cc3ccc4O)[C@H](O)c3ccc(c(Cl)c3)Oc3cc2cc(c3O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O[C@H]2C[C@](C)(N)[C@H](O)[C@H](C)O2)Oc2ccc(cc2Cl)[C@H]1O
SPK-0000144,Vancomycin,SPK-0000144-005,,,,,,,,,,,,,,,,,,,,,,CN[C@H](CC(C)C)C(=O)N[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]2C(=O)N[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)O)c4cc(O)cc(O)c4-c4cc3ccc4O)[C@H](O)c3ccc(c(Cl)c3)Oc3cc2cc(c3O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O[C@H]2C[C@](C)(N)[C@H](O)[C@H](C)O2)Oc2ccc(cc2Cl)[C@H]1O
SPK-0000144,Vancomycin,SPK-0000144-006,,,,,,,,,,,,,,,,,,,,,,CN[C@H](CC(C)C)C(=O)N[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]2C(=O)N[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)O)c4cc(O)cc(O)c4-c4cc3ccc4O)[C@H](O)c3ccc(c(Cl)c3)Oc3cc2cc(c3O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O[C@H]2C[C@](C)(N)[C@H](O)[C@H](C)O2)Oc2ccc(cc2Cl)[C@H]1O
SPK-0000144,Vancomycin,SPK-0000144-007,,,,,,,,,,,,,,,,,,,,,,CN[C@H](CC(C)C)C(=O)N[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]2C(=O)N[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)O)c4cc(O)cc(O)c4-c4cc3ccc4O)[C@H](O)c3ccc(c(Cl)c3)Oc3cc2cc(c3O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O[C@H]2C[C@](C)(N)[C@H](O)[C@H](C)O2)Oc2ccc(cc2Cl)[C@H]1O
SPK-0000144,Vancomycin,SPK-0000144-008,,,,,,,,,,,,,,,,,,,,,,CN[C@H](CC(C)C)C(=O)N[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]2C(=O)N[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)O)c4cc(O)cc(O)c4-c4cc3ccc4O)[C@H](O)c3ccc(c(Cl)c3)Oc3cc2cc(c3O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O[C@H]2C[C@](C)(N)[C@H](O)[C@H](C)O2)Oc2ccc(cc2Cl)[C@H]1O
SPK-0000144,Vancomycin,SPK-0000144-009,,,,,,,,,,,,,,,,,,,,,,CN[C@H](CC(C)C)C(=O)N[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]2C(=O)N[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)O)c4cc(O)cc(O)c4-c4cc3ccc4O)[C@H](O)c3ccc(c(Cl)c3)Oc3cc2cc(c3O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O[C@H]2C[C@](C)(N)[C@H](O)[C@H](C)O2)Oc2ccc(cc2Cl)[C@H]1O
SPK-0000144,Vancomycin,SPK-0000144-010,,,,,,,,,,,,,,,,,,,,,,CN[C@H](CC(C)C)C(=O)N[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]2C(=O)N[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)O)c4cc(O)cc(O)c4-c4cc3ccc4O)[C@H](O)c3ccc(c(Cl)c3)Oc3cc2cc(c3O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O[C@H]2C[C@](C)(N)[C@H](O)[C@H](C)O2)Oc2ccc(cc2Cl)[C@H]1O
SPK-0000144,Vancomycin,SPK-0000144-011,,,,,,,,,,,,,,,,,,,,,,CN[C@H](CC(C)C)C(=O)N[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]2C(=O)N[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)O)c4cc(O)cc(O)c4-c4cc3ccc4O)[C@H](O)c3ccc(c(Cl)c3)Oc3cc2cc(c3O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O[C@H]2C[C@](C)(N)[C@H](O)[C@H](C)O2)Oc2ccc(cc2Cl)[C@H]1O
SPK-0000144,Vancomycin,SPK-0000144-012,,,,,,,,,,,,,,,,,,,,,,CN[C@H](CC(C)C)C(=O)N[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]2C(=O)N[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)O)c4cc(O)cc(O)c4-c4cc3ccc4O)[C@H](O)c3ccc(c(Cl)c3)Oc3cc2cc(c3O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O[C@H]2C[C@](C)(N)[C@H](O)[C@H](C)O2)Oc2ccc(cc2Cl)[C@H]1O
SPK-0000144,Vancomycin,SPK-0000144-013,,,,,,,,,,,,,,,,,,,,,,CN[C@H](CC(C)C)C(=O)N[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]2C(=O)N[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)O)c4cc(O)cc(O)c4-c4cc3ccc4O)[C@H](O)c3ccc(c(Cl)c3)Oc3cc2cc(c3O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O[C@H]2C[C@](C)(N)[C@H](O)[C@H](C)O2)Oc2ccc(cc2Cl)[C@H]1O
SPK-0000144,Vancomycin,SPK-0000144-014,,,,,,,,,,,,,,,,,,,,,,CN[C@H](CC(C)C)C(=O)N[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]2C(=O)N[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)O)c4cc(O)cc(O)c4-c4cc3ccc4O)[C@H](O)c3ccc(c(Cl)c3)Oc3cc2cc(c3O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O[C@H]2C[C@](C)(N)[C@H](O)[C@H](C)O2)Oc2ccc(cc2Cl)[C@H]1O
SPK-0000144,Vancomycin,SPK-0000144-015,,,,,,,,,,,,,,,,,,,,,,CN[C@H](CC(C)C)C(=O)N[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]2C(=O)N[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)O)c4cc(O)cc(O)c4-c4cc3ccc4O)[C@H](O)c3ccc(c(Cl)c3)Oc3cc2cc(c3O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O[C@H]2C[C@](C)(N)[C@H](O)[C@H](C)O2)Oc2ccc(cc2Cl)[C@H]1O
SPK-0000144,Vancomycin,SPK-0000144-016,,,,,,,,,,,,,,,,,,,,,,CN[C@H](CC(C)C)C(=O)N[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]2C(=O)N[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)O)c4cc(O)cc(O)c4-c4cc3ccc4O)[C@H](O)c3ccc(c(Cl)c3)Oc3cc2cc(c3O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O[C@H]2C[C@](C)(N)[C@H](O)[C@H](C)O2)Oc2ccc(cc2Cl)[C@H]1O
SPK-0000144,Vancomycin,SPK-0000144-017,,,,,,,,,,,,,,,,,,,,,,CN[C@H](CC(C)C)C(=O)N[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]2C(=O)N[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)O)c4cc(O)cc(O)c4-c4cc3ccc4O)[C@H](O)c3ccc(c(Cl)c3)Oc3cc2cc(c3O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O[C@H]2C[C@](C)(N)[C@H](O)[C@H](C)O2)Oc2ccc(cc2Cl)[C@H]1O
SPK-0000144,Vancomycin,SPK-0000144-018,,,,,,,,,,,,,,,,,,,,,,CN[C@H](CC(C)C)C(=O)N[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]2C(=O)N[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)O)c4cc(O)cc(O)c4-c4cc3ccc4O)[C@H](O)c3ccc(c(Cl)c3)Oc3cc2cc(c3O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O[C@H]2C[C@](C)(N)[C@H](O)[C@H](C)O2)Oc2ccc(cc2Cl)[C@H]1O
SPK-0000144,Vancomycin,SPK-0000144-019,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Control / Reference compound,> 11.0,Visual,< 5.0,Acinetobacter baumannii,IID876,,Wild type,Wild type,,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CN[C@H](CC(C)C)C(=O)N[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]2C(=O)N[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)O)c4cc(O)cc(O)c4-c4cc3ccc4O)[C@H](O)c3ccc(c(Cl)c3)Oc3cc2cc(c3O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O[C@H]2C[C@](C)(N)[C@H](O)[C@H](C)O2)Oc2ccc(cc2Cl)[C@H]1O
SPK-0000144,Vancomycin,SPK-0000144-019,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Control / Reference compound,> 11.0,Visual,< 5.0,Escherichia coli,ATCC 25922,AECO001; NB27001,Wild type,,CLSI reference strain,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CN[C@H](CC(C)C)C(=O)N[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]2C(=O)N[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)O)c4cc(O)cc(O)c4-c4cc3ccc4O)[C@H](O)c3ccc(c(Cl)c3)Oc3cc2cc(c3O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O[C@H]2C[C@](C)(N)[C@H](O)[C@H](C)O2)Oc2ccc(cc2Cl)[C@H]1O
SPK-0000144,Vancomycin,SPK-0000144-019,Merck & Kyorin - GyrAB/ParCE inhibitors,"GyrAB/ParCE inhibitors

Contributed October 2020 by Merck & Kyorin

Method: CLSI broth microdilution
Media: CAMHB
Assay conditions: 37C, 18-24 hours
Solvent: 2% DMSO",Curated Data,> 16.0,MIC,Control / Reference compound,> 11.0,Visual,< 5.0,Pseudomonas aeruginosa,PAO1,ATCC BAA-47; ARC545; Pae545; PAM1020; APAE002; K767; K2732; NB52019,Wild type,aph(3')-IIb,Well characterized lab isolate,DMSO,2.0,"37C, 18-24 hours, microtiter plate",CAMHB,CLSI broth microdilution,Merck GyrAB/ParCE Data,CN[C@H](CC(C)C)C(=O)N[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]2C(=O)N[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)O)c4cc(O)cc(O)c4-c4cc3ccc4O)[C@H](O)c3ccc(c(Cl)c3)Oc3cc2cc(c3O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O[C@H]2C[C@](C)(N)[C@H](O)[C@H](C)O2)Oc2ccc(cc2Cl)[C@H]1O
SPK-0000144,Vancomycin,SPK-0000144-020,,,,,,,,,,,,,,,,,,,,,,CN[C@H](CC(C)C)C(=O)N[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]2C(=O)N[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)O)c4cc(O)cc(O)c4-c4cc3ccc4O)[C@H](O)c3ccc(c(Cl)c3)Oc3cc2cc(c3O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O[C@H]2C[C@](C)(N)[C@H](O)[C@H](C)O2)Oc2ccc(cc2Cl)[C@H]1O
SPK-0000144,Vancomycin,SPK-0000144-021,,,,,,,,,,,,,,,,,,,,,,CN[C@H](CC(C)C)C(=O)N[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]2C(=O)N[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)O)c4cc(O)cc(O)c4-c4cc3ccc4O)[C@H](O)c3ccc(c(Cl)c3)Oc3cc2cc(c3O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O[C@H]2C[C@](C)(N)[C@H](O)[C@H](C)O2)Oc2ccc(cc2Cl)[C@H]1O
SPK-0000144,Vancomycin,SPK-0000144-022,,,,,,,,,,,,,,,,,,,,,,CN[C@H](CC(C)C)C(=O)N[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]2C(=O)N[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)O)c4cc(O)cc(O)c4-c4cc3ccc4O)[C@H](O)c3ccc(c(Cl)c3)Oc3cc2cc(c3O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O[C@H]2C[C@](C)(N)[C@H](O)[C@H](C)O2)Oc2ccc(cc2Cl)[C@H]1O
SPK-0000144,Vancomycin,SPK-0000144-023,,,,,,,,,,,,,,,,,,,,,,CN[C@H](CC(C)C)C(=O)N[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]2C(=O)N[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)O)c4cc(O)cc(O)c4-c4cc3ccc4O)[C@H](O)c3ccc(c(Cl)c3)Oc3cc2cc(c3O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O[C@H]2C[C@](C)(N)[C@H](O)[C@H](C)O2)Oc2ccc(cc2Cl)[C@H]1O
SPK-0000144,Vancomycin,SPK-0000144-024,,,,,,,,,,,,,,,,,,,,,,CN[C@H](CC(C)C)C(=O)N[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]2C(=O)N[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)O)c4cc(O)cc(O)c4-c4cc3ccc4O)[C@H](O)c3ccc(c(Cl)c3)Oc3cc2cc(c3O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O[C@H]2C[C@](C)(N)[C@H](O)[C@H](C)O2)Oc2ccc(cc2Cl)[C@H]1O
SPK-0000144,Vancomycin,SPK-0000144-025,,,,,,,,,,,,,,,,,,,,,,CN[C@H](CC(C)C)C(=O)N[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]2C(=O)N[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)O)c4cc(O)cc(O)c4-c4cc3ccc4O)[C@H](O)c3ccc(c(Cl)c3)Oc3cc2cc(c3O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O[C@H]2C[C@](C)(N)[C@H](O)[C@H](C)O2)Oc2ccc(cc2Cl)[C@H]1O
SPK-0000144,Vancomycin,SPK-0000144-026,,,,,,,,,,,,,,,,,,,,,,CN[C@H](CC(C)C)C(=O)N[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]2C(=O)N[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)O)c4cc(O)cc(O)c4-c4cc3ccc4O)[C@H](O)c3ccc(c(Cl)c3)Oc3cc2cc(c3O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O[C@H]2C[C@](C)(N)[C@H](O)[C@H](C)O2)Oc2ccc(cc2Cl)[C@H]1O
